---
document_datetime: 2023-09-21 21:10:51
document_pages: 143
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/zynteglo-epar-public-assessment-report_en.pdf
document_name: zynteglo-epar-public-assessment-report_en.pdf
version: success
processing_time: 127.9752896
conversion_datetime: 2025-12-17 07:29:39.381172
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

26 April 2019 EMA/56140/2020/Corr. 1 Committee for Medicinal Products for Human Use (CHMP)

Medicinal product no longer authorised Assessment report Zynteglo International non-proprietary name: betibeglogene autotemcel Procedure No. EMEA/H/C/003691/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

1  Changes in this updated version consist in the redaction of personal data, in compliance with Regulation (EU) 2018/1725, updated INN and assigned ATC code.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Administrative information

| Name of the medicinal product:                 | Zynteglo                                                                                                                                                                                                                                                                                                                                                          |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                                     | bluebird bio (Netherlands) B.V. Stadsplateau 7 WTC Utrecht 3521AZ Utrecht The Netherlands                                                                                                                                                                                                                                                                         |
| Active substance:                              | authorised Autologous CD34+ cell-enriched population that contains haematopoietic stem cells transduced with lentiviral vector encoding the β A-T87Q -globin gene                                                                                                                                                                                                 |
| International Nonproprietary Name/Common Name: | betibeglogene autotemcel                                                                                                                                                                                                                                                                                                                                          |
| Pharmaco-therapeutic group (ATC Code):         | B06AX02: Other haematological agents                                                                                                                                                                                                                                                                                                                              |
| Therapeutic indication(s):                     | product no longer Zynteglo is indicated for the treatment of patients 12 years and older with transfusion- dependent β -thalassaemia (TDT) who do not have a β 0 /β 0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available (see sections 4.4 and 5.1). |
| Pharmaceutical form(s):                        | Dispersion for infusion                                                                                                                                                                                                                                                                                                                                           |
| Strength(s):                                   | 1.2-20 x 10 6 cells/ml                                                                                                                                                                                                                                                                                                                                            |
| Medicinal Route(s) of administration:          | Intravenous use                                                                                                                                                                                                                                                                                                                                                   |
| Packaging:                                     | bag (Fluorinated Ethylene Propylene)                                                                                                                                                                                                                                                                                                                              |
| Package size(s):                               | 1 bag (or more)                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................8                                                                                     |                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................8                                                          |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.......................................................10                                                                    |                                                                                                          |
| 2. Scientific discussion                                                                                                                                                       | ..............................................................................12                         |
| 2.1. Problem statement                                                                                                                                                         | .............................................................................................12          |
| 2.1.1. Disease or condition.........................................................................................12                                                         |                                                                                                          |
| 2.1.2. Epidemiology                                                                                                                                                            | ..................................................................................................12     |
| 2.1.3. Biologic features..............................................................................................13                                                       |                                                                                                          |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                                                                                    | ............................................13                                                           |
| 2.1.5. Management...................................................................................................13                                                         |                                                                                                          |
| 2.2. Quality aspects                                                                                                                                                           | ..................................................................................................15     |
| 2.2.1. Introduction....................................................................................................15                                                      |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................15                                                         |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                                                                              | ................................................................................21                       |
| authorised 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................24                                                                |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                                                                      | ......................24                                                                                 |
| longer 2.2.6. Recommendations for future quality development................................................25                                                                 |                                                                                                          |
| 2.3. Non-clinical aspects ............................................................................................25                                                       |                                                                                                          |
| 2.3.1. Introduction....................................................................................................25                                                      |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                                                                            | .................................................................................................25      |
| 2.3.3. Pharmacokinetics.............................................................................................32                                                         |                                                                                                          |
| 2.3.4. Toxicology                                                                                                                                                              | ......................................................................................................32 |
| no 2.3.5. Ecotoxicity/environmental risk assessment                                                                                                                            | .........................................................34                                              |
| product 2.3.6. Discussion on the non-clinical aspects                                                                                                                          | ................................................................35                                       |
| 2.3.7. Conclusion on the non-clinical aspects................................................................38                                                                |                                                                                                          |
| 2.4. Clinical aspects ..................................................................................................39                                                     |                                                                                                          |
| 2.4.1. Introduction....................................................................................................39                                                      |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................41                                                         |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................41                                                            |                                                                                                          |
| 2.4.4. Updated data on PD parameters: 13 December 2018...........................................51                                                                            |                                                                                                          |
| 2.4.5. Discussion on clinical pharmacology...................................................................52                                                                |                                                                                                          |
| Medicinal 2.4.6. Conclusions on clinical pharmacology.................................................................54                                                       |                                                                                                          |
| 2.5. Clinical efficacy                                                                                                                                                         | ..................................................................................................55     |
| 2.5.1. Dose response studies......................................................................................55                                                           |                                                                                                          |
| 2.5.2. Main studies                                                                                                                                                            | ...................................................................................................69    |
| 2.5.3. Updated data on efficacy parameters: 13 December 2018                                                                                                                   | ....................................95                                                                   |
| 2.5.4. Discussion on clinical efficacy..........................................................................                                                               | 101                                                                                                      |
| 2.5.5. Conclusions on the clinical efficacy...................................................................                                                                 | 105                                                                                                      |
| 2.6. Clinical safety                                                                                                                                                           | .................................................................................................. 105   |
| 2.6.1. Updated data on safety: 13 December 2018 (Studies HGB-205, HGB-206, LTF-303)........................................................................................... | HGB-207, 118                                                                                             |
| HGB-212, and 2.6.2. Discussion on clinical safety                                                                                                                              | ............................................................................ 119                         |
| 2.6.3. Conclusions on the clinical safety.....................................................................                                                                 | 122                                                                                                      |
| ......................................................................................                                                                                         |                                                                                                          |
| 2.7. Risk Management Plan                                                                                                                                                      | 124                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 2.8. Pharmacovigilance............................................................................................     | 129   |
|------------------------------------------------------------------------------------------------------------------------|-------|
| 2.9. New Active Substance.......................................................................................       | 129   |
| 2.10. Product information ........................................................................................     | 130   |
| 2.10.1. User consultation.........................................................................................     | 130   |
| 2.10.2. Labelling exemptions....................................................................................       | 130   |
| 2.10.3. Additional monitoring ...................................................................................      | 130   |
| 3. Benefit-Risk Balance............................................................................130                 |       |
| 3.1. Therapeutic Context .........................................................................................     | 130   |
| 3.1.1. Disease or condition.......................................................................................     | 130   |
| 3.1.2. Available therapies and unmet medical need.....................................................                 | 130   |
| 3.1.3. Main clinical studies .......................................................................................   | 131   |
| 3.2. Favourable effects ............................................................................................   | 131   |
| authorised 3.3. Uncertainties and limitations about favourable effects...........................................      | 132   |
| 3.4. Unfavourable effects.........................................................................................     | 133   |
| 3.5. Uncertainties and limitations about unfavourable effects .......................................                  | 134   |
| 3.6. Effects Table.................................................................................................... | 135   |
| 3.7. Benefit-risk assessment and discussion...............................................................             | 136   |
| 3.7.1. Importance of favourable and unfavourable effects............................................                   | 136   |
| 3.7.2. Balance of benefits and risks...........................................................................        | 137   |
| longer 3.7.3. Additional considerations on the benefit-risk balance .........................................          | 137   |
| 3.8. Conclusions ..................................................................................................... | 138   |
| 4. Recommendations...............................................................................138                   |       |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| aa              | amino acid                                               |
|-----------------|----------------------------------------------------------|
| Ab              | antibody                                                 |
| AE              | adverse event                                            |
| allogeneic HSCT | allogeneic haematopoietic stem cell transplantation      |
| ALT             | alanine aminotransferase                                 |
| AS              | active substance                                         |
| AST             | aspartate aminotransferase                               |
| ATMP            | advanced therapy medicinal product                       |
| AUC             | area under the curve                                     |
| BFU             | burst-forming units - erythroid                          |
| BM              | bone marrow                                              |
| BME             | authorised bone marrow engraftment                       |
| c/dg            | copies per diploid genome                                |
| CAT             | Committee for Advanced Therapies                         |
| CFC             | colony-forming cell                                      |
| CI              | confidence interval                                      |
| CKD-EPI         | longer Chronic Kidney Disease Epidemiology Collaboration |
| CPPs            | critical process parameters                              |
| CQAs            | critical quality attributes                              |
| CSR             | clinical study report                                    |
| DLco            | no diffusing capacity of the lungs for carbon monoxide   |
| DMSO            | dimethyl sulfoxide                                       |
| DNA             | deoxyribonucleic acid                                    |
| DP              | drug product                                             |
| DP VCN          | drug product vector copy number                          |
| EC              | European Commission                                      |
| ELISA           | product enzyme-linked immunosorbent assay                |
| EMA             | European Medicines Agency                                |
| EOI             | events of interest                                       |
| EoP             | End-of-production                                        |
| EU              | European Union                                           |
| EURD            | European Union reference date                            |
| FEP             | fluorinated ethylene propylene                           |
| Medicinal FP    | finished product                                         |
| GCP             | Good Clinical Practice                                   |
| G-CSF           | granulocyte-colony stimulating factor                    |
| GFR             | glomerular filtration rate                               |
| GLP             | Good Laboratory Practice                                 |
| GVHD            | graft-vs-host disease                                    |
| Hb              | haemoglobin                                              |
| HbA             | haemoglobin A                                            |
| HbA T87Q        | haemoglobin containing β A-T87Q -globin                  |

<div style=\"page-break-after: always\"></div>

| HbF                   | fetal haemoglobin                                                  |
|-----------------------|--------------------------------------------------------------------|
| HBV                   | hepatitis B virus                                                  |
| HCV                   | hepatitis C virus                                                  |
| HGVS                  | Human Genome Variation Society                                     |
| HIV                   | human immunodeficiency virus                                       |
| HIV-1                 | human immunodeficiency virus type-1                                |
| HLA                   | human leukocyte antigen                                            |
| HPC-A                 | hematopoietic progenitor cells obtained by apheresis               |
| HPLC                  | high-performance liquid chromatography                             |
| HRQoL                 | health-related quality of life                                     |
| HSC                   | haematopoietic stem cell                                           |
| HSCT                  | haematopoietic stem cell transplant(ation)                         |
| HTA                   | authorised health technology assessment                            |
| HTLV-1                | human T-lymphotrophic virus-1                                      |
| IL                    | interleukin                                                        |
| IL- 2Rγ               | interleukin-2 receptor gamma                                       |
| INN                   | international nonproprietary name                                  |
| IPC                   | in-process control                                                 |
| IS                    | integration site(s)                                                |
| ISA                   | longer integration site analysis/analyses                          |
| ITS                   | interrupted time series                                            |
| ITT                   | Intent-to-Treat                                                    |
| IV                    | intravenous                                                        |
| IVIM                  | in vitro immortalisation                                           |
| LAM-PCR               | product no linear amplification-mediated polymerase chain reaction |
| LCR                   | locus control region                                               |
| LIC                   | liver iron content                                                 |
| Lin-                  | lineage-depleted                                                   |
| LTC-IC                | long-term culture-initiating cell                                  |
| LT-HSCs               | long-term hematopoietic stem cells                                 |
| LVV                   | lentiviral vector                                                  |
| Medicinal %LVV+ cells | percentage of cells containing lentiviral vector sequences         |
| MAA                   | Marketing Authorisation Application                                |
| MAH                   | Marketing Authorisation Holder                                     |
| MCB                   | master cell bank                                                   |
| MDS                   | myelodysplastic syndrome                                           |
| MedDRA                | Medical Dictionary for Regulatory Activities                       |
| MRI                   | magnetic resonance imaging                                         |
| NC                    | not calculated                                                     |
| NE                    | neutrophil engraftment                                             |
| NOR                   | normal operating range                                             |
| nr                    | non-restrictive                                                    |
| NSG                   | NOD scid gamma                                                     |
| PAGE                  | polyacrylamide gel electrophoresis                                 |
| PAR                   | proven acceptable range                                            |

<div style=\"page-break-after: always\"></div>

| PB VCN   | peripheral blood vector copy number                                     |
|----------|-------------------------------------------------------------------------|
| PBMC     | peripheral blood mononuclear cell                                       |
| PCR      | polymerase chain reaction                                               |
| PCS      | potentially clinically significant                                      |
| PD       | pharmacodynamics                                                        |
| PE       | platelet engraftment                                                    |
| PIP      | paediatric investigation plan                                           |
| PK       | pharmacokinetics                                                        |
| POC      | proof-of-concept                                                        |
| PPQ      | process performance qualification                                       |
| pRBC     | packed red blood cell                                                   |
| QoL      | quality of life                                                         |
| qPCR     | quantitative polymerase chain reaction                                  |
| QRD      | Quality Review of Documents                                             |
| RBC      | red blood cell                                                          |
| RCL      | replication competent lentivirus                                        |
| RMP      | Risk Management Plan                                                    |
| RP-HPLC  | longer authorised reversed-phase high-performance liquid chromatography |
| RPR      | rapid plasma reagin                                                     |
| SAE      | serious adverse event                                                   |
| SAP      | Statistical Analysis Plan                                               |
| SCD      | sickle cell disease                                                     |
| SEP      | no Successful Engraftment Population                                    |
| SIN      | self-inactivating                                                       |
| SmPC     | Summary of Product Characteristics                                      |
| SOC      | system organ class                                                      |
| SOE      | schedule of events                                                      |
| SOP      | product standard operating procedure                                    |
| TDT      | transfusion- dependent β -thalassaemia                                  |
| TI       | transfusion independence                                                |
| TP       | Medicinal Transplant Population                                         |
| TR       | transfusion reduction                                                   |
| ULN      | upper limit of normal                                                   |
| VCN      | vector copy number                                                      |
| VOD      | veno-occlusive liver disease                                            |
| VSV-G    | vesicular stomatitis virus glycoprotein G                               |
| WBC      | white blood cell                                                        |
| WCB      | working cell bank                                                       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant bluebird bio (Netherlands) B.V. submitted on 21 August 2018 an application for marketing authorisation to the European Medicines Agency (EMA) for Zynteglo, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No. 726/2004.

Zynteglo was designated as an orphan medicinal product EU/3/12/1091 on 24 January 2013 in the following condition: treatment of ß-thalassaemia intermedia and major.

- If confirmed by further clinical investigations, the proposed product, Zynteglo, has the potential to exhibit an advantageous safety profile compared to patients treated with allogeneic haematopoietic stem cell transplantation (allogeneic HSCT) with a reduced risk of graft-versushost disease (GVHD), opportunity not to administer immunosuppressive agents, and a lower risk of immune-mediated graft rejection with an autologous transplantation is argued to be lower.  As compared to treatment using chronic pRBC transfusions, there is no risk of sensitisation to alloantigens and reduced risk of increased iron burden.
- Medicinal product no longer authorised Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Zynteglo as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the Orphan maintenance assessment report published under the 'Assessment history' tab on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/zynteglo Zynteglo was granted eligibility to PRIME on 15 September 2016 in the following indication: treatment of transfusion-dependent ß-thalassaemia. Eligibility to PRIME was granted at the time in view of the following: · The therapeutic armamentarium for the treatment of ß-thalassaemia can be considered insufficient. The symptomatic approach of transfusions combined with iron chelation therapy may result in a certain improvement of life expectancy. The challenges with regard to side effects, insufficiency of a non-curative approach as well as non-adherence as a result of the burden of treatment remain. The only curative treatment option, allogeneic haematopoietic stem cell transplant (HSCT), is associated with severe side-effects and reactions. The treatment of transfusion-dependent ß-thalassaemia (TDT), therefore, represents an unmet medical need. · Clinical data from 22 patients at that time suggested persistency of lentiviral vector (LVV) sequences in patients' peripheral blood cells with all patients producing therapeutic haemoglobin containing β A-T87Q -globin (HbA T87Q ), associated with clinically relevant improvements. The majority of patients producing varying amounts of endogenous HbF, HbE, and/or HbA, no longer required transfusion support by 6 months after drug product infusion in Phase 1/2 studies. Patients with at least 6 months follow-up w ho had β 0 /β 0  genotype and therefore no endogenous production of β -globin, showed a reduction in volume and/or frequency of transfusions requirements in the post-engraftment period compared to the 24 months prior to enrolment.
- The potential to significantly address the unmet medical need was therefore supported by the proof-of-concept (POC) both in non-clinical and clinical investigations as well as its correlation to clinical outcome parameters linked to clinical improvement and potential long-term wellbeing in patients.

<div style=\"page-break-after: always\"></div>

The applicant applied for the following indication: 'Adolescents and adults with transfusion-dependent β -thalassaemia (TDT) who do not have a β 0 mutation at both alleles of the β -globin ( HBB ) gene (i.e., patients  with  a  nonβ 0 /β 0   genotype),  for  whom  haematopoietic  stem  cell  (HSC)  transplantation  is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.'

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC as amended - complete and independent application

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own  tests and studies and/or bibliographic literature substituting/supporting certain test(s) or studies.

The applicant requested the active substance \"autologous CD34+ cell-enriched population that contains haematopoietic stem cells transduced with lentiviral vector encoding the β A-T87Q -globin gene\" contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

Medicinal product no longer authorised Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No. 1901/2006, the application included an EMA Decision(s) P/0067/2018 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP P/0067/2018 was not yet completed as some measures were deferred. Information relating to orphan market exclusivity Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No. 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication. Applicant's request(s) for consideration Conditional marketing authorisation and Accelerated assessment The  applicant  requested  consideration  of  its  application  for  a  conditional  marketing  authorisation  in accordance with Article 14-a of the above-mentioned Regulation. The applicant requested accelerated assessment in accordance to Article 14(9) of Regulation (EC) No. 726/2004. New active Substance status

## Scientific recommendation on Classification

The applicant bluebird bio (Netherlands) B.V. submitted on 21 August 2018 an application for Scientific recommendation  on  Classification  to  the  EMA  for  Zynteglo,  which  was  designated  as  an  Advanced Therapy Medicinal Product EMA/989166/2011 on 19 December 2011.

<div style=\"page-break-after: always\"></div>

## PRIME support

Upon granting of eligibility to PRIME, the Rapporteur was appointed by the CHMP. A kick-off meeting was  subsequently  organised  with  the  EMA,  Rapporteur,  assessors'  team  and  experts  from  relevant scientific committees. The objective of the meeting was to discuss the development programme and regulatory strategy for the product. The applicant was recommended to address the following key issues through relevant regulatory procedures: change in the manufacturing process and increase in potency attributes,  environmental risk  assessment,  characterisation of  transfusion  requirements  change over time for paediatric patients and pharmacodynamic model, post-authorisation registry, proposals for postauthorisation specific obligations, and maintenance of the orphan designation.

Medicinal product no longer authorised Protocol Assistance The applicant received Protocol Assistance from the CHMP on the development for the indication from the CHMP on: · 25 April 2015 (EMEA/H/SAH/038/1/2015/PA/SME/ADT/II), · 23 July 2015 (EMEA/H/SA/3150/1/2015/PA/SME/ADT/II), · 16 September 2016 (EMEA/H/SA/3150/1/FU/1/2016/PA/SME/ADT/I), · 21 April 2017 (EMEA/H/SA/038/2/2017/PA/SME/ADT/PR/III), and · 9 November 2017 (EMEA/H/SA/3150/1/FU6/2017/PA/SME/ADT/PR/I). The Protocol Assistance pertained to the following quality aspects: · Advice on manufacturing aspects and their impact on clinical trial material, particularly following changes to manufacturing site and improvement of the manufacturing process: robustness of characterisation and analytical methods, release and stability, specifications for clinical trials material, technology transfer, number of lots for Marketing Authorisation Application (MAA) submission, timing of data submission, qualification of the apheresis collection centres and traceability. The Protocol Assistance pertained to the following clinical aspects in the context of parallel EMA/health technology assessment (HTA) advice: · The suitability of data acquired with clinical trial material from the refined manufacturing process to support an MAA, including number of treated patients and their genotype. · Adequacy of the proposed endpoints. · The earliest time point for efficacy and safety data to support submission of a conditional MAA. · Statistical analysis plans. · Extrapolation models for prediction of both long-term efficacy and for inclusion of children in the trials. · Design of confirmatory trials and open label real-world monitoring to investigate long-term efficacy and safety. · Proposed pharmacovigilance and risk minimisation plans.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

CAT Rapporteur: Johannes Hendrikus Ovelgonne

CAT Co-Rapporteur: Violaine Closson Carella

CHMP Coordinator (Rapporteur): Paula   Boudewina van Hennik

CHMP Coordinator (Co-Rapporteur): Alexandre Moreau

<div style=\"page-break-after: always\"></div>

| Accelerated Assessment procedure was agreed-upon by CAT and CHMP on                                                                                                                                                                                                       | 26 July 2018     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                                                                                                                                                                  | 4 October 2018   |
| The Rapporteur's first Assessment Report was circulated to all CAT and CHMP members on                                                                                                                                                                                    | 21 December 2018 |
| The Co-Rapporteur's first Assessment Report was circulated to all CAT and CHMP members on                                                                                                                                                                                 | 21 December 2018 |
| In accordance with Article 6(3) of Regulation (EC) No. 726/2004, the Rapporteur and Co-Rapporteur declared that they had completed their assessment report in less than 80 days                                                                                           | 21 December 2018 |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                                                                                                       | 7 January 2019   |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                                                                                                  | 17 January 2019  |
| The following GCP inspection(s) were requested by the CHMP and their outcome taken into consideration as part of the Quality/Safety/Efficacy assessment of the product:                                                                                                   | authorised       |
| no longer - A GCP inspection of the Clinical Trial HGB-207 at 3 sites, an investigator site in the USA, an investigator site in Thailand and the sponsor in the USA, between 4 December 2018 and 4 January 2019. The outcome of the inspections carried out was issued on | 23 January 2019  |
| The CAT agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                                                                                                    | 25 January 2019  |
| The applicant submitted the responses to the CAT consolidated List of Questions on                                                                                                                                                                                        | 20 February 2019 |
| product The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CAT and CHMP members on                                                                                                                                   | 8 March 2019     |
| The Rapporteurs circulated the updated Joint Assessment Report on the responses to the List of Questions to all CAT and CHMP members on                                                                                                                                   | 15 March 2019    |
| Medicinal The CAT, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Zynteglo on                                                                         | 22 March 2019    |
| EC requested clarifications on the SmPC to the CAT/CHMP                                                                                                                                                                                                                   | 3 April 2019     |
| The CAT, in the light of the overall data submitted and the scientific discussion within the Committee, readopted a positive opinion for granting a marketing authorisation to Zynteglo on                                                                                | 17 April 2019    |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, readopted a positive opinion for granting a marketing authorisation to Zynteglo on                                                                               | 26 April 2019    |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Zynteglo is indicated for the treatment of patients 12 years and older with transfusiondependent β -thalassaemia (TDT) who do not have a β 0 /β 0  genotype, for whom HSC transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.

Medicinal product no longer authorised Per the 2014 Thalassaemia International Federation (TIF) Guidelines (Cappellini et al. 2014), the severity of disease for symptomatic patients is evaluated based on transfusion requirements. As such, patients wi th β -thalassaemia are classified either as transfusion-dependent or as non-transfusion dependent. Another classification of disease severity, which was used exclusively until recently, divided most patients with symptomatic disease into two groups: β -thalassaemia major and β -thalassaemia intermedia, with the  former  group  being  considered  more  severe,  including  patients  who  were  started  on  regular transfusions soon after birth, and the latter being considered less severe, including patients started on regular transfusions later in childhood or those only requiring intermittent transfusions throughout life. Transfusiondependent patients include those who have been historically diagnosed with β -thalassaemia major and some patients who are considered to have β -thalassaemia intermedia. 2.1.2. Epidemiology The incidence and prevalence of β -thalassaemia are geographically variable, with endemic populations primarily found in South Asia, the Middle East, North Africa, and Southern Europe (Colah et al. 2010; Galanello and Origa 2010; Cappellini et al. 2014). The β E  mutation is very common in people of Southeast Asian descent (Williams and Weatherall 2012). While migration is changing the global distribution of the disease,  β -thalassaemia  is  still  a  rare  disease  in  most  of  Europe.  The  total  annual  incidence  of symptomatic individuals is estimated at 1 in 100,000 throughout the world (Galanello and Origa 2010). Reliable sources of multinational epidemiology data in the EU for TDT are not widely available, which is compounded by differing terminologies used to describe transfusion dependence. The prevalence of TDT is higher in endemic Southern European countries such as Italy, where it is estimated that there are approximately 6000 cases of TDT (Angelucci et al. 2016). Northern European, non-endemic countries typically have a prevalence of &lt;1000 (Angelucci et al. 2016). Based on England National Health Service (NHS) Hospital Episode Statistics (HES) database data, 1,007 β -thalassaemia patients in England were identified  with  at  least  10  years  of  medical  records  (April  2005-March  2016).  Of  these,  524  were diagnosed with TDT. These numbers suggest a conservative estimate of prevalence in the EU of at least 10,000 patients.

Although  survival  with β -thalassaemia  has  dramatically  improved  over  the  past  20  years  due  to improvements  in  transfusion  and  iron  chelation  management  and  monitoring,  iron  overload  and associated  morbidities  remain  a  major  challenge  in  the  management  of  TDT  and  treatment-related complications are the primary source of mortality (Cappellini et al. 2014). Mortality for patients with TDT remains significantly increased compared to that of the general population, as exemplified by a historical prospective study in Greece of patients with TDT in which overall survival until the age of 50 was 65%

<div style=\"page-break-after: always\"></div>

and the standardised mortality rate (standardised for sex and ages 20 to 40 years) compared to the general population was 13.5 from 2002 to 2008 (Ladis et al. 2011).

## 2.1.3. Biologic features

Hundreds of β -thalassaemia mutations have been described that affect transcription, RNA processing, or translation of the β -globin gene and could result in clinical presentation of β -thalassaemia (Cao and Galanello 2010). Null mutations that eliminate the production of functional β -globin are referred to as β 0 mutations. Mutations that reduce expression of functional β -globin are referred to as β +  and produce varying quantities of functional β -globin. Genotypes of patients with β -thalassaemia are usually denoted according to these c lasses of mutation (i.e., β 0 /β 0 , β 0 /β + , β + /β + ). Certain common mutations may have their own designation, such as β E , that results in reduced production of β -globin because of alternative splicing,  as  well  as  a  single  amino  acid  change  (glutamic  acid  to  lysine  at  codon  26)  that  alters  its electrophoretic mobility. All mutations that are not null mutations are classified as nonβ 0   mutations, including β E . β -thalassaemia is an autosomal recessive disorder.

Zynteglo  is  an  Advanced  Therapeutic  Medicinal  Product  (ATMP)  and  was  classified  by  the  EMA Committee for Advanced Therapies (CAT) as a gene therapy medicinal product (EMA/505476/2012). The  active  substance  of  Zynteglo  is  an  autologous  CD34+  cell-enriched  population  that  contains hematopoietic stem cells transduced with lentiviral vector encoding the β A-T87Q -globin gene.

Medicinal product no longer authorised 2.1.4. Clinical presentation, diagnosis and stage/prognosis Absence or reduction in β -globin production results in an accumulation of excess uncomplexed α -globin chains  in  erythroblasts. The clinical  implications  of  the  α -globin/β -globin  imbalance  are  two-fold:  1) patients lack sufficient red blood cells (RBCs) and haemoglobin (Hb) to effectively transport oxygen throughout  the  body,  resulting  in  severe  anaemia;  and  2)  ineffective  erythropoiesis  can  lead  to morbidities via splenomegaly, marrow expansion, concomitant bone deformities, and iron overload. Individuals homozygous or compound heterozygous for mutant alleles are clinically heterogeneous and present  with  disease  that  ranges  in  severity  from  asymptomatic  to  transfusion-dependent  and  lifeshortening. The severity of β -thalassaemia is also a function of the degree of imbalance in the production of α - and nonα -globins. In its most severe form, TDT causes patients to have life-threatening anaemia requiring frequent and lifelong pRBC transfusions for survival, resulting in unavoidable iron overload which in turn, in the absence of appropriate and maintained iron chelation, can cause serious cardiac, liver, and endocrine comorbidities, and shortened lifespan compared to the general population. Patients who have been inadequately transfused and/or chelated can present with serious complications including cardiomyopathy,  pulmonary  hypertension,  osteoporosis,  skeletal  deformities,  arthropathy,  hepatosplenomegaly, delayed puberty and gonadal failure (Rund and Rachmilewitz 2005). Even with the correct application  of  blood  transfusions  and  chelation  treatments,  patients  with β -thalassaemia have many complications (Bonifazi et al. 2017). 2.1.5. Management About the product

Zynteglo is a gene therapy medicinal product designed to provide functional β -globin to patients with TDT, thus circumventing their need for chronic pRBC transfusions.

The applicant applied for the following indication: 'Adolescents and adults with transfusion-dependent β -thalassaemia (TDT) who do not have a β 0 mutation at both alleles of the β -globin ( HBB ) gene (i.e., patients  with  a  nonβ 0 /β 0   genotype),  for  whom  haematopoietic  stem  cell  (HSC)  transplantation  is

<div style=\"page-break-after: always\"></div>

appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.'

The CAT and CHMP agreed to the following indication:  'Zynteglo  is  indicated  for  the  treatment  of patients 12 years and older with transfusiondependent β -thalassaemia (TDT) who do not have a β 0 /β 0 genotype,  for  whom  haematopoietic  stem  cell  (HSC)  transplantation  is  appropriate  but  a  human leukocyte antigen (HLA)-matched related HSC donor is not available.'

It is intended for autologous use and should only be administered once. It is for intravenous infusion. The minimum recommended dose of Zynteglo is 5 × 10 6  CD34+ cells/kg. In clinical studies, doses up to 20 × 10 6  CD34+ cells/kg have been administered. The minimum recommended dose is the same for adults and adolescents 12 years of age and older (see Summary of Product Characteristics [SmPC]).

- The unmet medical need has been addressed. The therapeutic armamentarium for the treatment of ß-thalassaemia can be considered insufficient. The symptomatic approach of transfusions combined with iron chelation therapy may result in a certain improvement of life expectancy. The challenges with regard to side effects, insufficiency of a non-curative approach as well as non-adherence as a result of the burden of treatment remain. The only curative treatment option, allogeneic HSCT, is associated with severe side-effects and reactions. The treatment of TDT, therefore, represents an unmet medical need.

Medicinal product no longer authorised It  must  be  administered  in  a  qualified  treatment  centre  by  a  physician(s)  with  experience  in  HSC transplantation and in the treatment of patients with TDT (see section 4.2 of the SmPC). Manufacture of Zynteglo involves the isolation of CD34+ HSCs from the patient, followed by transduction of  these  cells ex  vivo with  BB305  lentiviral  vector  to  introduce  the β A-T87Q -globin  gene.  Successful transduction results in the integration of the β A-T87Q -globin gene into the genomic DNA of the patient's HSCs.  After  the  patient  has  undergone  myeloablation,  the  patient  receives  Zynteglo  via  a  single intravenous  infusion,  with  the  aim  of  reconstituting  their  HSC  repertoire  with  cells  stably  carrying integrated copies of the transgene. After engraftment and differentiation of the transduced HSCs in the patient, expression of β A-T87Q -globin is driven by the globin locus control region, which determines that genes  under  its  control  are  expressed  specifically  in  cells  of  the  erythroid  lineage.  This  treatment therefore has the potential to correct the α -globin/β -globin imbalance in erythrocytes and allow for the production of sufficient endogenous Hb to correct anaemia and enable transfusion independence. Type of Application and aspects on development The CHMP and CAT agreed to the applicant's request for an accelerated assessment as the product was considered to be of major public health interest. This was based on the preliminary results, the novel mode of action and the unmet medical need. The applicant requested consideration of its application for a Conditional Marketing Authorisation in accordance with Article 14-a of the above-mentioned Regulation, based on the following criteria: · The benefit-risk balance is positive. · It is likely that the applicant will be able to provide comprehensive data. The applicant will be able to  provide  comprehensive  data  relevant  to  the  initial  indication  including  long-term  safety  and efficacy data for adult and adolescent patients with TDT who have a nonβ 0 /β 0  genotype, post initial approval from the following sources: Phase 3 Study HGB-207, Phase 3 Study HGB-212 and longterm follow-up Study LTF-303.

- The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. The majority of patients with TDT who have a nonβ 0 /β 0 genotype treated with Zynteglo in Studies HGB-204 and HGB-205 have achieved TI (11 out of 14;

<div style=\"page-break-after: always\"></div>

78.6%). For Study HGB-207, 4 out of 5 TI-evaluable patients achieved TI (data cut: 13 December 2018), and 6 additional patients from the ongoing Study HGB-207 with available data at Month 6 produced close to 8 g/dL or more HbA T87Q at Month 6 and are predicted to achieve TI with ≥98% probability.  Achievement  of  TI  is  clinically  meaningful,  eliminating  the  need  for  regular  blood transfusions and associated comorbidities due to iron overload.

## 2.2. Quality aspects

## 2.2.1. Introduction

Medicinal product no longer authorised The  finished  product  (FP)  Zynteglo  (formerly  referred  to  as  LentiGlobin  for  TDT)  is  presented  as  a dispersion  for  infusion  containing  1.2  to  20  x  10 6   cells/mL  of  an  autologous  CD34+  cell-enriched population  that  contains  hematopoietic  stem  cells  (HSCs)  transduced  with  lentiviral  vector  (LVV) encoding the β A-T87Q -globin gene as active substance (AS). The only other ingredient is CryoStor CS5. The product is available in a 20 mL cryopreservation bag (or multiple bags), made of fluorinated ethylene propylene (FEP). 2.2.2. Active Substance The  active  substance  (AS)  consists  of  an  autologous  CD34+  cell-enriched  population  that  contains hematopoietic stem cells (HSCs) transduced with lentiviral vector (LVV) encoding the β A-T87Q -globin gene and is produced from two starting materials, the BB305 lentiviral vector and autologous hematopoietic progenitor cells obtained by apheresis (HPC-A). The section on the active substance is separated into two parts; part 1 for the LVV and part 2 for the transduced autologous cells. The active substance (transduced autologous cells) is formulated into the FP by formulation in the cryopreservation solution and filling into cryopreservation bags. General information (lentiviral vector) BB305 LVV is a replication-defective, self-inactivating (SIN), third-generation human immunodeficiency virus type-1 (HIV-1)-based LVV pseudotyped with envelope protein of the vesicular stomatitis virus (i.e., vesicular  stomatitis  virus  glycoprotein  G;  VSVG),  carrying  the  human  β -globin  gene  with  a  single modification  at  codon  87  under  the  transcriptional  control  of  the  erythroid  specific  human  β -globin promoter and erythroid specific enhancer elements (DNase I hypersensitive sites HS2, HS3, and HS4) of the β -globin locus control region (see Figure 1) . The β A-T87Q -globin variant can be distinguished from the wildtype β A -globin by HPLC. Figure 1: BB305 LVV Provirus Sequence Map

<!-- image -->

Figure definitions: dU3, promoter deleted unique 3'; R, repeat; U5 unique 5'; Ψ+, packaging signal; cPPT, central polypurine tract; RRE, rev responsive element; UTR, untranslated region; E3, Exon3; I2, Intron2; E2*, Exon2 with threonine87glutamine codon; I1, intron1; E1, Exon1; Prom, promoter; HS2 -HS3 -HS4, hypersensitive site 2,3,4; ppt, polypurine tract .

BB305 LVV contains proteins responsible for forming the LVV particle that are encoded by the helper plasmids that are used to transfect human embryonic kidney (HEK293T) cells during LVV production.

<div style=\"page-break-after: always\"></div>

## Manufacture, characterisation and process controls (lentiviral vector)

## LVV Manufacturing process

BB305 LVV is produced by transient transfection. BB305 LVV buds from the production cells, is harvested, purified via chromatography, and formulated prior to frozen storage.

The LVV manufacturing process begins with thawing HEK293T cells from the working cell bank (WCB). These cells are transfected with plasmid BB305 and packaging plasmids and incubated at a specified temperature and duration.

Medicinal product no longer authorised Subsequently,  the  supernatants  containing  the  LVV  are  collected.  This  crude  harvest  is  clarified  by filtration, purified by chromatography, concentrated and formulated. The sterile filtered BB305 LVV is filled in vials. For each process step, critical process parameters (CPPs), non-CPPs, and in-process controls (IPCs) are provided. The parameters are controlled within specified ranges. LVV Control of materials Sufficient  detail  was  provided  on  the  raw  and  starting  materials  used  and  their  quality  control  is appropriately described. The testing of the master cell bank (MCB) and WCB and end-of-production (EoP) cells is in agreement with Ph. Eur. 5.2.3 and Ph. Eur. 5.14. Plasmids An  overview  of  the  sites  involved  in  plasmid  manufacturing  and  a  detailed  description  of  the manufacturing  process  and  its  development,  control  and  validation  is  provided.  Each  plasmid  is manufactured from a bacterial WCB and further purified. The generation and testing of the cell banks (MCB and WCB), including testing EoP cells is described in detail. The controls of the plasmids are in agreement with Ph. Eur. 5.14 and the section on bacterial cells used for manufacture of plasmid vectors for human use. Release specifications for the plasmids include tests for purity), strength, identity and safety. Testing of the MCB, WCB and EoP cells is in agreement with the requirements of Ph. Eur. 5.14. Method descriptions and validation summaries are provided. Generally  stability  of  the  plasmids  over  a  shelf  life  of  36  months  at  ≤ -65°C  has  sufficiently  been demonstrated. LVV Control of critical steps and intermediates Process characterisation  studies  were  deployed  to  identify  the  impact  of  the  process  parameters  on critical  quality  attributes  (CQAs)  and  establish  proven  acceptable  range  (PAR)  for  the  process parameters. The choice and ranges of the various process parameters studied are considered appropriate.

## LVV Process validation

The BB305  LVV  commercial  manufacturing  process was  validated.  BB305  LVV  batches  were manufactured  under  a  prospectively  established  validation  protocol.  All  measured  parameters  and attributes  met  the  pre-defined  protocol  acceptance  criteria.  All  process  parameters  were  within  the normal operating range (NOR). All process parameter and performance attribute results met the protocol acceptance criteria.

<div style=\"page-break-after: always\"></div>

A media-fill program is implemented to confirm the ability to conduct aseptic processing. The sterilizing filter was validated for its intended use.

Qualification of shipping of LVV to long-term storage facilities was demonstrated.

## LVV Manufacturing process development

The  manufacturing  process  history  has  been  adequately  described.  Comparability  data,  including extensive characterisation of transduced cells, were provided.

A risk assessment on the potential extractables of single-use product-contact materials was provided and demonstrated that an extractable study was not necessary.

Medicinal product no longer authorised LVV Characterisation Characterisation testing of BB305 LVV was performed. This elucidation includes the analysis of particle size distribution, potential aggregation, particle buoyant  density, particle morphology,  protein composition, total nanoparticle count, and activity as assessed by the transduction of CD34+ target cells. These revealed some minor differences between the LVV of the clinical and commercial process. Relevant  process-related  impurities  have  been  identified.  Their  removal  is  addressed  in  process validation and characterisation studies. Specifications (lentiviral vector) The release and stability specifications for BB305 LVV cover potency, identity, safety, purity, appearance, and quality. Replication  competent  lentivirus  (RCL)  test  is  in  place  and  appropriately  validated.  The  main consideration with respect to RCL safety of the product is the design of the LVV, based on which the chance of formation of RCL is considered very remote (also see ERA assessment) and the clinical data that have not given any indication of RCL. The applicant has provided further justifications for the limits proposed for each of the CQA. Quantitative acceptance criteria are based on data from manufacturing history. The Applicant committed to review the specifications again when additional batches have been manufactured. LVV Batch analyses Release testing results are provided for BB305 LVV batches. Three consecutive BB305 LVV batches were manufactured under a prospectively established validation protocol. LVV Reference standard The reference standard was manufactured using the proposed commercial LVV manufacturing process. The qualification and characterisation tests and results, and the stability testing strategy of the reference standard are considered to be appropriate. LVV Container closure

BB305 LVV is filled into break-resistant, transparent, plastic vials that are stoppered with chlorobutyl, elastomeric stoppers and capped with flip-off, aluminium seals. Tests on extractables and leachables have been performed using appropriate worst-case conditions. The results of these tests have been provided during the procedure and gave no reason for concern; therefore, the container closure system can be accepted and considered to be appropriately qualified.

<div style=\"page-break-after: always\"></div>

## Stability (lentiviral vector)

The proposed shelf life for the lentiviral vector is 24 months frozen.

Stability  batches  have  been  placed  on  stability  at  the  intended  long-term  storage  condition  to demonstrate the biological and physical stability through the proposed 2 years shelf-life. Data from primary batches and supportive batches remain within specification.

The primary batches were also placed on stability at an accelerated storage condition. The results of these studies were completed and provided during assessment.

<!-- image -->

Medicinal product no longer authorised General information (transduced autologous cells) The AS consists of an autologous CD34+ cell-enriched population that contains hematopoietic stem cells transduced with BB305  lentiviral vector (LVV) encoding  the β A-T87Q -globin gene  (international nonproprietary name [INN] request pending). The β A-T87Q globin gene is the human, adult, β A -globin gene with a glutamine amino acid residue substituted for a threonine at position 87. The mechanism of action is described as engraftment in the bone marrow (BM) of the transduced CD34+ HSCs and differentiation, to produce RBC containing biologically active β A-T87Q -globin that will combine with α -globin to produce functional Hb. Manufacture, characterisation and process controls (transduced autologous cells) Manufacturer The AS is manufactured and controlled at Apceth BioPharma GmbH, Ottobrunn, Germany. MIA and GMP certificate references are provided. The latest inspection was conducted on 2018-06-19. A QP declaration is also provided. Manufacturing process The  manufacturing  process  starts  from  the  starting  material,  the  haematopoietic  progenitor  cells obtained by apheresis (HPC-A) and follows a continuous process up to formulation and filling of the FP. HPC-A  is  subject  to  a  platelet  wash  and  CD34+  cell  enrichment.  The  purpose  of  the  CD34+  cell enrichment step is to separate CD34+ cells from other cells. After  enrichment,  a  pre-transduction  stimulation  is  performed.  The  purpose  of  the  Pre-Transduction Stimulation Culture process step is to make cells receptive to transduction. The cells are then transduced with BB305 LVV. Cells are then washed and re-suspended. These washed cells constitute the active substance. The process is continuous until formulation of the FP. No reprocessing is described.

Information on buffers, media and objectives of the individual process steps are included.

Tabular overviews of CPPs and IPCs have been adequately described.

The description of the manufacturing process is considered to be adequate and sufficient information and detail in relation to process parameters targets and ranges for each step has been provided.

## Control of Materials

Raw materials

<div style=\"page-break-after: always\"></div>

An adequate overview of the compendial and non-compendial raw materials used in the active substance manufacturing process is provided.

Compendial raw materials of human origin have a marketing authorisation in the EU.

For all raw materials, representative certificates of analysis CoAs or CoCs are provided. In general, the provided information demonstrates appropriate quality of the raw materials.

Representative  certificates  of  analysis  for  the  non-equipment  product-contact  materials  have  been provided.

Medicinal product no longer authorised Two components of the active substance manufacturing process were identified for extractables testing through a risk assessment. From both materials some compounds were above the Analytical Evaluation Threshold (AET). For all extractable compounds the Maximum Acceptable Concentration (MAC) calculated on justified Permissive Daily Exposure (PDE) was greater than the estimated concentration within the extraction solution. Apheresis material HPC-A consists of autologous peripheral blood mononuclear cells (PBMCs) collected by apheresis from each patient following mobilisation of leukocytes. Apheresis is performed by apheresis collection centres (ACC) that are certified as either Tissue or Blood Establishments in accordance with national legislation implementing relevant EU Directives. Qualification of the apheresis centres by the Applicant involves apheresis  assessment,  quality  audits,  quality  agreement,  on-site  training  and  a  follow-up  and maintenance program. A brief description of the HPC-A collection process is provided. Collection of PBMCs is performed following standard operating procedures. The apheresis collection devices and kits are specified and CE-declarations of conformity are provided. Control of critical steps and intermediates The IPCs in the AS manufacturing process are defined. The actions taken in case an action limit is not met are sufficiently described and acceptable. The limits of the currently proposed IPCs are justified by in-process data from FP. Specified process steps were identified as critical. Process validation and/or evaluation As the manufacturing process of Zynteglo is continuous, process validation is discussed in the FP section. Manufacturing Process Development Development Several manufacturing process versions have been described during development. The nomenclature corresponds to FP manufactured for the initial clinical trial (Study HGB-205), and FP manufactured before (Study HGB-204) and after optimization of the manufacturing process (Study HGB-207 and 212).

The proposed manufacturing changes, and the steps to ensure that the clinical batches from earlier processes were representative of the clinical profile of refined process product, were discussed in 4 Protocol Assistance procedures prior to submission of the Marketing Authorisation application.

The results  of  studies  sufficiently  demonstrate  that  FP  manufactured  according  to  base  and  refined processes is comparable. The observed differences could be acceptable from a safety and efficacy point of view. Uncertainties were adequately addressed by the Applicant in response to the LoQ.

<div style=\"page-break-after: always\"></div>

It is sufficiently demonstrated that FP batches manufactured according to the refined process at different sites are comparable.

Medicinal product no longer authorised Changes made to the manufacturing process at the commercial manufacturing site were supported by data  that  demonstrate  that  consistent  potency  can  be  obtained.  Comparability  between  the  refined manufacturing process and the commercial manufacturing process was not sufficiently addressed. In response to questions, the Applicant indicates that the change was aimed to target VCNs to retain product efficacy while reducing theoretical risk of oncogenesis. The available data were, however, initially too limited to conclude on comparable product efficacy as it was insufficiently demonstrated that clinical data from base manufacturing process batches, can be considered representative of the commercial process. Tight  control  of  potency  attributes  (i.e.  within  the  range  of  refined  process  batches)  was  therefore considered necessary but was not provided by the proposed specifications. This issue was raised as a Major Objection because sub-potent batches are a considerable risk to the patient in case of sub-optimal efficacy because, based on the SmPC, the treatment cannot be repeated. In response, the Applicant agreed to revise the acceptance limits or provided further justification to maintain the proposed criteria for potency attributes. The Applicant provided a commitment to re-evaluate the acceptance criteria for potency attributes when batch release data from an additional 20 commercial FP batches are available. The re-evaluation will also consider the available clinical data and will aim to demonstrate that the release specification  acceptance  criteria  are  sufficient  to  ensure  consistent  clinical  efficacy  and  safety.  This commitment will be included as an Annex II condition. Control strategy A summary of the FP manufacturing process design and development, including classification of quality attributes  and  justification  for  IPCs  is  provided.  Assessment  of  criticality  of  process  parameters  and definition of their operational range was based on a risk estimate and process characterisation studies (DOE). Further detail was provided on the risk assessment and the characterisation studies during the procedure. The  provided  information sufficiently justifies  the  proposed  AS  process  parameter classification and PARs. Characterisation Functional characterisation Functional characterisation results demonstrate an increased in some potency attribute levels in batches manufactured according to the refined process compared to batches manufactured according to the base process. Differences  in  characterisation  results  were  observed  in  VCN  distribution  across  cell  populations  for refined and commercial process finished product lots as compared to base process lots. As cells with high VCN could be at higher risk of insertional mutagenesis, an acceptance criterion was introduced to ensure  the  distribution  of  VCN  was  adequately  controlled  within  the  range  of  clinical  batches  as requested. In this context, the Applicant has committed to provide the finalised data of the test method once available.

## Impurities

With  regard  to  product-derived  impurities,  extensive  phenotypic  characterization  was  performed, demonstrating that the percentage of cellular impurities is low.

The CD34+ cell and transduced cell levels are controlled at FP release.

## Specification (transduced cells)

No specification for the active substance (AS) is provided as the AS is manufactured and processed into FP without interruption. An AS reference standard is not required.

<div style=\"page-break-after: always\"></div>

As the manufacturing process of Zynteglo is continuous, no container closure system is described for the AS.

## Stability (transduced cells)

Zynteglo AS is manufactured and processed into the FP without interruption. Stability testing of the AS is not applicable.

## Comparability Exercise for Active Substance

See under manufacturing process development.

Medicinal product no longer authorised 2.2.3. Finished Medicinal Product Description of the product and pharmaceutical development Description and composition of the finished product: The FP is a dispersion for infusion, filled in one or two bags, each containing 1.2 to 20 x 10 6  cells/mL in 20 mL Cryostor CS5, a commercially available cryopreservation solution. Zynteglo is an autologous, advanced therapy medicinal product (ATMP) suitable for infusion and conveys functional copies of the β A-T87Q -globin gene in HSCs to myeloablated patients who have TDT. The applicant has provided key attributes and their control is included in the section on physicochemical and biological properties. The posology as described in SmPC is a minimum of 5 × 10 6  CD34+ cells/kg body weight. The patient population is limited to nonβ 0 /β 0  genotype, transfusion-dependent adolescents and adults. If the initial lot of FP for any patient does not contain the minimum cell dose, the patient may undergo additional  cycles  of  mobilization  and  apheresis  in  order  to  obtain  more  cells.  The  autologous  cells obtained from each additional cycle of mobilization and apheresis may be manufactured to produce an additional lot of FP. In this case, more than one lot would be used to make up the dose. Up to four bags of FP may be used per dose. Pharmaceutical development The Applicant has adequately justified the selection of CryoStor CS5 cryopreservation media as excipient for the formulation of the FP. An overview of the manufacturing process development has been provided (see also section on active substance above). Container closure system, microbiological attributes, and compatibility The primary container closures selected for the FP are sterile, individually packaged, single-use FEP bags. Sufficient information on the selection of the container closure system has been provided. The selected container closure system supports product stability and is expected to be suitable for its intended use.

<!-- image -->

The  suitability  of  the  primary  container  closure  was  determined  by  evaluating  the  biocompatibility, physiochemical, and extractables data provided by the manufacturer. Extractables testing was performed on the primary container closure in a solution simulating a worst-case organic extraction.

The Applicant has provided a brief discussion of relevant aspects for microbiological safety, including testing of the FP and the steam sterilized container, which is considered acceptable.

<div style=\"page-break-after: always\"></div>

## Manufacture of the product and process controls

## Manufacturer

The FP is manufactured at apceth BioPharma GmbH Ottobrunn, in Germany, directly in continuity of the AS manufacturing process.

## Description of the manufacturing process and process controls

To manufacture Zynteglo FP, the AS cells are resuspended in CryoStor CS5 at a concentration of 1.2 x 10 6  to 20 x 10 6  cells/mL and filled into cryopreservation bags. Each bag is placed in a secondary container and a chilled metal cassette, and frozen before being placed in the vapour phase of liquid nitrogen for storage. Upon request, the Applicant provided additional information on process parameters and their classification  and  the  justification  of  the  proposed  ranges.  The  provided  information  is  considered adequate and sufficiently justifies the proposed FP process parameters, process parameter classification and PARs.

Medicinal product no longer authorised Process validation and/or evaluation The  PPQ  study  was  performed  using  healthy  donor  cells.  This  approach  has  been  accepted.  Three consecutive FP batches were manufactured from apheresis material. The  PPQ  study  results  suggest  that  the  intended  commercial  manufacturing  process  is  capable  to consistently yield a product meeting the acceptance criteria. The available batch analysis data support consistency of the FP manufactured at the commercial site. Aseptic process simulation studies Aseptic  process  simulation  (media  fill  simulation)  was  successfully  completed  for  three  consecutive process simulation runs. It was confirmed that the media fill simulation covers all the aseptic processing steps. Shipping validation The shipping system used for transporting Zynteglo FP from the manufacturing facility to FP infusion centres within the European Union Regions has been qualified, taking a risk-based approach through Operational Qualification and Performance Qualification under worst case conditions. Control of excipients Information on the composition and specification of the excipient is provided. Ph. Eur. or equivalent quality of the ingredients is sufficiently demonstrated. Container closure system The  primary  container  closure for Zynteglo  is  a  20-mL  fluorinated  ethylene  propylene  (FEP) cryopreservation bag.

Sufficient information on the container closure system has been provided. The choice of this container is appropriate for the type of product. Information on extractables/leachables and microbiological attributes has also been provided.

## Product specification

## Specification

<div style=\"page-break-after: always\"></div>

The proposed commercial FP release specification includes potency, identity, purity, strength, safety (sterility, endotoxin, mycoplasma), and quality. Upon request, the Applicant has indicated at what stage the FP release tests are performed.

The set of specifications is in line with regulatory requirements.

## Analytical procedures and reference standards

An overview of the analytical methods and their validation has been provided. In general, is has been demonstrated that methods are appropriately validated and give no reason for concern.

Medicinal product no longer authorised A reference standard is not used in the testing and release of the FP. Batch analysis Batch  analysis  data  include  batches  manufactured  according  to  clinical  studies.  The  data  support consistency of the FP manufactured at the commercial site. Batch analysis data of (additional) batches manufactured according to the commercial process were provided upon request. All the provided results conform to the FP specification. Stability of the product The proposed shelf life for Zynteglo FP is 1 year frozen at ≤ -140 ° C. The product should be stored in the vapour phase of liquid nitrogen at ≤ -140 ° C until ready for thaw and administration.  Once thawed, it can be kept at room temperature (20°C to 25°C) for a maximum of 4 hours. The product should be kept in the infusion bag(s) in the metal cassette(s) and should not be re-frozen after thawing. Stability studies have been performed in accordance with current ICH/CHMP guidelines. Long term stability data sup port the proposed shelf life of 1 year at ≤ -140°C. All results reported comply with the specifications and no trends are observed. Stability at 25°C was studied. Results complied with the specifications after 4 hours. In the SmPC it is stated that the product has a maximum shelf life of 4 hours. This is considered to be acceptable. Comparability exercise for finished medicinal product See pharmaceutical development. Adventitious agents Non-viral adventitious agents

The information provided on the control of non-viral adventitious agents is considered adequate. Control of  contamination  of  the  manufacturing  facility  is  briefly  described  by  referring  to  cGMP  compliance, personnel, cleaning/sanitization, single-use materials, facility design and procedural controls. Media fill simulation studies have been successfully performed.

Animal  derived  materials  are  discussed  with  regards  to  the  risk  for  BSE/TSE  (Bovine  Spongiform Encephalopathy/Transmissible Spongiform Encephalopathy). Relevant BSE/TSE certificates of suitability have been provided. The risk for BSE/TSE is considered negligible.

<div style=\"page-break-after: always\"></div>

## Viral adventitious agents

Virus safety relies on the adequate control of starting materials and raw materials. The manufacturing process of LVV, AS and FP contains no steps capable of inactivating or removing viruses.

An overview table is provided of the testing for potential adventitious agents performed at various stages of the process (starting materials, in process LVV, final LVV, FP).

For all materials of human or animal origin assessments of the risk for adventitious virus transmission are performed. In general, the information on human- and animal-derived materials is considered to be sufficient and gives no reason for concern.

The quality of Zynteglo active substance and FP is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

Medicinal product no longer authorised 2.2.4. Discussion on chemical, pharmaceutical and biological aspects The dossier content submitted has been of adequate quality; however, several issues have been raised during the procedure. Most issues could be adequately addressed by the Applicant during the procedure. The initial concerns with regard to the presence of cells with higher VCN in the finished product were adequately addressed by the Applicant. An acceptance criterion is implemented that will also limit cells with high VCN and data are provided that demonstrate that potential overestimation of potency has no clinical relevance. In addition, the Applicant indicates that the changes used in the commercial process were aimed not only at improving process consistency but also to target VCN values to retain product efficacy while reducing theoretical risk of oncogenesis. This is supported by the provided data for the commercial batches. The intention is acknowledged from a safety point of view. The available data were initially, however, too limited to conclude on comparable product efficacy. Tight control of potency attributes (i.e. within the range of refined process batches) was therefore considered necessary but was not provided by the proposed specifications. Therefore, during the procedure this issue was raised as a Major Objection because sub-potent batches are a considerable risk to the patient due to the risks associated with of sub-optimal efficacy because the treatment cannot be repeated. In response to this major concern, the Applicant agreed to increase the specification or provided further justification to maintain the specification for potency attributes. In addition, the Applicant provided a commitment to re-evaluation of the justified initial specification when data from the release testing of an additional 20 commercial finished product batches are available. This is acceptable. However, it was considered that the reevaluation of the specification should be extended to other potency tests and the Applicant should also take into account the available clinical data. The Applicant has agreed to the following Annex II condition: in order to further confirm the appropriateness of the acceptance criteria, the Marketing Authorisation Holder (MAH) should re-evaluate the acceptance criteria for attributes related to potency tests using batch release data and clinical results after 6 months follow-up of 20 patients treated with commercial batches. 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The CAT has identified the following measures necessary to address the identified quality developments issues that may have a potential impact on the safe and effective use of the medicinal product:

<div style=\"page-break-after: always\"></div>

- In order to further confirm the appropriateness of the acceptance criteria, the applicant should re-evaluate the acceptance criteria for attributes related to potency tests using batch release data and clinical results after 6 months follow-up of 20 patients treated with commercial batches.

The CHMP endorse the CAT assessment regarding the conclusions on the chemical, pharmaceutical and biological aspects as described above.

## 2.2.6. Recommendations for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CAT recommends the following points for investigation:

Zynteglo contains autologous HSCs modified to express the transgenic protein β A-T87Q -globin, the primary pharmacodynamic effect after engraftment and differentiation of the HSCs is the production of β A-T87Q globin. The β A-T87Q -globin expressed by the integrated transgene can be distinguished from the wild type β A -globin and other globins by RPHPLC, using standards containing β A-T87Q -globin and other globins with known retention times. The relative amount of β A-T87Q globin produced is reported as the %β A-T87Q -globin.

Medicinal product no longer authorised 14 recommendations aimed at improving control of raw materials, providing additional stability data for starting materials, installing in process controls and/or limits for LVV and active substance manufacture, completing characterisation of LVV particles, providing further data on LVV and finished product test methods, revising acceptance criteria as warranted, re-evaluation of specifications after manufacture of additional batches of LVV and finished product, implementing additional test methods and acceptance criteria, respectively. The CHMP endorse the CAT assessment regarding the recommendations for future quality development. 2.3. Non-clinical aspects 2.3.1. Introduction The non-clinical data package included a series of in vitro experiments as well as in vivo animal studies, either  using  a  test  article  manufactured  according  to  a  base  manufacturing  process  or  a  refined manufacturing process. I n  vivo pivotal  studies  were  combined  to  assess  therapeutic  proof-of-concept  (POC),  pharmacology, biodistribution, general safety, single-dose toxicity and genotoxicity of BB3ept05 LVV-transduced cells. Considering the nature of the final drug product (human autologous thalassaemic CD34+ haematopoietic stem cells transduced with the BB305 lentiviral vector), the test articles used during non-clinical studies were surrogates, and consisted of either thalassaemic mouse bone marrow cells transduced with BB305 LVV,  or  human  healthy  donor  HSCs  transduced  with  BB305  LVV,  administered  to β -thalassaemic (Hbb th1 / th1 ) mice and immunodeficient NOD scid gamma (NSG) mice, respectively. 2.3.2. Pharmacology Primary pharmacodynamic studies

Primary pharmacodynamics was assessed in all in vitro and in vivo non-clinical studies.

<div style=\"page-break-after: always\"></div>

## In vitro studies :

Table 1: In vitro primary pharmacodynamic studies

| Study number   | Species/Strain                                                                                     | Test or Control Articles               | Method of Admin.   | Doses cells/ kg   | Gender and No. per Group   | Noteworthy Findings                                                                                                                                                                                                                                                              |
|----------------|----------------------------------------------------------------------------------------------------|----------------------------------------|--------------------|-------------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NC-11- 001     | Human SCD (β S /β E , lacking β A ) BM CD34+ cells (98.3% CD34+); MS-5 stromal cell line           | HPV569 LVV or BB305 LVV                | In vitro           | NA                | NA                         | As compared to HPV569 LVV, BB305 LVV was a more efficient transducer of human SCD BM CD34+ cells. After transduction with BB305 LVV, β A-T87Q -globin represented 22% of the total β -like-globin produced by SCD BM CD34+ cells.                                                |
| NC-11- 004     | Human SCD (β S /β +thal , low levels of β A ) BM CD34+ cells (99.7% CD34+); MS-5 stromal cell line | HPV524 LVV, HPV569 LVV or BB305 LVV    | In vitro           | NA                | NA                         | As compared to HPV569 LVV and HPV524 LVV, BB305 LVV was a more efficient transducer of human SCD BM CD34+ cells. After transduction with BB305 LVV, β A-T87Q globin represented 32% of the total β -like- globin produced by SCD BM CD34+ cells.                                 |
| B2-16- 276     | Human healthy donor mPB and BM CD34+ cells                                                         | BlaM LVV, BB313 (GFP) LVV or BB305 LVV | In vitro           | NA                | NA                         | authorised As compared to the base manufacturing process, manufacturing BB305 LVV- transduced HSCs with a refined manufacturing process resulted in a greater proportion of transduced (%LVV+) cells and higher VCN values, without affecting cellular or colony differentiation |

Medicinal product no longer authorised NC-11004 Human (β S /β of  β cells CD34+); stromal cell line B2-16276 Human donor  mPB and BM CD34+ cells In two different studies (NC-11-001 and 004) the effect of transduction with earlier versions of the BB305 LVV (HPV569 LVV and HPV524 LVV) and BB305 LVV on vector copy number (VCN) values and β A-T87Q globin production in SCD (β S /β E , lacking β A ) BM CD34+ cells in colony-forming cell (CFC, reflecting late progenitors) and long-term culture initiating cell (LTC-IC, reflecting early progenitors) culture assays was  determined.  BB305  LVV  largely  outcompeted  HPV569  LVV  and  performed  slightly  better  than HPV524 LVV in transduction efficiency (VCN) of both early and late progenitors, erythroid and nonerythroid cell precursors and in percentage of LVV+ cells. After transduction with BB305 LVV, β A-T87Q globin represented 22% of the total β -like-globin produced by SCD BM CD34+ cells. Study B2-16-276 showed that, compared to the base manufacturing process, there was an increase in the proportion of colonies  with  a  VCN  greater  than  4 copies  per  diploid  genome  (c/dg)  in  the  refined  manufacturing process. Overall, most colonies have VCN values between 1 and 4 c/dg with the refined manufacturing process. Several individual colonies of cell lot 518 bb305\\_13913 and \\_20113 have a VCN upper limit close to or above 10 c/dg. In contrast, the VCN of cultured long-term repopulating cells was below 2.5 c/dg.  Each  DP  lot  contains  both  long-term  hematopoietic  stem  cells  (LT-HSCs)  and  short-term repopulating cells. It is assumed that 1% of CD34+ cells are LT-HSCs according to the Applicant. In vivo studies : BB305 LVVtransduced cells were evaluated in the β -thalassaemic (Hbb th1 / th1 ) mouse model and in the NSG mice.

<div style=\"page-break-after: always\"></div>

Table 2: Overview of in vivo primary pharmacodynamic studies

<!-- image -->

| Study number   | Species/S train                                     | Test or Control Articles                                                                                                                                                                                                                                         | Method of Admin.                         | Doses cells/kg   | Gender and No. per Group         | Noteworthy Findings                                                                                                                                                                                                                                                                                                                                                                                                 |
|----------------|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NC-11- 002     | CD45.2+ C57BL/6 Hbb th1/th1 β - thalass- aemic mice | Mock-, HPV569 LVV- or BB305 LVV-transduced CD45.2+ C57BL/6 Hbb th1/th1 β -thalassaemic mouse syngeneic Lin- BMCs                                                                                                                                                 | IV (primary trans- plantation)           | 11×10 6          | no longer 8 to 11 M or 7 to 11 F | Primary transplantation of HPV569 LVV- or BB305 LVV-transduced BMCs from primary donor β -thalassaemic mice into primary recipient β -thalassaemic mice resulted in successful and equivalent BM engraftment, correction of dyserythropoiesis, productive expression of β A-T87Q- globin, and effective treatment of β -thalassaemia, thereby showing gene therapy POC correction of the β -thalassaemic phenotype. |
| NC-12- 019     | CD45.1+ C57BL/6 mice                                | Medicinal Month 4 BMCs from CD45.2+ C57BL/6 Hbb th1/th1 β -thalassaemic mice that received primary transplantation of mock-, HPV569 LVV- or BB305 LVV-transduced CD45.2+ C57BL/6 Hbb th1/th1 β - thalassaemic mouse syngeneic Lin- BMCs in Study No. NC-11- 002. | product IV (secondary trans- plantation) | 240×10 6         | 17 to 23 M or 9 to 21 F          | Secondary transplantation of HPV569 LVV- and BB305 LVV- transduced BMCs from primary recipient/secondary donor β - thalassaemic mice into wildtype mice resulted in successful and equivalent BM engraftment, and maintained improvement of the gene therapy- corrected β -thalassaemic phenotype.                                                                                                                  |
| B2-15- 161     | NSG mice                                            | Mock- or BB305 LVV-transduced human CD34+ HSCs                                                                                                                                                                                                                   | IV (trans- plantation)                   | 50×10 6          | 10 to 15 F                       | Transduction of human heathy donor CD34+ HSCs with BB305 LVV using the refined manufacturing process had no adverse effects on long-term BME in immunodeficient, myeloablated NSG                                                                                                                                                                                                                                   |

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|            |          |                                       |                        |        |      | mice. As compared to the base manufacturing process, the refined manufacturing process resulted in comparable long-term BME, with no differences in BM cellular differentiation, but with higher %LVV+ cells, VCN values and β A-T87Q -globin production in LTE BMCs.                                                                                                                                                                                                                                                                              |
|------------|----------|---------------------------------------|------------------------|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B2-16- 200 | NSG mice | BB305 LVV-transduced human CD34+ HSCs | IV (trans- plantation) | 42×106 | 15 F | longer authorised Transduction of human CD34+ HSCs with BB305 LVV with the base manufacturing process or the refined manufacturing process had no adverse effects on long-term BME in immunodeficient, myeloablated NSG mice. As compared to Process 1, Process 2 resulted in slightly lower long-term BM engraftment, with no differences in BM cellular differentiation, but with higher %LVV+ cells, VCN values and β A-T87Q -globin production in LTE BMCs. Highly-transduced HSCs did not appear to give rise to highly- transduced LTE BMCs. |

## Medicinal product no longer authorised LVV-transduced human IV (transplantation) 42×106 15 F

<div style=\"page-break-after: always\"></div>

Short-term repopulating cells contained in the CD34+ drug product have a restricted lifespan in vivo and primarily contribute to short-term hematopoietic reconstitution, whereas long-term repopulating cells contribute to long-term repopulating into both myeloid and lymphoid cell lineages.

Moreover, it is highlighted that transduction of CD34+ cells is stochastic within a given drug product and committed progenitors are presumably more easily transduced than primitive cells.

It is hypothesised that cells with a higher VCN were mainly committed progenitors of short-term lifespan (i.e., do not participate in long term engraftment) mitigating the risk of insertional mutagenesis. As data on VCN in LT-HSCs is lacking, this hypothesis could not be verified.

Medicinal product no longer authorised Transduction of CD34+ HSCs of healthy donors with the refined manufacturing process resulted in VCN between 2 and 6 c/dg depending on cell lot, LVV lot and operator. However, drug product VCN variability can also be attributed to (uncontrollable) intrinsic inter-patient differences of CD34+ HSCs and not the manufacturing process or LVV potency. Experiments comparing peripheral blood CD34+ HSC with those from bone marrow showed comparable VCN. These studies confirm that the refined manufacturing process yields increased LVV+ CD34+ cells with VCN in range of approximately 4 c/dg. In 92% of the transplanted animals, donor cell engraftment was above 80% with an average 0.8-3.6 c/dg. There was no difference between male and female engraftment rate. In literature, differences have been attributed to male specific expression of a MHC antigen. The differences observed in study NC-11002 are not due to engraftment but most likely due to experimental variance and were not toxicologically relevant. Engraftment of transduced cells resulted in increased haemoglobin and haematocrit levels, increased RBC counts and decreased reticulocyte% compared to mock control animals after 2 and 3 months. After 4 months, for animals given BB305 LVV-transduced BMC, the ratio of β A-T87Q -globin in peripheral blood was above 30%. These improvements were largely comparable between HPV569 LVV- and BB305 LVVtransduced groups. There were no differences on WBC count, peripheral blood or bone marrow cell subsets compared to the sham group. Platelet counts appeared to be deceased in female transduced mice and slightly reduced in males at 2 months. Slight reductions in platelet counts were still apparent after 3 months in males and females. This is due to an overestimation of platelets in mock animals due to abnormal erythrocytes being counted by the analyser, which is a known phenomenon. Ter119+ CD71 cells, which are erythroid progenitors, were significantly increased in bone marrow of mice transplanted with  BB305  LVV-transduced  BMC  compared  to  sham  mice.  This  corresponded  with  improved dyserythropoiesis. In BB305 LVV-transduced BMC transplanted mice, differentiated erythroid cell counts were 40% higher than mock controls. Haemoglobin and haematocrit were increased and reticulocytes were decreased in animals expressing VCN of 1-2.6 c/dg. Homeostasis was not investigated (also see Study NC-12-019). Total bilirubin concentration was decreased in animals given HPV569 LVV- or BB305 LVV-transduced BMC compared to mock controls. This was related to reduced destruction of RBC and haemoglobin  degradation  in  mice  treated  with  transduced  BM  cells.  BB305  LVV-transduced  BMC transplanted mice had reduced spleen weight and corresponded to a reduced spleen size compared to sham mice. This variability stems from (uncontrollable) intrinsic inter patient differences of CD34+ HSCs and not the manufacturing process or LVV potency.

Subsequently, bone marrow harvested from β -thalassaemic  (Hbb th1 / th1 )  mice  transduced  with  either HPV569 LVV or BB305 LVV was transplanted in lethally irradiated (11 Gy) CD45.1 C57BL/6. Hbb th1 / th1 mice were transduced with Lin depleted Hbb th1 / th1  CD45.2 four months earlier. Mice were followed for 6 months post-transplant. Engraftment was obtained with more than 90% of donor cells in bone marrow of secondary recipients after 6 months. High engraftment of CD45.2 cells was reached in both males and females in all groups after 4 months. Average percentage of CD45.2 cells was in excess of 85%. After 6

<div style=\"page-break-after: always\"></div>

months, engraftment of CD45.2 cells remained high. There appeared to be an increase in variance in BB305 males. Nevertheless, average CD45.2 reached 90% or more in all groups.

The  average  vector  copy  number  per  cell  in  the  bone  marrow  (BM)  4  months  post-Bone  Marrow Transplant (BMT) was 1.61 ± 0.95 and 2.33 ± 1.36 copies per cell for HPV569 and BB305 lentiviral vectors respectively. Five months post-BMT, the average VCN in blood cells was 1.63 ± 1.02 and 2.31 ± 1.40 copy per cell for HPV569 LVV and BB305 LVV respectively. At the end of the study, the average VCN per cell in the bone marrow of mice prematurely dead or sacrificed at the end of the study was 1.39±  0.82  and  2.02  ±  1.52  copies  per  cell  for  HPV569  LVV  and  BB305  LVV  groups  respectively, suggesting  that  stable  reconstitution  had  been  achieved.  The  maximum  (individual  highest)  VCN measured in bone marrow in this study was 3.7 c/dg.

Two studies with the product to be used in the clinic were undertaken in which BB305 LVV-transduced human CD34+ cells were administered to immunodeficient, myeloablated NSG ((non-obese diabetic (NOD)  severe  combined  immune  deficiency  (scid)  interleukin-2  receptor  gamma  (IL2Rγ)  knockout (gamma)) mice. Transduction of human healthy donor CD34+ HSCs with BB305 LVV occurred in the presence of the base manufacturing process or the refined manufacturing process). These NSG mice are immunodeficient and characterised by the absence of mature T or B cells, lack of functional NK cells and deficiencies in cytokine signalling; they are therefore unable to reject the human CD34+ HSCs. Of note, NSG (and  wildtype)  mice  do  not  support  the  differentiation  of  human  HSCs  into  erythrocytes,  and therefore, β A-T87Q -globin production (which relies upon an erythroid promoter and is therefore restricted to cells of erythroid lineage) cannot be directly measured in NSG mice receiving BB305 LVV-transduced HSCs. Rather, BME is assessed by evaluating individual BM samples for relative numbers (%) of humanorigin haematopoiesis-derived cells, composite VCN values and Integration Site Analysis (ISA) profiles, and by placing pooled BM samples into ex vivo colony cultures to determine the colony composite VCN values, proportion (%) of colonies transduced and the relative amounts (%) of β -globin chains, including %β A-T87Q -globin, produced by the colonies.

Medicinal product no longer authorised Red blood cell count, haemoglobin and mean corpuscular haemoglobin concentration, mean corpuscular and packed cell volume were increased in animals given HPV569 LVV- and BB305 LVV-transduced BMC compared to mock control animals. Reticulocyte counts were decreased. From the haematology data, it is clear that thalassaemic phenotype is improved, although mean corpuscular haemoglobin and mean corpuscular  haemoglobin  concentration  remain  somewhat  lower  than  wildtype  historical  controls. Furthermore, anisochromia and anisocytosis were observed in transplanted animals, consistent with the phenotype of β -thalassaemia.  Minimal  changes in  platelet  count  were  observed  in  HPV569  LVV  and BB305 LVV transduced animals compared to mock controls. Nevertheless, the changes in platelets are minimal and are not considered to be toxicologically relevant. Monocytes and neutrophils were increased in females but not males treated with BB305 LVV-transduced BMC. However, the data are mostly within control values of historical data, and therefore not considered to be related to treatment. There is minimal variability in BMC chimerism (%CD45.2+ cells) and moderate variability in %Gr1/Mac1+ myeloid cells, %CD3+ T cells and %B220+ B cells after 4, 5 and 6 months suggesting that there are no drug product related effects on homeostasis. These transduced BMCs, containing β -globin, abrogate the typical thalassaemic phenotype. Furthermore, re-transplantation of transduced bone marrow results in successful engraftment of CD45.2 cells with a stable VCN and a maintained correction of the β -thalassaemic phenotype for the duration of the study.

In a first in vivo experiment in NSG mice (B2-15-161), elements of the manufacturing process were refined. As a result, the applicant switched their production process to the refined manufacturing process The products resulting from these two processes were once more compared in an in vivo experiment in NSG mice (B2-16-200). For each of the studies, CD34+ cells from one healthy human donor were used. In both studies, colony or composite (culture) VCN value, the % of LVV positive cells were determined

<div style=\"page-break-after: always\"></div>

on test article (before transplantation) and BM-derived materials 2 and 4 months post-transplantation. BME analyses were performed 2 and 4 months post-transplantation. In study 15-161 the test article material was cultured in several ways to discriminate between the early (LTC-IC) and the late progenitors (colony-forming  cell,  CFC)  and  provide  information  on  transduction  efficiency  in  these  two  cell populations. In study 16200, the %β A-T87Q -globin was determined for burst-forming units - erythroid (BFU) and cultured erythrocytes.

From both studies it becomes clear that the switch to the refined manufacturing process yields higher VCN values and a higher percentage of LVV positive cells, resulting in higher β A-T87Q -globin expression levels. It does not seem to influence BM engraftment as this is quite similar between mock-treated and product-treated animals, where the product is generated by either process.

As becomes apparent from the analysis with material from the refined manufacturing process, VCN values in pre-transplantation material, representing early and late progenitors, are higher as compared to VCN values obtained from 2 or 4 months post transplantation material, which may be representative for engrafted cells. Also, the colony VCN values obtained from LTC-IC cultured test material (reflecting early progenitors) are lower compared to colony VCN values from CFC cultured test material (reflecting late progenitors). β A-T87Q -globin expression from BFU or cultured erythrocytes seems to be higher from the pretransplantation  material,  compared  to  β A-T87Q -globin expression from  BFU  or cultured erythrocytes using BM material 2 or 4 months post-transplantation. Higher β A-T87Q -globin expression from pre-transplantation  material  as  compared  to  post-transplantation  material  may  indicate  higher insertional activity in myeloid lineage late progenitor CD34+ cells that will not engraft and these cells are likely to disappear shortly after transplantation. Cells obtained from the BM 2 or 4 months posttransplantation rather reflect the early progenitors that have engrafted. Apparently, for these cells lower VCN levels are observed. Data thus seem to indicate that the high VCN values present in the pretransplantation material are mainly present in late progenitors that are not likely to engraft, which is regarded as a positive signal with regards to the mutagenic risk related to insertion. However, these suggestions are only based on data generated with cells retrieved from two healthy donors (one donor for study B2-15-161 and one donor for study B2-16-200), which is regarded quite limited.

Medicinal product no longer authorised The proportion of early and late progenitors present in transduced HSCs were estimated from LTC-IC and CFC cultures. CFC cultures on post-transplant bone marrow or peripheral blood of TDT patients were not performed. However, data on patients with sickle cell disease (from Study HGB-206) are available. These  data  suggest  that  the  proportion  of  PB  and  BM  cells  above  5  c/dg  decline  with  longer  term engraftment, supporting the notion that hematopoietic colony-forming cells with high VCN values are less able to establish long-term BM engraftment in humans. Related to the switch to the refined manufacturing process the VCN values and the percentage of LVV+ cells increased, but these two parameters also showed a larger variability. It is not clear whether this phenomenon is also observed in the clinical results, for instance as a larger variety in efficiency. The level of LVV positive cells before and 4 months after transplantation is higher in study B2-16-200 (85% pre-transplantation  -&gt;  67%  4  months  post-transplantation)  as  compared  to  B2-15-161  (53%  pretransplantation -&gt; 43% 4 months post-transplantation). Also, the maximal colony VCN values for both studies differ. The colony VCN of pre transplantation material prepared under the refined manufacturing process reached a maximum of ~8 c/dg in study B2-15-161, whereas the maximal colony VCN pre transplantation was ~16 c/dg in study B2 15-200. In the latter study, the variability of colony VCN numbers is also higher for the refined manufacturing process, in both pre- and post-transplantation samples. Based on these data obtained with cell material from 2 healthy donors it appears that there is a batch to batch variability, which is attributable in large part to inherent differences in the transducibility of individual donor's HSCs for which the reason is not yet understood.

<div style=\"page-break-after: always\"></div>

Although  it  was  not  the  purpose  of  these  studies,  the  product  could  be  considered  generally  safe according to a safety evaluation on the basis of animal observations, body weights and haematology parameters. However, in these studies (B2-15-161 and B2-16-200) no data is presented on persistence of BB305 LVV-transduced cells in other tissues/organs (other than peripheral blood and bone marrow), such as spleen, thymus, and lymph nodes. As studies NC-11-002 and NC-12-019 showed persistence of BB305 LVVtransduced β -thalassaemic mouse BM-derived cells in bone marrow, peripheral blood and/or lymphoid tissues (thymus and lymph nodes) of mice through Month 4 or Month 6, it is thus assumed that transduced cells were furthermore also distributed to a non-exhaustive list of tissues/organs.

## Secondary pharmacodynamic studies

The  four  pivotal  single-dose  toxicity  studies  included  studies  evaluating  BB305  LVV-transduced β -thalassaemic mouse BMCs and administered by primary transplantation to Hbbth1/th1 β -thalassaemic mice initially and then by secondary (serial) transplantation to wildtype C57BL/6 mice. Pivotal singledose toxicity studies also evaluated BB305 LVV-transduced healthy human donor HSCs manufactured by using the refined manufacturing process and administered by primary transplantation to immunodeficient (NSG) mice. Although not fully Good Laboratory Practice (GLP) compliant, these in vivo studies (NC-11-002, NC-12-019, B2-15-161 and B2-16-200) were pivotal and combined pharmacology, biodistribution, single-dose toxicity and genotoxicity studies, conducted in the murine animal model of β -thalassaemi a (C57BL/6 Hbbth1/th1 β -thalassaemic mice) and in the immunodeficient NSG mice.

Medicinal product no longer authorised No stand-alone secondary pharmacodynamics studies were performed with BB305 LVV-transduced BMCs and/or HSCs (see discussion on non-clinical aspects). Safety pharmacology programme No stand-alone safety pharmacology studies were performed with BB305 LVV-transduced BMCs and/or HSCs (see discussion on non-clinical aspects). Pharmacodynamic drug interactions No pharmacodynamic drug interaction studies were conducted (see discussion on non-clinical aspects). 2.3.3. Pharmacokinetics As Zynteglo is an ex viv o genetically modified autologous HSC-based product, traditional absorption, distribution, metabolism and excretion (ADME) studies are not relevant for Zynteglo. The  pharmacokinetic  and  biodistribution  properties  of  BB305  LVVtransduced  β -thalassaemic  mouse BMCs were evaluated in vivo in a pivotal combined therapeutic POC, pharmacology, single-dose toxicity and genotoxicity study in the β -thalassaemic mice. The pharmacokinetics and biodistribution of BB305 LVV-transduced human healthy donor HSCs were also evaluated in vivo in  the  NSG mice. To assess biodistribution and in vivo persistence of BB305 LVV-transduced cells in animals, different markers/parameters were used in nonclinical  studies:  β A-T87Q -globin  production,  percent  transduced (%LVV+) cells or colonies, vector copy number (VCN) values. 2.3.4. Toxicology

## Single dose toxicity

Four pivotal single dose toxicity studies were conducted in immunocompetent and immunodeficient mice with a surrogate of Zynteglo FP, via the IV route.

<div style=\"page-break-after: always\"></div>

Table 3: Overview of single dose toxicity studies and findings

<!-- image -->

| Study number   | Species/ Strain                                            | Test or Control Articles                                                                                                                                                                                                          | Method of Admin.                  | Doses cells/kg   | Gender and No. per Group   | Observed Maximum Nonlethal Dose (cells/kg)   | Toxicity Noteworthy Findings                                                                                                                                                                                                                                                              |
|----------------|------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|------------------|----------------------------|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NC-11- 002     | CD45.2+ (Ly5.2+) C57BL/6 Hbb th1/th1 β - thalassaemic mice | Mock-, HPV569 LVV- or BB305 LVV-transduced CD45.2+ C57BL/6 Hbb th1/th1 β -thalassaemic mouse syngeneic Lin- BMCs                                                                                                                  | IV (primary trans- plantation)    | 11×10 6          | 8 to 11 M or 7 to 11 F     | 11×10 6                                      | authorised No toxicity associated with primary transplantation of HPV569 LVV- or BB305 LVV- transduced BMCs from primary donor β -thalassaemic mice into primary recipient β -thalassaemic mice. No evidence of oncogenesis related to insertional mutagenesis.                           |
| NC-12- 019     | CD45.1+ (Ly5.1+) C57BL/6 mice                              | Month 4 BMCs from CD45.2+ C57BL/6 β -thalassaemic Hbb th1 / th1 mice that received primary transplantation of mock-, HPV569 LVV- or BB305 LVV- transduced CD45.2+ C57BL/6 Hbb th1 / th1 β -thalassaemic mouse syngeneic Lin- BMCs | IV (secondary trans- plantation)  | 240×10 6         | 17 to 23 Mor 9 to 21 F     | longer 240×10 6                              | No toxicity associated with secondary transplantation of HPV569 LVV- and BB305 LVV-transduced BMCs from primary recipient/secondary donor β -thalassaemic mice into secondary recipient wildtype mice. No evidence of clonal expansion or oncogenesis related to insertional mutagenesis. |
| B2-15- 161     | NSG mice                                                   | Mock- or BB305 LVV- transduced human CD34+ HSCs                                                                                                                                                                                   | IV (BM trans- plantation)         | 50×10 6          | no 10 to 15 F              | 50×10 6                                      | No toxicity associated with BB305 LVV-transduced human HSCs manufactured by the base manufacturing process or the refined manufacturing process. No evidence of clonal expansion or oncogenesis related to insertional mutagenesis.                                                       |
| B2-16- 200     | NSG mice                                                   | BB305 LVV-transduced human CD34+ HSCs                                                                                                                                                                                             | product IV (BM trans- plantation) | 42×10 6          | 15 F                       | 42×10 6                                      | No toxicity associated with BB305 LVV-transduced human HSCs manufactured by the base manufacturing process or the refined manufacturing process. No evidence of clonal expansion or oncogenesis related to insertional mutagenesis.                                                       |

<div style=\"page-break-after: always\"></div>

## Repeat dose toxicity

No repeated dose toxicity studies were performed as the treatment foresees only one unique injection (see discussion on non-clinical aspects).

## Genotoxicity

The BB305 LVV genotoxic potential has been studied during in vitro and in vivo studies.

## Carcinogenicity

Medicinal product no longer authorised No carcinogenicity studies were submitted with Zynteglo. Reproduction toxicity No developmental and/or reproductive toxicity (DART) studies were submitted to support the use of Zynteglo for the treatment of TDT. Toxicokinetic data Persistent exposure to BB305 LVV-transduced mouse BMCs and/or to mouse HSC-derived BMCs was shown through 4 months or 6 months in all animals of both sexes. Local tolerance Local tolerance was assessed in the course of in vivo studies. Other toxicity studies No immunotoxicity studies have been performed. 2.3.5. Ecotoxicity/environmental risk assessment As this product contains a genetically modified organism, an environmental risk assessment has been conducted in accordance with Directive 2001/18/CE on the deliberate release into the environment. Transduced cells of Zynteglo FP are not able to survive in the environment; they are not infectious and are eliminated in non-target people by their immune system. Immunodeficient people, other than the patient for whom the product is intended, will not come into contact with Zynteglo as they will not be involved in administration of the product. Zynteglo FP cells would be recognised as foreign and eliminated by the immune system of an exposed person other than the cell donor (DePolo et al. 2000). It cannot be excluded that in immunocompromised people other than the specific patients, Zynteglo FP would persist and assume the function of normal CD34+ cells with expression of β A-T87Q -globin. Due to the low immunogenicity of β A-T87Q -globin observed in clinical studies, it is not anticipated that this would cause an  adverse  effect.  Additionally,  administration  to  the  correct  patient  is  assured  by  traceability procedures.

<!-- image -->

Residual amounts of free particles of BB305 LVV are below the level of quantification in Zynteglo FP. In the event a free particle would be present, lentiviral vectors pseudotyped with VSV-G have been reported to be inactivated by human serum complement (98.8% after 1 hour) if the LVV particles have not entered cells. Besides, BB305 LVV is inactivated rapidly under environmental conditions.

<div style=\"page-break-after: always\"></div>

In conclusion, neither Zynteglo FP nor BB305 LVV are expected to be released into the environment at large. Zynteglo contains transduced, autologous, human cells which are re-infused into the same patient. It is the goal of the product to proliferate within the patient and the cells cannot survive outside of the patient and do not compete with other species in the natural environment.

## 2.3.6. Discussion on the non-clinical aspects

The non-clinical program was well conducted and consisted in four pivotal and combined in vivo studies conducted  to  assess  proof  of  concept,  pharmacology,  biodistribution,  single  dose  toxicity  and genotoxicity of Zynteglo FP cells. Even if not fully compliant to GLP principles, these four in vivo combined studies allowed the assessment of both primary pharmacodynamics and toxicity.

Medicinal product no longer authorised No  secondary  pharmacodynamics  studies  were  performed  which  is  considered  acceptable  since  the secondary pharmacodynamic effects of BB305 LVV-transduced BMCs (i.e. normalisation of total β -globin and  Hb  levels,  normalisation  of  the  hematologic  parameters  and  correction  of  the  β -thalassaemic phenotype) were evaluated in of pivotal pharmacology studie s in the β -thalassaemic murine animal model.  Results  showed  that  treatment  of  thalassaemic  mice  resulted  in  the  correction  of  the β -thalassaemic phenotype. No safety pharmacology studies were performed which is considered acceptable as there was no evidence of adverse effects on the circulatory, respiratory, neurologic or digestive systems observed in any of the in vivo studies conducted. Considering the nature and origin of the cells (autologous human cells) and the  absence  of  undesirable  effects  observed  during in  vivo studies,  the  lack  of  stand-alone  safety pharmacology studies is considered acceptable. Transduction efficiency in vitro Several individual colonies of cell lot 518 bb305\\_13913 and \\_20113 had a VCN upper limit close to or above  10  c/dg.  In  contrast,  the  VCN  of  cultured  long-term  repopulating  cells  was  below  2.5  c/dg. Therefore, it is understood that cells containing high VCN are likely early progenitors and are not likely to  reconstitute  in  bone  marrow.  Transduction  of  CD34+  HSCs  of  healthy  donors  with  the  refined manufacturing process resulted in VCN between 2 and 6 c/dg depending on cell lot, LVV lot and operator. This variability stems from (uncontrollable) intrinsic inter patient differences of CD34+ HSCs and not the manufacturing process or LVV potency. Effects observed in the in vivo study in the homologous animal model In 92% of the transplanted animals, donor cell engraftment was above 80% with an average 0.8-3.6 c/dg. However, the submitted data representing successful engraftment did not differentiate between HPV569 LVV- or BB305 LVV-transduced cells. Furthermore, females transplanted with male BMCs appear to have identical engraftment rates. Gender differences are noted in the haematological, pathological and histopathological assessment. This is in line with literature where it has been reported that reciprocal transplantation can result in gender differences. In addition, because the drug product is an autologous application,  such  differences  are  not  expected.  Platelet  counts  appeared  to  be  deceased  in  female transduced mice and slightly reduced in males at 2 months. Slight reductions in platelet counts are still apparent after 3 months in males and females. This is due to an overestimation of platelets in mock animals due to abnormal erythrocytes counted by the analyser, which is a known phenomenon.

Four animals died during the study but the cause of death could not be attributed to a treatment related effect.  Microscopic  changes  in  mock-transduced  mice  showed  marked  to  severe  increases  in extramedullary haematopoiesis in spleen. This also corresponded to a minimal to moderate increase in erythroid cells in bone marrow and is typical for thalassaemic mice. These changes were still present in HPV569  and  BB305  transduced  mice,  albeit  at  much  lower  severity,  representing  correction  of  the

<div style=\"page-break-after: always\"></div>

thalassaemic phenotype. No other microscopic changes were noted. The presence of tumours or tumour cells (e.g. lymphoma) was not recorded in study NC-11-002 (primary transplantation). In study NC-12019 (secondary transplantation) leukaemia/lymphoma was observed which was attributed to the long time since donor cells irradiation (10 months prior to the end of this study, vs 4 months in study NC-11002). As irradiation to support grafting of BB305 LVV-transduced CD34+ cells is not part of the clinical treatment, this observation is not regarded of relevance for human.

## Effects observed in the in vivo study in the non -homologous animal model

Medicinal product no longer authorised Related to the switch from to the refined manufacturing process, the VCN values and the percentage of LVV+ cells increased, but the results of these two parameters showed a larger variability. It is not clear whether this phenomenon is also revealed within the clinical results, for instance in a larger variability in efficacy. The in level of LVV positive cells before and 4 months after transplantation is higher in study B2-16-200 (85% pre transplantation, sample vs 67% in BM sampled 4 months post transplantation) as compared  to  B2-15-161  (53%  pre  transplantation,  43%  4  months  post  transplantation).  Also  the maximal colony VCN for both studies differed. The colony VCN of pre-transplantation material prepared under the refined manufacturing process reached a maximum of ~8 c/dg in study B2-15-161, whereas the maximal colony VCN pre transplantation was ~16 c/dg in study B2 15-200. In the latter study, the variability of colony VCN numbers is also higher for the refined manufacturing process as compared to Process 1, in both pre- and post-transplantation samples. As becomes apparent from the analysis with material from the refined manufacturing process, VCN values in pre-transplantation material, representing early and late progenitors, are higher as compared to VCN values obtained from 2 or 4 months post transplantation material, which may be representative for engrafted cells. Also the colony VCN values obtained from LTC-IC cultured test material (reflecting early progenitors) are lower compared to colony VCN values from CFC cultured test material (reflecting late progenitors). β A T87Q -globin expression from BFU or cultured erythrocytes seems to be higher from the pretransplantation  material,  compared  to  β A-T87Q -globin expression from  BFU  or cultured erythrocytes using BM material 2 or 4 months posttransplantation. Higher β A-T87Q -globin expression from pre-transplantation  material  as  compared  to  post-transplantation  material,  may  indicate  higher insertional activity in myeloid lineage late progenitor CD34+ cells that will not engraft and these cells are likely to disappear shortly after transplantation. Cells obtained from the BM 2 or 4 months posttransplantation rather reflect the early progenitors that have engrafted. Apparently, for these cells lower VCN levels are observed. Data thus seem to indicate that the high VCN values present in the pretransplantation material are mainly present in late progenitors that are not likely to engraft, which is regarded as a positive signal with regards to the mutagenic risk related to insertion. However, these suggestions are only based on data generated with cells retrieved from two healthy donors (one donor for study B2-15-161 and one donor for study B2-16-200) and on data present in literature (Charrier et al., 2010). VCN data from LTC-IC cultured from BB305 LVV-transduced human CD34+ cells would have provided further support for this explanation.

In  these  studies  (B2-15-161  and  B2-16-200)  no  data  is  presented  on  persistence  of  BB305  LVVtransduced cells in other tissues/organs (other than peripheral blood and bone marrow), such as spleen, thymus, and lymph nodes. Since studies NC-11-002 and NC-12-019 showed persistence of BB305 LVVtransduced β thalassaemic mouse BM -derived cells in bone marrow, peripheral blood and/or lymphoid tissues (thymus and lymph nodes) of mice through Month 4 or Month 6, it is thus assumed that in the studies  B2-15-161 and B2-16-200 the transduced cells also distribute also distribute tissues/organs similar to what observed in studies NC-11-002 and NC-12-019.

## Mutagenic or tumorigenic risk

An in vitro in vitro immortalisation (IVIM) assay (NC-12-016) was conducted to analyse the potential of the LVV to induce an immortalized or a transformed phenotype in the transduced mouse lineage depleted

<div style=\"page-break-after: always\"></div>

(Lin-) BMCs cells. Evidence of in vitro genotoxicity was observed in the GRV (RFS91) and LVV (l.v-SF) positive controls in an IVIM assay, confirming the sensitivity of the assay. The mutagenic potential was strongly reduced for HPV524 LVV, HPV569 LVV and BB305 LVV. Of these, BB505 LVV showed the least genotoxic potential. In this in vitro assay, insertions were found in or near the following genes; inside Cdk17, Rad21, Cdk14, or Cadps2, near Pth2r and an insertion upstream of Pdha 2. None of these genes are related to haematopoietic malignancies. Neither is for any of the six gene products an apparent relationship with oncogenicity established. In human, IS in all of the six genes were identified, but none of them were among the top 10 clones or resulted in a malignancy. The issue of the integration and the potential effect upon treatment of patients with BB305 LVV-transduced CD34+ cells will also be further followed in the long-term registry for this GTMP with integrative LVV.

Medicinal product no longer authorised Based on available data it is not possible to conclude that the refined manufacturing process resulted in 1.3-fold more unique mappable IS, and 1.2-fold higher proportion of unique mappable IS within CIS. These observations are rather indicative for the variability between the different batches generated under the refined manufacturing process. However, the variability around this mean is very large. For instance, for cell batch 1 transduced via the base manufacturing process, the unique mappable IS and unique mappable CIS in IS are high, whereas these are low for the same cell batch, transduced with the refined manufacturing process. Remarkably, for cell batch 3 the exact opposite observation is made. For cell batch 2, the transduction method only results in a small difference of mappable IS or CIS in IS. Variability in percentage of LVV+ cells and colony and composite VCN in early and late progenitors as well as uncertainties on level of unique mappable IS in CIS (see above) hamper the estimation whether the tumorigenic risk is purely theoretical or whether this might be a small but real risk for the patient. The  applicant  provided  a  discussion  on  the  extent  of  the  potential  tumorigenic  risk  including  (DP) characterisation  data  on  10  patients  treated  with  BB305-LVV  transduced  CD34+  cells.  The  highly polyclonal  semi-random integration profile  that  is  expected  for  SIN  LVVs  is  observed  in  mouse  and confirmed in human. In the &gt; 550,000 unique, mappable ISs identified no contribution of one individual IS reached &gt;30% at any single time point. Clonal outgrowth or haematologic malignancies in any of the patients receiving Zynteglo was not observed yet. Together this indicates that the risk for tumorigenesis upon transduction of CD34+cells with BB305 LVV is rather limited and is likely theoretical, also for  DP manufactured with the refined manufacturing process. Patients benefit more from treatment / product transduced with BB305 LVV using the refined manufacturing process (increased β A-T87Q -globin and total haemoglobin concentrations) as compared to the base manufacturing process. The requested (DP) characterisation data on 10 patients treated with BB305 LVV-transduced CD34+ cells lacked VCN data on LTC-IC cultured cells. This was regarded essential to support the proposed hypothesis that HSCs with high VCN values (and greater numbers of IS) fail to establish long-term engraftment. Currently, this hypothesis is supported by results from mouse studies and by literature data (Charrier, 2010) but not by clinical data with the current product for the proposed indication. It would have been of interest to observe a relationship between VCN of early progenitors and MOI, viral batch used and clinical parameters as β -globin production, Hb and transfusion independence. As VCN data on the early progenitors or long-term repopulating cells is missing, such a relationship cannot be identified.

## Genotoxicity

The BB305 LVV genotoxic potential has been studied during in vitro and in vivo studies. In an IVIM assay, BB305 LVV-transduced mouse bone marrow cells showed reduced mutagenic potential as compared to positive control LVVs. Insertion site analysis of pre-transplantation transduced mouse BMCs and human CD34+ HSCs displayed the expected SIN LVV integration profile, with no enrichment for insertion in or near cancer-related genes.

<div style=\"page-break-after: always\"></div>

There was no evidence that higher VCN values are associated with enrichment for integration within cancer-related  genes  or  increased  risk  of  insertional  mutagenesis  leading  to  oncogenesis.  In  the nonclinical  studies  conducted, ISA profiles of BB305 LVVtransduced β -thalassaemic mouse BMCs at Months 4 or 6 post-transplantation suggested that there was no preferred integration in the MDS1-EVI1 (MECOM), LMO2 or HMGA2 genes. Comparison of the Top 10 IS has not revealed any evidence of clonal dominance. Integration occurred across the genome, with no enrichment for integration near cancerrelated genes.

## Carcinogenicity

Medicinal product no longer authorised No carcinogenicity studies were conducted with Zynteglo. The final product is intended for a single IV administration, and conventional long-term carcinogenicity studies in rodents do not apply to ATMPs. However,  from  a  risk-based  perspective,  as  the  final  product  consists  of  (immature)  CD34+  HSCs transduced by a lentiviral vector, insertional mutagenesis resulting in oncogenesis (e.g., leukaemia/lymphoma) was the primary theoretical safety concern identified by the Applicant. As the refined manufacturing process has been shown to induce a greater proportion of transduced (%LVV+) cells, higher composite VCN values and greater β A-T87Q -globin production, a huge number of in vitro/ and in vivo genotoxicity studies were consequently conducted with the aim to assess the risk related with SIN LVV-mediated insertional mutagenesis, when using Zynteglo. No tumorigenicity and no evidence of an oncogenesis event related to insertional mutagenesis were observed in the nonclinical studies using BB305 LVVtransduced β -thalassaemic mouse BMCs or human healthy donor HSCs. Reproduction toxicity Zynteglo in contraindicated in pregnant women as reflected in section 4.3 of the SmPC, this is because of myeloablative conditioning. Toxicokinetic data Persistent exposure to BB305 LVV-transduced mouse BMCs and/or to mouse HSC-derived BMCs was demonstrated through 4 months or 6 months in all animals of both sexes. Local tolerance Local tolerance was assessed in the course of in vivo studies. No adverse effects were noted at the site of injection. The absence of studies is considered acceptable. Other toxicity studies No  immunotoxicity  studies  have  been  performed  since  immunogenicity  with β A-T87Q -globin  is  not anticipated. Patients will be immunosuppressed at the time of treatment (busulfan conditioning) and Zynteglo is given on a single unique occasion. Environmental Risk Assessment

Considering the data provided, Zynteglo is not expected to pose a risk to the environment, providing handling precautions are carried out as stated in the SmPC in order to minimise any potential risks to the environment. Patients treated with Zynteglo are informed not to donate blood, bone marrow or organs in order to prevent transplantation of Zynteglo FP cells to immunodeficient persons as indicated in section 4.4 of the SmPC.

The CHMP endorse the CAT discussion on the non-clinical aspects as described above.

## 2.3.7. Conclusion on the non-clinical aspects

Overall, the nonclinical program has been well conducted and supports the approval of Zynteglo. The

<div style=\"page-break-after: always\"></div>

risk of insertional mutagenesis has also been adequately addressed in the non-clinical studies.

The CHMP endorse the CAT conclusions on the non-clinical aspects as described above.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

Medicinal product no longer authorised The Clinical trials were performed in accordance with Good Clinical Practice (GCP) as claimed by the applicant. The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC. · Tabular overview of clinical studies Table 4: Overview of Clinical Studies Evaluating the Drug Product in Patients with TDT

<!-- image -->

| Study Identifier (Status); Location of CSR or Protocol (as applicable)             | Study Title                                                                                                                                                                                                                                                                                                                           | Number of Patients with TDT 1 and Genotype                                                                                     | Drug Product Characteristics and Recommended Cell Dose                 | longer Recommended Busulfan Average Daily AUC   | Primary Efficacy Endpoint(s) from Study Protocol                                                                                                                                                                                                                                                                                                                                                    | Data Cut Dates                                                                                                                                                                 |
|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HGB-205 (ongoing) Module 5.3.5.2 Interim CSR HGB - 205 (patients with TDT only 2 ) | A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β -Hemoglobinopathies (Sickle Cell Anemia and β -Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral β A-T87Q -globin Globin Vector (LentiGlobin BB305 Drug Product)                     | 7 planned (TDT or SCD 2 ) 4 TDT treated 4 TDT completed (all non- β 0 /β 0 )                                                   | no Original manufacturing process ≥3.0 × 10 6 CD34+ cells/kg           | 4000 to 5200 µM*min 3                           | RBC transfusion requirements (measured in milliliters [mL] per kilogram [kg]) per month and per year post-transplant. Number of total in- patient hospitalization days (post-transplant discharge) at 6, 12, and 24 months.                                                                                                                                                                         | Interim CSR Data Cut: 11 Oct 2017 Module 2.7.2/2.7.3 Data Cut: 07 Mar 2018 Additional Data Cut: 13 Dec 2018                                                                    |
| HGB-204 (completed: 21 February 2018) Module 5.3.5.2 CSR HGB - 204                 | A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Patients with β -thalassemia Major by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral β A-T87Q -globin Vector (LentiGlobin BB305 Drug Product)                                                                 | product 18 planned 18 treated 18 completed (10 non- β 0 /β 0 ; 8 β 0 /β 0 ) 1 discontinued before conditioning                 | Base manufacturing process ≥3.0 × 10 6 CD34+ cells/kg                  | 3600 to 5000 µM*min 3                           | The sustained production of ≥2.0 g/dL of haemoglobin A (HbA) containing β A- T87Q -globin for the 6 months between Month 18 and Month 24 post-transplant.                                                                                                                                                                                                                                           | CSR Data Lock Point: 07 Mar 2018 Module 2.7.2/2.7.3 Data Cut: 07 Mar 2018 Additional Data Cut: 13 Dec 2018                                                                     |
| HGB-207 (ongoing) Module 5.3.5.2 Interim CSR HGB - 207                             | Medicinal A Phase 3, Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Patients with Transfusion- dependent β - Thalassemia, who do not have the β 0 /β 0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral β A-T87Q -Globin Vector in Patient s ≤50 Years of Age | 23 planned (15 for ≥12 and ≤50 years of age; 8 for <12 years of age) 15 treated 0 completed 1 discontinued before conditioning | Refined or commercial manufacturing process ≥5.0 × 10 6 CD34+ cells/kg | 3800 to 4500 µM*min 4                           | The proportion of patients who meet the definition of 'transfusion independence' (TI). TI is defined as a weighted average Hb ≥9 g/dL without any RBC transfusions for a continuous period of ≥12 months at any time during the study after drug product infusion. (Calculation of time period of TI will start when patients achieve an Hb ≥9 g/dL with no transfusions in the preceding 60 days). | Interim CSR Data Cut: 22 Feb 2018 Module 2.7.2/2.7.3 Data Cut: 22 Feb 2018 Additional Module 2.7.2/2.7.3 Late- Breaking Data Cut: 15 May 2018 Additional Data Cut: 13 Dec 2018 |

<div style=\"page-break-after: always\"></div>

| Study Identifier (Status); Location of CSR or Protocol (as applicable)             | Study Title                                                                                                                                                                                                                                                                                                       | Number of Patients with TDT 1 and Genotype                                                                                                                                                                            | Drug Product Characteristics and Recommended Cell Dose                 | Recommended Busulfan Average Daily AUC   | Primary Efficacy Endpoint(s) from Study Protocol                                                                                                                                                                                                                                                                                                                                    | Data Cut Dates                                                                                      |
|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| HGB-212 (ongoing) Module 5.3.5.2 Protocol HGB- 212                                 | A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Patients with Transfusion- dependent β - Thalassemia, who have a β 0 /β 0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral β A-T87Q -Globin Vector in Patient s ≤50 Years of Age | 15 planned (5 for ≥18 and ≤50 years of age; 10 for <18 years of age) 5 treated 0 completed                                                                                                                            | Refined or commercial manufacturing process ≥5.0 × 10 6 CD34+ cells/kg | 3800 to 4500 µM*min 4                    | authorised The proportion of patients who meet the definition of 'transfusion reduction' (TR), defined as demonstration of a ≥60% reduction in volume of packed red blood cell (pRBC) transfusion requirements (in mL/kg) in the post- treatment time period of Months 12 to 24, compared to the average annual transfusion requirements in the 24 months prior to study enrollment | CSR Data Cut: NA Module 2.7.2/2.7.3 Data Cut: 07 Mar 2018 Additional Data Cut: 13 Dec 2018          |
| LTF-303 (ongoing) Module 5.3.5.2 Interim CSR LTF - 303 (patients with TDT only 5 ) | A Longterm Follow-up of Patients with Hemoglobinopathies Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with Lentiviral Vector                                                                                                                                            | Long-term follow-up for all patients with a haemoglobinopathy who received drug product during bluebird bio- sponsored studies 5 22 treated patients with TDT enrolled (18 from Study HGB-204; 4 from Study HGB- 205) | Not applicable                                                         | Not applicable                           | For patients with TDT, assessments include, but are not limited to interval transfusions required (pRBC mL/kg), haemoglobin levels, therapeutic phlebotomies, iron chelator use, and measures of iron overload.                                                                                                                                                                     | CSR Data Cut: 21 Nov 2017 Module 2.7.2/2.7.3 Data Cut: 07 Mar 2018 Additional Data Cut: 13 Dec 2018 |

Medicinal product no longer authorised 1  Number of patients as of 13 December 2018 2  Note: patients with SCD (N=3 treated) were not included in the efficacy analysis for this module or in the interim CSR HGB 205. A final CSR for HGB205 with data from all patients will be written after completion of the study. 3 Changed from 3200 to 4400 μM*min in Protocol HGB -205 Version 7.0 (19 May 2016) and in Protocol HGB-204 Version 3.1 (17 March 2014). 4 Changed from 4000 to 5000 μM*min in Protocol HGB -207 Version 3.0 (19 June 2018) and in Protocol HGB-212 Version 2.0 (19 June 2018). 5  Note: patients with SCD were not included in the efficacy analysis for this module or the interim CSR LTF-303. A final CSR for LTF-303 with data from all patients will be written after completion of the study Methods of pooling data: Pools are described as used in the SAP submitted with the MAA. Data for patients in long-term follow-up LTF-303 were integrated with their data from parent studies and presented by parent studies within the pools described below. · For pooled PD analysis, the All Studies nonβ 0 /β 0  Pooling (HGB-204, HGB-205 TDT patients, HGB-207) was the primary analysis set. The PD analysis was also performed on the All Studies Pooling  (HGB-204,  HGB-205  TDT  patients,  HGB-207  and  HGB-212  that  includes  all genotypes). · For pooled efficacy analysis, the Phase 1/2 Studies nonβ 0 /β 0   Pooling (HGB-204, HGB-205 TDT patients) was the primary analysis set. The efficacy analysis was also performed on the Phase 1/2 Studies Pooling (HGB-204, HGB-205 TDT patients). Studies HGB-207 and HGB212 were not included in the pooled efficacy analysis, because these studies were recently initiated and are currently ongoing, and therefore few patients were evaluable for efficacy endpoints.

- The  All  Studies  nonβ 0 /β 0   Pooling  (HGB-204,  HGB-205  TDT  patients,  HGB-207)  was  the primary analysis set for correlation analysis. The correlation analysis was also performed on the  All  Studies  Pooling  (HGB-204,  HGB-205  TDT  patients,  HGB-207  and  HGB-212  that includes all genotypes).
- The Phase 1/2 Studies nonβ 0 /β 0  Pooling (HGB-204, HGB-205 TDT patients) were used to fit the  linear  regression  model,  the  repeated  measures  mixed  model,  and  the  exact  logistic regression model to predict relevant outcomes in HGB-207.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Pharmacokinetics

No pharmacokinetics studies were submitted (see discussion on clinical pharmacology).

Because  of  the  nature  of  Zynteglo,  conventional  methods  cannot  be  used  for  pharmacokinetic monitoring. No  dedicated PK-PD  studies have  been  conducted  because  the standard clinical pharmacology studies such as dose escalation/dose range finding, human absorption, metabolism and excretion,  drug-drug  interaction  and  special  population  studies  are  not  considered  feasible  for  gene therapy products.

<!-- image -->

Medicinal product no longer authorised 2.4.3. Pharmacodynamics Mechanism of action After collection of mobilised peripheral blood samples, the patient's autologous cells, enriched for CD34+ HSCs, undergo ex vivo transduction with BB305 lentiviral vector (LVV) (one cycle of transduction) to produce  Zynteglo  finished  product,  which  is  then  infused  intravenously  (IV)  into  the  patient  after myeloablative busulfan conditioning to prepare bone marrow (BM) 'niches' for engraftment of the HSCs. Zynteglo  finished  product  is  intended  for  autologous  use  only,  as  a  single  IV  administration (transplantation), to treat nonβ 0 /β 0  TDT. The  BB305  lentiviral  vector  (LVV),  used  for  the  transduction  of  autologous  HSCs,  is  a  replicationdefective, self-inactivating (SIN), third-generation, human immunodeficiency virus type 1 (HIV-1)-based LVV, pseudotyped with the vesicular stomatitis virus glycoprotein G (VSV-G). The BB305 LVV encodes a single amino acid (aa)-modified huma n β A globin protein (β A  threonine [Thr; T] to glutamine [Gln; Q] at aa position 87 [β A-T87Q -globin]) under the transcriptional control of the erythroidspecific human β -globin promoter and erythroid-specific enhancer elements (DNase I hypersensitive sites HS2, HS3, and HS4) of the human β -globin locus control region (LCR). Zynteglo finished product addresses the underlying genetic cause of TDT by adding functional copies of the β A-T87Q -globin gene. It provides a one-time treatment for patients with TDT, potentially eliminating the need for life-long supportive care with regular transfusions and iron chelation therapy. For TDT, production of the transgenic protein, β A-T87Q globin, provides/restores the synthesis of functional β -globin chains. After engraftment and differentiation of the HSCs from Zynteglo finished product, the in vivo expression of the integrated β A-T87Q -globin transgene in cells of the erythroid lineage allows the formation of HbA T87Q (i.e., α 2 β A-T87Q 2). Restoration of functional β -globin production should reduce the accumulation of excess uncomplexed  α -globin  in  erythroblasts,  thus  preventing  premature  death  of  the  cells,  enhancing erythropoiesis, preventing haemolysis, increasing total Hb levels and greatly reducing or eliminating the need for transfusions. Primary and Secondary pharmacology

Pharmacodynamic parameters were evaluated in both Phase 1/2 (HGB-204 and HGB-205) and Phase 3 (HGB-207 and HGB-212) studies, as well as in long-term follow-up Study LTF-303.

## Analytical methods

The measurement of pharmacodynamics (PD) parameters that detect the presence of integrated proviral sequences and the expression of the transgene in differentiated cells can be used to determine successful delivery and persistence of the drug product. If the patient's HSCs are successfully transduced, they incorporate the β A-T87Q -globin gene into their genome, and therefore their progeny contain the transgene.

<div style=\"page-break-after: always\"></div>

Therefore, the presence of LVV sequences in differentiated nucleated peripheral blood cells indicates the presence  of  transduced  cells  amongst  their  HSC  precursors.  The  presence  of  LVV  sequences  in  the genomic DNA of differentiated cells is detected using quantitative polymerase chain reaction (qPCR) and is expressed as vector copy number (VCN) (VCN, i.e., vector copies per diploid genome, c/dg). Because VCN is determined on a heterogeneous population of cells, VCN is a composite value, dependent both on % cells transduced as well as number of copies per transduced cell. Although all nucleated cells derived from a successfully transduced HSCs will have LVV sequences in their genome and contribute to the VCN in peripheral blood, only cells within the erythroid lineage will produce the transcription factors required to drive expression of the β A-T87Q -globin,  because the transgene is under the control of the erythroid lineage specific globin LCR. Only cells o f the erythroid lineage will express the transgenic β AT87Q -globin and subsequently contain HbA T87Q that results from the combination of endogenous α -globin with the transgenic β A-T87Q -globin . The presence of β A-T87Q -globin is detected using RP-HPLC. The levels of β A-T87Q -globin in blood were evaluated.

After drug product administration via IV infusion, PB VCN was monitored at all scheduled visits to monitor engraftment of transduced HSCs. Total Hb also was measured, and HbA T87Q , HbA, HbA2, HbF, and HbE (as relevant) were calculated at all scheduled visits after drug product administration to monitor both transgene expression and expression of endogenous globins.

Medicinal product no longer authorised In clinical studies using Zynteglo, both VCN in drug product (DP VCN) and VCN in peripheral blood (PB VCN) of treated patients are reported. DP VCN is measured in genomic DNA from pooled colony-forming cells after 14 days of in vitro culture. PB VCN is measured in genomic DNA from peripheral blood cells (i.e., VCN of nucleated cells derived from HSCs after differentiation in vivo, within the treated patient). RP-HPLC methods were developed and validated for relative quantification of globin chains; the methods were able to separate wildtype β A globin (β A ) from the transgene product β A-T87Q globin (β A-T87Q ). The relative levels of α -globin and of the β -like  globins (% β -like  globin chains), in conjunction with the determination of total Hb in another sample in the same visit window, allowed for the calculation of the proportion and quantity of the following Hb fractions that comprise total Hb (with associa ted β -likeglobins involved): HbA T87Q (β A-T87Q ), HbA (β A ), HbE (β E ; only for patients with the β E  mutation), HbA2 (δ), and HbF (γA and γG). Primary pharmacology For pooled PD analysis, the All Studies nonβ 0 /β 0  Pooling (HGB-204, HGB-205 TDT patients, HGB-207) was the primary analysis set. The PD analysis was also performed on the All Studies Pooling (HGB-204, HGB-205 TDT patients, HGB-207 and HGB-212 that includes all genotypes). All 4 studies had a similar study design. All studies were single arm studies enrolling patients with genetic defects in their β -globin gene (thalassaemia or sickle cell disease). All patients underwent haematopoietic stem  cell  collection  (mobilisation  with  granulocyte  colony-stimulating  factor  [G-CSF]  and  plerixafor followed by apheresis for patients with TDT), and myeloablative conditioning using busulfan before the administration  of  Zynteglo.  During  each  parent  study,  busulfan  concentrations  were  monitored  and busulfan dosing adjusted to target recommended AUC to effectively remove endogenous untransduced HSCs.

## Study population

As of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies, a total of 33 patients ≥ 12 years of age with TDT have been treated, of these 24 patients having the nonβ 0 /β 0  genotype.

Across Studies HGB-204, HGB-205 and HGB-207, similar median cell doses were administered with an overall median (min, max) total cell dose administered to patients with TDT of all genotypes (all studies)

<div style=\"page-break-after: always\"></div>

of 8.100 (5.00, 19.40)×10 6  CD34+ cells/kg, and to patients with TDT of nonβ 0 /β 0  genotype (all studies) was 7.950 (5.00, 19.40)×10 6  CD34+ cells/kg.

Myeloablation of the patients before drug product infusion is required to deplete endogenous HSCs, thus allowing repopulation of the patient with HSCs containing the transgene without dilution due to the presence  of  untransduced  cells.  Busulfan  was  used  as  a  single  agent. Busulfan's  effectiveness  in myeloablation  is  dependent  on  pharmacologic  exposure,  as  measured  by  the  AUC,  and  dosing  was adjusted based on PK monitoring to meet the targeted AUC levels as defined in each protocol. Busulfan average daily AUC used during these studies: median (min, max) of 4337.0 (3030, 5789) uM*min in patients of nonβ 0 /β 0  genotype (in Studies HGB-204, HGB-205, and HGB-207; N=24).

<!-- image -->

<!-- image -->

|         | no   |
|---------|------|
| product |      |

Medicinal product no longer authorised Vector Copy Number (VCN) within Cell Samples DP VCN data from Studies HGB-204, HGB-205, HGB-207 and (the long-term follow up study) LTF-303 provided the following values for patients of nonβ 0 /β 0  genotype: median (min, max) DP VCN was highest in Study HGB-207 (3.350 [2.40, 5.40] c/dg; N=10), followed by that in Study HGB-205 (1.300 [0.80, 2.10] c/dg; N=4) and lowest in Study HGB-204 (0.750 [0.30, 1.05] c/dg); N=10). Study HGB-204 included both nonβ 0 /β 0  gen otype and β 0 /β 0  genotype patients. The DP VCN values were as follows: median (min, max) of 0.750 (0.30, 1.05) c/dg for patients of nonβ 0 /β 0  genotype (N=10) vs 0.650 (0.30, 1.50) c/dg for patient s of β 0 /β 0  genotype (N=8) for patients treated in Study HGB-204. PB VCN was determined in peripheral blood of patients from Month 1 through Month 48 (Table 5 and Figure 2). Table 5: PB VCN Summary (TP) Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies

<div style=\"page-break-after: always\"></div>

Figure 2: VCN Over Time in Peripheral Blood for Nonβ 0 /β 0 , by Patient

<!-- image -->

<!-- image -->

Medicinal product no longer authorised Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies Note: Symbols indicate individual patients. Blue = patients from Study HGB-204, red = patients from Study HGB205, and green = patients from Study HGB-207. Patients who achieved transfusion independence (TI) at any time are represented with solid lines, and patients who have not yet achieved TI are represented with dashed lines. HbA T87Q  in Peripheral Blood Median HbA T87Q  levels in the nonβ 0 /β 0  patients are shown in Figure 3 with parent study indicated by colour: red (HGB-205), blue (HGB-204), and green (HGB-207). The median (min, max) for HbA T87Q  at Month 6 for patients with nonβ 0 /β 0  genotype for Study HGB-204 was 4.153 (1.03, 8.52) g/dL, for Study HGB-205 was 7.543 (4.94, 9.59) g/dL, and for Study HGB-207 was 9.409 (3.35, 10.47) g/dL. Data indicate that HbA T87Q  levels generally increase from Month 1 through approximately Month 6 to Month 9, after which time they stabilise. Figure 3 : HbA T87Q  Over Time in Peripheral Blood for nonβ 0 /β 0 , by Patient

Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies Note: Symbols indicate individual patients. Blue = patients from Study HGB-204, red = patients from Study HGB205, and green = patients from Study HGB-207. Patients who achieved transfusion independence (TI) at any time are represented with solid lines, and patients who have not yet achieved TI are represented with dashed lines.

<div style=\"page-break-after: always\"></div>

## Relationship Between HbA T87Q  Levels at Early Time points (Months 6 or 9) vs HbA T87Q  Levels at Later Time points (Month 18 or 24)

Due to similarity of HbA T87Q  kinetics over time between patients, HbA T87Q  values at early time points tend to correlate with HbA T87Q  values at later time points. Using data on the nonβ 0 /β 0  genotype patients from the  Phase  1/2  studies,  strong  correlations  were  observed  between  the  HbA T87Q   value  at  Month  6 (r  = 0.9252) or Month 9 (r = 0.9809) and HbA T87Q  measured at Month 24. This suggests that HbA T87Q values measured at these two time points, particularly at Month 9, could be used to predict HbA T87Q levels at Month 24 (see Figure 4).

<!-- image -->

Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies

## Hb Fractions Over Time

Hb fractions over time are presented in Figure 5 for transfusion-free patients of nonβ 0 /β 0   genotype, where transfusion-free is defined as not receiving a pRBC transfusion for a continuous period of at least 12 months. Endogenous HbE or HbA make important contributions to total Hb for patients of nonβ 0 /β 0

<div style=\"page-break-after: always\"></div>

genotype who were able to be maintained transfusion-free in Studies HGB-204 and HGB-205. In these Phase 1/ 2 studies, at Month 24 for transfusion-free patients of nonβ 0 /β 0  genotype, median (min, max) HbA T87Q  was 6.600 (3.80, 10.13; N=12) g/dL, HbE was 2.900 (2.08, 4.78; N=8) g/dL, HbA was 2.551 (1.00, 6.44; N=4) g/dL, HbF was 0.384 (0.08, 1.37; N=12) g/dL, and HbA2 was 0.328 (0.19, 0.56; N=12) g/dL.

Panel A shows that HbA T87Q  levels increase initially as patients begin to express the transgene and reach plateau levels around Month 6 to Month 9. In Phase 1/2 studies, median (min, max) HbA T87Q  was 6.600 (3.80, 10.13; N=12) g/dL at Month 24 for transfusion-free patients of nonβ 0 / β 0  genotype.

Medicinal product no longer authorised Panel B shows the kinetics of HbE in patient s with at least one β E  allele. After drug product infusion, HbE kinetics paralleled that of HbA T87Q , with endogenous levels of HbE, reaching plateau levels by Months 6 to 9. In Phase 1/2 studies, median (min, max) HbE was 2.900 (2.08, 4.78; N=8) g/dL at Month 24 for transfusion-free patients of nonβ 0 /β 0  genotype. Panel C shows kinetics of HbA in patient s with at least one β +  allele. After drug product infusion, HbA levels initially decreased as patients stopped pRBC transfusions and exogenous red blood cells (RBC) were metabolized, and then plateau by Months 6 to 9, reflecting endogenous HbA production. In Phase 1/2 studies, median (min, max) HbA was 2.551 (1.00, 6.44; N=4) g/dL at Month 24 for transfusion-free patients of nonβ 0 /β 0  genotype. Panel D shows kinetics of HbF in all transfusion-free patients of nonβ 0 /β 0  genotype. HbF levels tended to show a peak around 2 to 3 months after drug product infusion. The variability of HbF (in Phase 1/2 studies, median (min, max) HbF was 0.384 (0.08, 1.37; N=12) g/dL at Month 24 for transfusion-free patients of nonβ 0 /β 0  genotype) reflected variation in the levels of HbF that patients stably expressed. Panel  E  shows  that  in  general,  HbA2  contributed  relatively  low  amounts  to  the  total  Hb  levels  of transfusion-free patients. In Phase 1/2 studies, median (min, max) HbA2 was 0.328 (0.19, 0.56; N=12) g/dL at Month 24 for transfusion-free patients of nonβ 0 /β 0  genotype. Figure 5: Boxplot of Hb fractions over time among transfusion-free patients of Nonβ 0 /β 0 Genotype

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Medicinal product no longer authorised Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies Ratio of α -globin to β -like-globins In study HGB-205: After becoming transfusion independent, all patients were able to maintain a stable α/β -like ratio close to 1, ranging from 0.86 in one patient through 1.26 in another patient at Month 24. In Study HGB-204: After becoming transfusion independent, the patients were able to maintain a stable α/β -like ratio close to 1 with ratios ranging from 1.07 through 1.34 at Month 24. Relationship between Dosing Characteristics and PD Parameters

In general, the highest HbA T87Q  after drug product infusion was reported for the patients with the highest DP VCN. Despite the existence of one patient in Study HGB-207 that had a much lower HbA T87Q  than DP VCN, results showed a correlation for patients of nonβ 0 /β 0  genotypes (p=0.0001; Table 6). Only limited data for Phase 3 studies conducted with the refined or commercial manufacturing process are available.

<div style=\"page-break-after: always\"></div>

| X-axis (Independent)   | Y-axis (Mependent)   | Population   | R value           | p-value            |
|------------------------|----------------------|--------------|-------------------|--------------------|
| DP VCN                 | PBVCN at M6          | TP           | R=0.6916 R=0.6424 | p=<0.0001 p=0.0023 |
| DP VCN                 |                      |              |                   |                    |
| DP VCN                 |                      |              |                   |                    |

<!-- image -->

Table 6: Relationships between dosing characteristics and PD parameters (Pearson correlations)

<!-- image -->

| Model                  | X Y                |   Estimated Slope | 95% CI of Slope   | p-value   |
|------------------------|--------------------|-------------------|-------------------|-----------|
| Model 1 HbA T87Q at    | M6 HbA T87Q at M12 |              0.86 | (0.59, 1.14)      | <0.0001   |
| Model 2 HbA T87Q at    | M6 HbA T87Q at M24 |              0.91 | (0.68, 1.15)      | <0.0001   |
| Model 3 HbA T87Q at    | M9 HbA T87Q at M18 |              1.11 | (0.95, 1.28)      | <0.0001   |
| Model 4 HbA T87Q at M9 | HbA T87Q at M24    |              1.11 | (0.97, 1.25)      | <0.0001   |

As a sensitivity analysis, the repeated measures mixed model was applied to assess HbA T87Q  expression post Month 6 and up to Month 24 (inclusive). Model 5 used HbA T87Q  at Month 6 as a predictor while including visits (Months 9, 12, 15, 18, 21, and 24) as a categorical covariate. The results of Model 5 were very similar to those of Model 1 and Model 2.

Medicinal product no longer authorised Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies Predictive Modelling Development of Models Given the strong correlation between HbA T87Q  at early and later time points, linear regression models can be used to predict HbA T87Q  at Month 12/24 or Month 18/24 for Study HGB-207 patients using their observed HbA T87Q  data at Month 6 or Month 9. To establish the linear relationship, data from the nonβ 0 /β 0  patients of Studies HGB-204 and HGB-205 were used (N=14) (Table 7). Table 7: Fitted Univariate Linear Regression Models Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies

## Use of Models to Predict HGB-207 Results

The fitted models were applied to predict HbA T87Q  at either Months 12, 18, or 24, based on Study HGB207 patients with observed HbA T87Q  at Months 6 or 9 (Table 8). These models predict that 5/6 of these patients will be producing approximately 9 g/dL or greater of HbA T87Q  at Months 12, 18 and 24 in Study

<div style=\"page-break-after: always\"></div>

HGB-207. Therefore, total Hb is expected to consistently reach levels such that chronic pRBC transfusions are no longer required (&gt;9 g/dL) (Cappellini et al. 2014).

Table 8: Predicted HbA T87Q  Expression at Later Timepoints of Study HGB-207 Patients

Table 9: Univariate Exact Logistic Regression Models: Achieving TI at Any Time and HbA T87Q at Months 6 and 9

<!-- image -->

Medicinal product no longer authorised Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies Despite the similar ranges of HbA T87Q  produced by patients with nonβ 0 /β 0 and β 0 /β 0   genotypes,  the observed clinical outcomes were different in these 2 groups in Phase 1/2 studies. Within Study HGB-204, only 1/8 (12.5%) patient s of β 0 /β 0  genotype was able to achieve TI by the end of the study, presumably because patient s of β 0 /β 0  genotype produce n o endogenous β -globin. In contrast, the majority (8/10, 80%) of patients of nonβ 0 /β 0  genotype in Study HGB-204 were able to meet the criteria to establish TI, presumably because of the contributions of endogenous globins. Based on results presented Month 6/9 HbA T87Q  values are associated with HbA T87Q  values at Month 12/18/24. Thus Month 6/9 HbA T87Q  values were also used to predict the binary outcome of whether or not patients would achieve TI at Month 24, or at any time during the study. Relationship of HbA T87Q  Production to Clinical Outcome Model Development Exact logistic regression models were fitted to 14 nonβ 0 /β 0  patients from Studies HGB-204 and HGB205 to evaluate the relationship between the probability of achieving TI at Month 24/any time and HbA T87Q  at Month 6/9. The HGB-204 and HGB-205 nonβ 0 /β 0  patients were pooled to increase sample size for a more accurate fit. Among the 14 patients, 11 patients achieved TI at any time/Month 24 and 3 patients did not achieve TI at any time/Month 24. Model 6 established the relationship between probability of achieving TI at any time and the continuous HbA T87Q  (g/dL) value at Month 6. This suggested that the probability of achieving TI at any time and the HbA T87Q   (g/dL)  at  Month  6  were  highly  correlated.  Model  7  showed  a  similar  relationship  between probability of achieving TI at any time and the HbA T87Q  (g/dL) at Month 9.

| Model:   | X              | Y                             |   Exactodds ratio | 95%CIof Exactodds ratio   |   p-value |
|----------|----------------|-------------------------------|-------------------|---------------------------|-----------|
| Model 6  | HbAT87Q at M6  | Probability of TI at Any Time |              2.01 | (0.94, 6.92)              |    0.0824 |
| Model 7  | HbA T87Q at M9 | Probability of TI at Any Time |              1.99 | (0.96, 6.47)              |    0.0714 |

<div style=\"page-break-after: always\"></div>

## Subgroup analysis

## Subgroup Analysis of PB VCN

Subgroup analyses for PB VCN were performed by age (12 to &lt;18 vs ≥18 years of age), gender (male vs female), and race (Asian vs White; data shown in summary of Clin. Pharmacology). All subgroups showed similar kinetics, with median PB VCN values stabilizing by approximately Month 6.

Subgroup Analysis of HbA T87Q

Subgroup analyses for HbA T87Q were performed by age (12 to &lt;18 vs ≥18 years of age;), gender (male vs female) and race (Asian vs White). All subgroups show similar kinetics, with HbA T87Q  values stabilizing by approximately 6 to 9 months. No meaningful differences were observed (data shown in summary of Clin. Pharmacology).

<!-- image -->

All patients with TDT with a nonβ 0 / β 0  genotype who received Zynteglo with at least 3 months of followup produced HbA T87Q  (N=10, HGB-204; N=4, HGB-205; N=14, HGB-207; N=1, HGB-212). For patients with at least 6 months of follow-up, HbA T87Q  generally increased steadily after Zynteglo infusion and stabilised  by  approximately Month 6 to 9 post infusion. Patients had a Month 6 median (min, max) HbA T87Q  of 4.90 (1.0, 9.6) g/dL in the Phase 1/2 studies (N=14, HGB-204 and HGB-205) and 9.49 (3.4, 10.6) g/dL in the ongoing Phase 3 study (N=11, HGB-207). Phase 3 studies are conducted with the refined or commercial manufacturing process, resulting in increased drug product vector copy number (DP VCN), PB VCN, and HbA T87Q  as compared to Phase 1/2 studies. With the increased HbA T87Q  levels in Phase 3 studies, endogenous haemoglobin (Hb) may not be as important a determinant of total Hb post

Medicinal product no longer authorised 2.4.4. Updated data on PD parameters: 13 December 2018 An additional data cut was performed of the HGB-207, HGB-212, and LTF-303 clinical databases on 13 December 2018. As of 13 December 2018, a total of 42 patients ≥ 12 years of age with TDT have been treated, of these 32 patients having the nonβ 0 /β 0  genotype. All patients were administered Zynteglo with a median (min, max) dose of 7.80 × 10 6  (5.0, 19.4) CD34+ cells/kg (N=32). Patients remained in the hospital for a median (min, max) of 44.0 (27, 92) days from conditioning through discharge (N=32). Median (min, max) DP VCN was 3.400 (2.40, 5.60) c/dg (N = 15). Once established, PB VCN levels generally stabilise by Month 6; PB VCN at Month 6 was 2.451 (0.25, 5.41) c/dg for patients of nonβ 0 /β 0 genotype in Study HGB-207, (N = 11). For patients in all studies, both PB VCN and HbA T87Q  levels have been persistent through last follow-up (up to Month 60 as of 13 December 2018) . Table 10: VCN for studies HGB-204, HGB-205 and HGB-207 Data as of 13 December 2018

<div style=\"page-break-after: always\"></div>

treatment, and patients may be able to increase total Hb to levels sufficient to achieve and maintain transfusion independence (TI) regardless of genotype and endogenous β -globin production.

HbA T87Q  remained generally stable through Month 24 with a median (min, max) of 6.44 (1.1, 10.1) g/dL (N=14, HGB-204 and HGB-205), and through long-term follow-up in LTF-303, demonstrating stable integration of the β A-T87Q -globin gene into long-term HSCs and stable expression of the β A-T87Q -globin gene in cells of the erythroid lineage (Figure 6).

Figure 6: Median HbA T87Q  over time for nonβ 0 /β 0  patients

<!-- image -->

The  presence  of  integrated  viral  sequences  and  the  subsequent  expression  of  the  transgene  are presented as pharmacodynamic (PD) parameters to determine the incorporation and persistence of the drug product. The presence of LVV sequences and vector copy numbers can be established in the drug product, bone marrow cells and peripheral blood cells (PB VCN). When HSCs are transduced with BB305 LVV, they incorporate β A-T87Q -globin  gene in their genome. The HbA T87Q  will be produced by all their progenitor cells that have differentiated into the erythroid lineage.

Medicinal product no longer authorised Data as of 13 December 2018 Ratio of α -globin to β -like-globins: In patients in study HGB 207, with at least 6 months of followup, the median α -globin to β -like-globin chain ratio, as observed at last visit, was 1.07, range of 1.02 to 1.14, (N=11). 2.4.5. Discussion on clinical pharmacology Because  of  the  nature  of  Zynteglo,  conventional  methods  cannot  be  used  for  pharmacokinetic monitoring. No  dedicated PK-PD  studies have  been  conducted  because  the standard clinical pharmacology studies such as dose escalation/dose range finding, human absorption, metabolism and excretion,  drug-drug  interaction  and  special  population  studies  are  not  considered  feasible  for  gene therapy products.

PD parameters have been presented from two finalised phase 1/2 clinical trials (HGB-204 and HGB-205) and 2 ongoing phase 3 clinical trials (HGB-207 and HGB-212). After drug product administration via IV infusion, PB VCN was monitored at all scheduled visits to monitor engraftment of transduced HSCs. For optimization of drug product, transduction, and transplantation procedures, PB VCN was a useful marker,

<div style=\"page-break-after: always\"></div>

even though PB VCN is considered to be of limited relevance as clinical outcome. The ultimate goal of the  therapy  is  to  achieve  adequate  amounts  of  total  haemoglobin  (Hb)  to  obtain  transfusion independence (primary efficacy endpoint), and for this purpose HbA T87Q  levels can be used as surrogate. HbA T87Q   production  alone  or  supplemented  with  endogenous  Hb  (e.g.  HbE,  HbF,  etc)  is  required  to achieve levels of 9 g/dl or higher to meet the definition of transfusion independence.

In all studies, successful engraftment was achieved in all patients, and busulfan doses and total cell doses  were  sufficient  to  achieve  effective  haematopoietic  reconstitution.  A  dose  effect  could  not  be investigated for Zynteglo due to the individual nature of the product. In Phase 1/2 clinical studies HGB205 and HGB-204, the minimum recommended dose of Zynteglo was 3.0 × 10 6  CD34+ cells/kg; this was based on practice for autologous transplantation. The recommended cell dose is a single dose of drug product with ≥5.0 x 10 6  CD34+ cells/kg body weight. The doses administered in clinical studies to date are 5.0 to 19.4 × 10 6  CD34+ cells/kg. The minimum recommended dose is the same for adults and adolescents 12 years of age and older (see Summary of Product Characteristics [SmPC]). An upper dose limit has not been determined. As a matter of fact, the number of CD34+ cells administered to a patient is limited by the number of cells that could be collected from the patient. There is no maximum dose of CD34+ cells for infusion of autologous cell products prescribed in the literature.

There appears to be an inverse correlation between HbA T87Q production and endogenous β -globin at Month 6 in patients not receiving pRBC transfusions.

Medicinal product no longer authorised All patients with TDT who received Zynteglo had LVV sequences in peripheral blood cells at their last visit. In all studies the VCN in peripheral blood was generally lower than in the DP, this is likely due to a dilution effect as busulfan only ablates HSCs and not mature white blood cells. PB VCN kinetics over time are  similar  between  patients,  showing  a  plateau  at  approximately  6  months  after  Zynteglo  infusion followed by stable expression over time (a c orrelation coefficient of ≥0.9 between PB VCN at Month 24 versus PB VCN at Month 6). Stable values were maintained in the patient with the longest follow up of approximately 60 months after drug product infusion. All  patients  who  received  Zynteglo  produce d  Hb  containing  β A-T87Q -globin  (HbA T87Q ).  Median  HbA T87Q levels increase from Month 1 through approximately Month 6 to Month 9, after which time they stabilize. Significant correlations (p&lt;0.0001) were observed between HbA T87Q  at Month 6 or Month 9 and that at Month 24 (HGB-204 and HGB-205). The amount of HbA T87Q  produced was variable between patients. For β 0 /β 0  patients in Phase 1/2 Study HGB-204, the within patient variability can be explained by dilution after periodic pRBC transfusions, on which the majority were still dependent. For nonβ 0 /β 0  patients, the variation in HbA T87Q  production between patients could be due to a variety of factors associated with drug product manufacturing and administration as well as between-patient variability. Additional analyses indicate that there is a relationship between PB VCN and HbA T87Q  which appears to be linear at PB VCN levels below approximately 1.0 c/dg, but that above that, the curve flattens out, appearing to plateau at &gt;2.0 c/dg (R² = 0.8, p&lt;0.0001, N = 34). A similar relation is noted between DP VCN and HbA T87Q  at Month 6 (R² = 0.6, p&lt;0.0001, N = 34). In general, patients with the highest DP %LVV+ cells had the highest PB VCN after drug product infusion and, as a consequence, a similar relationship with HbA T87Q  at Month 6 (R² = 0.7, p&lt;0.0001).

Nonβ 0 /β 0   patients produce low amounts of endogenous HbA or HbE (depending on type of β -globin mutation),  as  well  as  HbA2  and  HbF.  All  endogenous  Hb  fractions  (i.e.,  HbF,  HbA2,  HbA  or  HbE  as relevant)  reached  stable  levels  by  approximately  the  same  time  as  the  transgenic  HbA T87Q   (i.e.,  by approximately 6 to 9 months) in patients no longer receiving pRBC transfusions and were maintained at stable levels out to at least 24 months.

In HGB-204 and HGB-205, patients were reported with an α/β chain ratio of above 1 at Month 24, which in most cases was an increase from the ratio before transplantation. The synthesis of these chains is

<div style=\"page-break-after: always\"></div>

very tightly coordinated so that the ratio of alpha globin to ß globin is normally 1 +/- 0.05. The clinical relevance of this observed imbalance in α/β chains and the increase from baseline is no t known. There might be a ceiling of β -globin or total Hb within a cell at which mechanisms of metabolism or downregulation exist that prevent β -globin accumulation. However, it is unclear whether dysregulation of these mechanisms of degradation of excess β -globin could occur.

Medicinal product no longer authorised Study HGB-207 is still ongoing with a median follow-up time of 5.59 (0.8, 13.2) months. In line with the results from the phase 1/2 studies, the preliminary data from study HGB-207 showed production of HbA T87Q .  A linear regression model was built based on studies HGB-204 and HGB-205 in order to predict levels of HbA T87Q  at Month 12/24 with data from Month 6. The Applicant performed multiple correlations providing  a  strong  correlation  on  the  kinetics  of  PB  VCN  and  HbA T87Q   at  different  time  points.  The correlations and regression models suggested that Month 9 had a stronger relationship with Months 18 and 24 (r = 0.9760 and 0.9809, respectively) than Month 6 data have with Months 12 and 24 (r = 0.8929 and 0.9252, respectively); thus the models predicting outcomes based on Month 9 data are preferred. Logistic regression models were also fitted using data from the 14 nonβ 0 /β 0  patients from HGB-204 and HGB-205, in order to evaluate the relationship between the probability of achieving TI at Month 24/any time and HbA T87Q  at Month 6/9. However, the models have not been validated given the small patient sample. The prediction intervals were wide, which reflects the uncertain prediction in the models. Thus, no conclusion can be drawn in light of the model uncertainties. During the clinical studies, the drug manufacturing process was changed for optimization of transgene expression. This change in manufacturing process in studies HGB-205, HGB-204, and HGB-207 had a clear influence on the median DP VCN achieved with the highest median DP VCN in HGB-207, consistent with improved transduction efficiency of the refined and commercial manufacturing processes. A relation between the DP VCN and PD parameters has been shown and thus this process change also influenced PB VCN and HbA T87Q  levels. In line with this, higher HbA T87Q  levels were obtained in patients treated in Studies HGB-207 and HGB-212, as compared to patients treated in Study HGB-204. Therefore, even though clinical experience with the commercial manufacturing process in Phase 3 studies is more limited, high rate of transfusion independence could be expected. 2.4.6. Conclusions on clinical pharmacology The  presented  data  show  that  Zynteglo  administration  at  all  tested  doses  resulted  in  successful engraftment in all patients with LVV sequences integrated into HSCs, resulting in transgene expression and subsequent β A-T87Q -globin  in  treated  nonβ 0 /β 0   patients.  Transgene  expression  and β A-T87Q -globin production plateaued at approximately 6 to 9 months after Zynteglo infusion, although long-term followup is limited. Despite some uncertainties identified with the regression model used to predict HbA T87Q  at Months 12/24 in study HGB-207, it confirmed that the results were in line with previous phase 1/2 studies conducted with the product. The CHMP endorse the Committee for Advanced Therapies (CAT) assessment regarding the conclusions on the Clinical pharmacology as described above.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical efficacy

## 2.5.1. Dose response studies

## Phase 1/2 study HGB-205

Study HGB-205 was an \"O pen Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β -Hemoglobinopathies (Sickle Cell Anemia and β -Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced ex vivo with a Lentiviral β A-T87Q -Globin Vector\" (Zynteglo finished product).

Medicinal product no longer authorised Drug product in this study was manufactured using the original manufacturing process. Study Participants Inclusion Criteria: 1. Between 5 and 35 years of age, inclusive. · Adult patients (between 18 and 35 years of age, inclusive, at the time of consent) must be able to provide written consent. · For paediatric patients (between 5 and 17 years of age, inclusive, at the time of consent), a competent parent or legal guardian must be able to provide written informed consent. When possible, involvement of the child &gt;7 years of age in the decision is highly recommended, and written assent will be obtained and should be clearly documented. · Patients  aged  5  to  14  years  require  the  approval  from  the  Comité  de  Surveillance  prior  to enrollment. 2. Have severe SCD or TDT, regardless of the genotype (e.g., β 0 /β 0 , β + /β + , β E /β 0 , β S /β S , β S /β 0 , β S /β + ), with the diagnosis confirmed by Hb studies. Patients with TDT must be stable and maintained on an appropriate iron chelation regimen. Transfusion dependence is defined as requiring at least 100 mL/kg/year of packed RBCs. 3. Be  eligible  for  allogeneic  haematopoietic  stem  cell  transplantation  (allogeneic  HSCT)  based  on institutional medical guidelines, but without a matched, related donor. 4. Be willing and able, in the Investigator's opinion, to comply with the study procedures outlined in the study protocol. If a paediatric patient, the patient's parent/legal guardian also must be willing and able to comply with the study procedures outlined in the study protocol. 5. Have been treated and followed for at least the past 2 years in a specialised centre that maintained detailed medical records, including transfusion history. Exclusion Criteria

1. Availability  of  a  willing,  10/10-matched  HLA-identical  sibling  haematopoietic  cell  donor,  unless recommendation for enrolment is provided by the Comité de Surveillance following a review of the case.
2. Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 or HIV-2), human Tlymphotrophic virus-1 or -2 (HTLV-1 or HTLV-2), vesicular stomatitis virus glycoprotein (VSV-G) antibody (Ab).
3. Clinically significant, active bacterial, viral, fungal, or parasitic infection.
4. Contraindication to anaesthesia for bone marrow harvesting.

<div style=\"page-break-after: always\"></div>

5. Any prior or current malignancy, myeloproliferative or immunodeficiency disorder.
6. A white blood cell (WBC) count &lt;3 × 10 9 /L and/or platelet count &lt;120 × 10 9 /L.
7. Receipt of an allogeneic transplant.
8. Receipt of erythropoietin within 3 months before hematopoietic stem cell transplantation (HSCT) harvest.
9. Immediate family member with a known or suspected Familial Cancer Syndrome (including but not limited to breast, colorectal, ovarian, prostate, and pancreatic cancers).

Medicinal product no longer authorised 10. Diagnosis of significant psychiatric disorder of the patient that could seriously impede the ability to participate in the study. 11. Active relapsing malaria. 12. Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile patients. Females of childbearing potential must agree to use a medically acceptable method of birth control  such  as  oral  contraceptive,  intrauterine  device,  barrier  and  spermicide,  or  contraceptive implant/injection throughout the 27-month study period. 13. History of major organ damage including: · Liver disease, with transaminase levels &gt;3× upper limit of normal. (This observation will not be exclusionary if a liver biopsy shows no evidence of extensive bridging fibrosis, cirrhosis, or acute hepatitis). · Histopathological evidence of extensive bridging fibrosis, cirrhosis, or acute hepatitis on liver biopsy. · Heart disease, with a left ventricular ejection fraction &lt;25%. · Kidney disease with a calculated creatinine clearance &lt;30% normal value. · Severe iron overload, which in the opinion of the physician is grounds for exclusion. · A cardiac T2* &lt;10 ms by magnetic resonance imaging (MRI). · Evidence of clinically significant pulmonary hypertension requiring medical intervention. 14. Any other condition that would render the patient ineligible for HSCT, as determined by the attending transplant physician. 15. Participation in another clinical study with an investigational drug within 30 days of Screening. 16. Patients who have the desire to become a parent within the 27-month study period. 17. Prior receipt of gene therapy.

18. An assessment by the Investigator that the patient or parents of the patient will not comply with the study procedures outlined in the study protocol.
19. Hydroxyurea therapy within 3 months before haematopoietic stem cell collection.

## Baseline data

Seven  patients  satisfied  the  eligibility  criteria  for  this  study:  4  adolescents  with  TDT  and  3 adolescents/young adults with SCD were enrolled and treated.

All  4  patients  with  TDT  enrolled  in  this  study  were  of  a  nonβ 0 /β 0   genotypes.  Three  patients  were compound heter ozygous for the β 0 and β E alleles (β E /β 0  genotype). The remaining patient had a β + /β +

<div style=\"page-break-after: always\"></div>

genotype (homozygous for the IVS I-110 G  A  mutation,  a  β +   mutation  that  consistently  results  in dramatically  reduced  β -globin  production  and  is  responsible  for  severe  disease;  Human  Genome Variation Society [HGVS] nomenclature HBB :c.93-21G&gt;A). Patients received a single intravenous dose of Zynteglo ranging from 8.79 × 10 6  to 13.6 × 10 6  CD34+ cells/kg. Drug product vector copy number (DP VCN) ranged from 0.8 to 2.1 c/dg.

## Outcomes and estimation

Table 11: Summary of Key Efficacy Results

| no      |
|---------|
| product |

<!-- image -->

Medicinal product no longer authorised Data as of 11 October 2017 Table 12: Change in pRBC Transfusion Requirements (TP)

|   138.8 |   10.5 |   8.2 |   8.2 |   0.0 |   -138.8 |   -100.0 |   0.0 |   -10.5 |   -100.0 |   10.6 |
|---------|--------|-------|-------|-------|----------|----------|-------|---------|----------|--------|
|   187.7 |     12 |  10.6 |   9.5 |     0 |   -187.7 |     -100 |     0 |     -12 |     -100 |   13.2 |
|   176   |     13 |   8.1 |   8.7 |     0 |   -176   |     -100 |     0 |     -13 |     -100 |    8.5 |
|   197.3 |     13 |  10.8 |   9.5 |     0 |   -197.3 |     -100 |     0 |     -13 |     -100 |   11.4 |

Souce:Table14.2.4

Abbrev.:BL,baseline;Hb,hemoglobin; pRBC,packed red blood cell

2 Weighted average Hb nadir is defined as an average area umder the cuve where the Hb closest but within 3 days prior to a transfusion is used as the Hb nadir. Hbvalues on the dayof the transfusion will be considered for nadir calculations.

1 2-year period prior to enrollment

3Hb value that higgered a pRBC transfusion pre-enrollment, as reported by treating physician

Data as of 11 October 2017

<!-- image -->

<div style=\"page-break-after: always\"></div>

Three of the 4 patients with TDT in this study achieved TI. Of the 4 TDT patients, 3 patients received their last pRBC transfusion within 13 days after Zynteglo infusion and all 3 patients remained transfusionfree through Month 24. These 3 patient s maintained a total Hb ≥9.0 g/dL from Month 1 through end of the study at Month 24.

One patient who was homozygous for IVS-I-110 mutation was not able to maintain a total Hb ≥9.0 g/dL in the absence of pRBC transfusions and received last pRBC transfusion on Day 94 when total Hb dropped to 7.4 g/dL. The weighted average Hb between 6 months after drug product infusion and last study visit was 8.5 g/dL, which was above his average pre-enrolment pre-transfusion nadir of 8.1 g/dL. His HbA T87Q levels  increased  slowly  and  stabilized  by  Month  9  at  6.40  g/dL  with  a  total  Hb  of  8.2  g/dL,  and  he remained transfusion free through Month 24.

<!-- image -->

Medicinal product no longer authorised HbA T87Q   concentration  at  Month  24  for  the  3  patients  who  achieved  TI  ranged  from  7.27 g/dL  to 10.13 g/dL. These 3 patients all had the genotype β E / β 0  and therefore also were producing ≥ 2.0 g/dL of HbE. TI  status  was  maintained  stably  through  the  end  of  the  study,  up  to  a  duration  of  approximately 22 months, with a weighted average Hb during the period of TI for 3 patients ranging from 10.6 to 13.1 g/dL The 3 patients who achieved TI had a decrease in liver iron content (LIC) during the study, and 2 of the 3 patients discontinued iron chelation therapy and started phlebotomy. The patient who did not achieve TI did not show an improvement in LIC and remained on iron chelation therapy. All  patients  had  normal  cardiac  iron  content  (MRI  results:  myocardial  T2*  &gt;20  ms)  at  baseline  and throughout the study. The 3 patients who achieved TI had near normal levels of serum transferrin receptor, and 2 of these 3 patients had normal levels of reticulocytes, whereas the patient who did not achieve TI had higher than normal levels of both reticulocytes and serum transferrin receptor. One patient who achieved TI had no nucleated  RBCs  (erythroblasts)  in  peripheral  blood,  whereas  erythroblasts  were  still  detected  in  the peripheral blood of the other 3 patients.

<div style=\"page-break-after: always\"></div>

## Phase 1/2 study HGB 204

This was a single-arm, multi-site, single dose, Phase 1/2 study in which patients with TDT were treated with Zynteglo finished product. TDT was defined as patients who received at least 100 mL/kg/year of pRBCs or ≥ 8 transfusions of pRBCs per year in each of the 2 years prior to enrolment. Treatment was staggered with a second patient beginning myeloablative conditioning only after the first patient 1) engrafted (defined as 3 consecutive absolute neutrophil count [ANC] laboratory values ≥ 0.5 × 10 9 /L obtained on different days); and 2) had no Zynteglo finished product treatment-related serious adverse event (SAE) unexpected to occur with HSCT.

- Medicinal product no longer authorised Eighteen patients (15 adults and 3 adolescents) were treated with a single dose of Zynteglo finished product;  10  patients  had  a  nonβ 0 / β 0   genotype  and  8  patients  had  a β 0 / β 0   genotype.  The  base manufacturing process used in Study HGB-204 was similar to that used in Study HGB-205 but was optimized for multi-site clinical use. Inclusion Criteria: 1. Patients between 12 and 35 years of age, inclusive, at the time of consent or assent (as applicable), and  able  to  provide  written  consent  (adults,  or  legal  guardians,  as  applicable)  or  assent (adolescents). 2. Diagnosis  of β -thalassemia  major  and  a  history  of  at  least  100  mL/kg/year  of  pRBCs  or ≥ 8 transfusions of pRBCs per year for the prior 2 years. 3. Documented baseline, or pretransfusion, Hb level of ≤ 7 g/dL. 4. Clinically stable, have a Karnofsky performance status of ≥ 60, and eligible to undergo HSCT. 5. Treated and followed for at least the past 2 years in a specialized centre that maintained detailed medical records, including transfusion history. Exclusion Criteria: 1. Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 or HIV-2), hepatitis B virus (HBV), or hepatitis C virus (HCV). (Note that patients who are positive for anti-HBV antibody [to either core or envelope proteins] or for anti-HCV antibody are eligible as long as they have a negative HBV or HCV viral load by qPCR. Where clinically and/or regionally indicated, one or more of the following tests may be performed, in which case positive results would exclude the patient from  participating:  human  T-lymphotrophic  virus-1  (HTLV-1)  or  HTLV-2,  syphilis  (rapid  plasma reagin [RPR]), toxoplasmosis, Trypanosoma cruzi, or West Nile Virus). 2. Active bacterial, viral, fungal, or parasitic infection. 3. A white blood cell (WBC) count &lt;3 × 10 9 /L, and / or platelet count &lt;100 × 10 9 /L not related to hypersplenism. 4. Uncorrected bleeding disorder.
5. Any prior or current malignancy or myeloproliferative or immunodeficiency disorder.
6. Immediate family member with a known or suspected Familial Cancer Syndrome (including but not limited  to  hereditary  breast  and  ovarian  cancer  syndrome,  hereditary  non-polyposis  colorectal cancer syndrome and familial adenomatous polyposis).
7. Prior HSCT.
8. Advanced liver disease, defined as:

<div style=\"page-break-after: always\"></div>

- a. Baseline alanine aminotransferase (ALT) or direct bilirubin value &gt;3 × the upper limit of normal (ULN), or
- b. Liver biopsy demonstrating cirrhosis, any evidence of bridging fibrosis, or active hepatitis.
9. Baseline estimated glomerular filtration rate (GFR) &lt;70 mL/min/1.73 m 2 , as determined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation for ≥ 18 years of age, and Bedside Schwartz equation calculator &lt;18 years of age (see http://www.kidney.org/professionals/kdoqi/gfr\\_calculator.cfm).
10. Uncontrolled seizure disorder.

Patients had the right to withdraw from the study at any time for any reason. After giving informed consent or assent (if applicable), patients could withdraw or be withdrawn from study-related procedures and treatments (e.g., mobilization/apheresis, busulfan conditioning) under the following conditions:

Medicinal product no longer authorised 11. Diffusion capacity of carbon monoxide (DLco) &lt;50% of predicted (corrected for Hb and/or alveolar volume, as clinically indicated). 12. A cardiac T2* &lt;10 ms by MRI 13. Any other evidence of severe iron overload that, in the investigator ' s opinion, warrants exclusion. 14. Clinically significant pulmonary  hypertension, as defined by the requirement  for ongoing pharmacologic treatment or the consistent or intermittent use of supplemental home oxygen. 15. Participation in another clinical study with an investigational drug within 30 days of Screening. 16. Failure to obtain appropriate informed consent. 17. Any other condition that would render the patient ineligible for HSCT, as determined by the attending transplant physician or investigator. 18. Contraindications to the conditioning regimen. 19. Prior receipt of gene therapy. 20. Diagnosis of significant psychiatric disorder of the patient that could seriously impede the ability to participate in the study. 21. Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile patients.  Females  of  child-bearing  potential  are  required  to  use  effective  contraception  from Screening through at least 6 months after Zynteglo finished product infusion. Male patients are required  to  use  effective  contraception  (including  condoms)  from  Screening  through  at  least  6 months after Zynteglo finished product infusion. 22. An assessment by the investigator that the patient would not comply with the study procedures outlined in the protocol. Patient Withdrawal

- withdrawal of consent or assent (if applicable),
- the  patient  was  unable  to  comply  with  protocol-defined  visits  or  other  requirements  of  the protocol,
- any  medical  condition  which,  in  the  opinion  of  the  investigators,  put  the  patient  at  risk  for continuing treatment or follow-up studies, or
- adequate  cells  were  not  collected  during  harvests,  or  failure  of  transduced  cells  to  be

<div style=\"page-break-after: always\"></div>

dispositioned for clinical use.

In addition, after patients were treated with Zynteglo finished product, they could have been withdrawn from the study under the following additional condition: the patient had undetectable VCN (&lt;0.0003 c/dg) in peripheral blood cells for 2 consecutive measurements at least 1 month apart and at least 12 months after Zynteglo finished product infusion.

## Blood Transfusions

Within the period of 30 days prior to and during mobilization and apheresis, the patient's transfusion regimen was adjusted to maintain a minimum of 10 g/dL of Hb to suppress dyserythropoiesis, which can impede the isolation of CD34+ cells-enriched for undifferentiated HSC.

| Subjects who Discontinued from Study             | n (%)   | 1 (9.1)   |   0 | 1 (5.3)   |
|--------------------------------------------------|---------|-----------|-----|-----------|
| Reasons for Study Discontimuation: Adverse Event | n (%)   | 0         |   0 | 0         |
| Investigator Decision                            | n (%)   | 1 (9.1) b |   0 | 1 (5.3) b |

Medicinal product no longer authorised During follow-up, the goal was to maintain a target Hb ≥ 9 g/dL. In general, transfusions were to be avoided for Hb ≥ 9 g/dL, unless the need was medically justified (e.g., as a pre-requirement for surgery). It  was  recommended that patients should receive pRBC transfusions for any Hb &lt;7.0 g/dL, and for clinically symptomatic anaemia, irrespective of Hb level. Efficacy Variables The following assessments were performed to determine the efficacy of Zynteglo finished product: · pRBC transfusion requirements (mL/kg/year and number of transfusions/year) · Hb nadirs, total Hb (and Hb fractions) In addition, exploratory analyses of the following parameters were performed, as available data allowed: · Assessment  of  stress  erythropoiesis/dyserythropoiesis  (reticulocytes  and  nucleated  RBCs  in blood,  soluble  transferrin  receptor  in  blood,  and  qualitative  assessment  of  bone  marrow,  as available) · Iron burden (LIC by MRI or SQUID; cardiac T2* on MRI; clinical chemistry laboratory iron studies) · Iron chelator use and phlebotomy · Health Related Quality of Life (HRQoL) questionnaires (these questionnaires were introduced late in the study, such that most patients lacked baseline responses) · Days and number of in-patient hospitalisations (annualised, post-discharge) Table 13: Disposition by Genotype (ITT)

Source: Table 14.1.1.2;Listing 16.2.1.1

Defined as ANC≥0.5 x 10°/L for 3 consecutive days post-LentiGlobin BB305 Drug Product infusion o1 ANC =0.5 x 109/L for 3 consecutive measurements done on separate days.

b Discontinued from the study due to inadequate stem cell mobilization (Listing 16.2.1.1)

Data as of 07 March 2018

<div style=\"page-break-after: always\"></div>

Table 14: Summary of key demographic and medical history parameters, including transfusion history for the 2 years prior to study enrolment (TP, by Genotype)

<!-- image -->

<!-- image -->

Eighteen patients with TDT were treated with Zynteglo finished product and all completed the study. All patients had successful neutrophil and platelet engraftment (PE).

Primary  Efficacy  Endpoint  (Per  Protocol): Proportion  of  Patients  with  Sustained  Production  of ≥2.0 g/dL of HbA T87Q  Between Month 18 and Month 24.

16/18 patients (88.9%; lower 1-sided 95% confidence interval of 69.0%) treated with Zynteglo finished product were producing ≥ 2.0 g/dL of HbA T87Q  at their Month 18 Visit, and all of these patients maintained this production through Month 24. The 2 patients producing less than 2.0 g/dL HbA T87Q  at their Month 18

<div style=\"page-break-after: always\"></div>

and 24 Visit were both treated with Zynteglo finished product with low DP VCN (0.3 c/dg and 0.45 c/dg, respectively), and their subsequent low PB VCN resulted in the low HbA T87Q  production.

Table 15: Proportion of patients with sustained production of ≥2.0 g/dL of HbA T87Q  between Month 18 and Month 24 (TP)

<!-- image -->

| Parameter                                       | Statistic           | non-β/βo (N=10)   | ββo (N=8)      | Overall (N=18)   |
|-------------------------------------------------|---------------------|-------------------|----------------|------------------|
| Subjects with ≥2.0 g/dL of HbA17Q at Month 18 a | n (%) Lower l-sided | 9 (90.0%) 60.6    | 7 (87.5%) 52.9 | 16 (88.9%) 69.0  |

<!-- image -->

<!-- image -->

Medicinal product no longer authorised Data as of 07 March 2018 Proportion of Patients Who Achieved Transfusion Independence Of the 8 patients of nonβ 0 / β 0  genotype who achieved TI after infusion with Zynteglo finished product, all 8 remained TI at Month 24. Their last pRBC transfusion before becoming TI was at median (min, max) of 2.00 (0.3, 5.8) months after Zynteglo finished product infusion, and their TI status was maintained with  a  median  (min,  max)  weighted  average  Hb  of  9.99  (9.3,  12.8)  g/dL.  The  individual  weighted average Hb for patients after they achieved TI were above their weighted nadirs before study entry when they were receiving pRBC transfusions, with one exception: 1 patient who had an average weighted nadir of 9.7 g/dL before treatment and 9.3 g/dL during TI. TI patients of nonβ 0 /β 0  genotype at Month 24 produced between 3.80 to 9.60 g/dL of HbA T87Q , with the remainder of their total Hb made of up other endogenous Hb fractions, primarily by HbE (2.64 to 4.78 g/dL) in patients with a β E  allele or HbA (1.80 to 6.44 g/dL) in patients with a β +  allele.  Patients of nonβ 0 / β 0  genotype who did not achieve TI were those that produced the lowest HbA T87Q  among nonβ 0 /β 0  patients, 2.92 g/dL and 1.10 g/dL, respectively at Month 24.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 16: Transfusion Independence, by Genotype (TP)

| Parameter                                        | Statistic                 | Non-βo/βo (N=10)   | BP/βO (N=8)   | Overall (N=18)   |
|--------------------------------------------------|---------------------------|--------------------|---------------|------------------|
| TI at any time 4                                 | n(%) Lower 1-sided 10 %56 | 8 (80.0) 49.3      | 1 (12.5) 0.6  | 9 (50.0) 29.1    |
| Subjects with TI at 24 Months                    | n(%)                      | 8 (80.0)           | 0             | 8 (44.4)         |
| Subjects with Tl, sensitivity failure analysis b | n(%)                      | 8 (80.0)           | 0             | 8 (44.4)         |
| Duration of TI (months) (TI at                   | N                         | 8                  | 1             | 9                |

<!-- image -->

Medicinal product no longer authorised Data as of 07 March 2018 The median (min, max) time between Zynteglo finished product infusion and last pRBC transfusion for all patients was 12.58 (0.3, 24.4) months, with a median (min, max) duration of not receiving pRBC transfusions at their last visit of 11.52 (0.2, 24.0) months. The wide range in these values reflect the fact that some patients no longer required pRBC transfusions after only a few weeks after drug product infusion, whereas other patients required regular transfusions throughout the study.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 7: Duration of Transfusion Periods, by Genotype (TP)

<!-- image -->

<!-- image -->

Transfusion requirements for all patients (β 0 /β 0  and nonβ 0 /β 0 ) for the following time periods were also compared, using the 2-year period prior to study enrolment versus the period starting from 6 months after infusion with Zynteglo through to Month 24.

Medicinal product no longer authorised Data as of 07 March 2018 Transfusion Reduction

- 14/18 (77.8%, lower 1-sided 95% confidence interval of 56.1%) patients had at least a 60% reduction in transfusion requirements during the period from 6 months through approximately 24 months after Zynteglo finished product infusion, compared with their Baseline pre-treatment transfusion levels, while maintaining Hb nadirs within 1 g/dL of their pretreatment nadirs.
- In general, patients producing higher amounts of HbA T87Q  were more likely to achieve greater reductions in pRBC transfusion requirements (patient s of β 0 /β 0  genotype) and/or a greater likelihood of achieving TI (patients of nonβ 0 /β 0  genotype).

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Interrupted Time Series Analyses

pRBC transfusion requirement over time was also analysed by interrupted time series (ITS, Kontopantelis et al., 2015) for β 0 / β 0  patients. The monthly pRBC transfusion volume during each of the 48 months (24 months prior to drug product infusion and 24 months post-drug product infusion) was calculated for each patient, and then the mean pRBC transfusion volume over all β 0 / β 0  patients was calculated for each of these 48 months. Due to the expected high volume of transfusion around drug product infusion, the month immediately prior to and after the drug product infusion were excluded from this analysis. The results show that monthly pRBC transfusion volume is significantly lower for β 0 / β 0  patients after drug product infusion (p&lt;0.0001). The lines before and after drug product infusion represent regression lines fitted by the ITS model. The drop represents the reduction in transfusion 1 month after drug product infusion as fitted by the model.

<!-- image -->

<!-- image -->

Medicinal product no longer authorised Figure 8: Interrupted Time Series Regression Model: Monthly pRBC Transfusion Volume Preand PostDrug Product Infusion (β 0 /β 0  Patients)

<div style=\"page-break-after: always\"></div>

## Iron burden

Iron overload during the study was evaluated by assessing LIC and cardiac T2* by MRI or SQUID, and serum  ferritin,  serum  iron,  transferrin,  and  transferrin  saturation  in  peripheral  blood.  Patients  who produced sufficient HbA T87Q  to become TI may be expected eventually to have a reduced iron burden compared  to  patients  who  continue  to  require  regular  pRBC  transfusions,  after  undergoing  iron chelation/removal  regimens  to  remove  excess  iron  previously  accumulated  during  their  disease. Therefore,  comparisons  within  these  exploratory  analyses  focus  on  TI  versus  non-TI  patients,  to determine if any differences were detectable during this study.

<!-- image -->

Medicinal product no longer authorised A transient increase in iron burden (as deduced from LIC and serum ferritin levels) was observed in several patients, presumably due to pretreatment hypertransfusion and/or delay in restarting chelation regimens after Zynteglo finished product infusion, and to the effect of myeloablation and transplantation. Figure 9: Liver Iron Burden (MRI/SQUID Iron Assessment) Over Time, by Patient (TP) Data as of 07 March 2018 16/18  patients  had  myocardial  T2*  &gt;20  ms  at  Baseline  and  throughout  the  study;  2  patients  had abnormal cardiac iron content throughout the study.

Measurement  of  myocardial  iron  is  key  to  the  clinical  management  of  patients  at  risk  of  siderotic cardiomyopathy. The cardiovascular magnetic resonance relaxation parameter R2* (assessed clinically via its reciprocal T2*) measured in the ventricular septum is used to assess cardiac iron. Particulate intracellular iron causes shortening of the magnetic resonance relaxation parameter T2* (and hence increase in its reciprocal, R2*) due to microscopic magnetic field inhomogeneity.

Cardiac iron content was evaluated by MRI at Baseline (last value prior to conditioning), Month 12 and Month 24. No trend in cardiac iron content was observed: median % change from Baseline to Month 24

<div style=\"page-break-after: always\"></div>

value was -5.26% for patients who achieved TI at any time during the study (N=9) versus 0% change for patients who did not achieve TI.

Serum Ferritin: The majority of patients who achieved TI and who were evaluable (having values at both Baseline and Month 24) showed improvements in ferritin (7/8 patients), serum transferrin (7/9 patients), serum iron (7/9 patients), and transferrin saturation (5/7 patients). The decrease in ferritin levels is generally greater for patients who achieved TI status versus patients who did not achieve TI status by Month 24: median change from Baseline at Month 24 was -26.1% for TI patients, versus -5.1% for nonTI patients, although results were variable between patients.

Table 17: Serum Ferritin at Month 24, by TI Status (TP)

<!-- image -->

| longer   |
|----------|

Medicinal product no longer authorised Data as of 07 March 2018 Serum transferrin: serum transferrin values for individual patients who achieved TI, at Baseline and at Month 24 shows that transferrin levels improved in 7/9 patients who achieved TI, generally in alignment with the patients who showed a ferritin decrease at Month 24. Stress Erythropoiesis/Dyserythropoiesis Although all patients who had achieved TI had some normal values in some exploratory assays for stress erythropoiesis, no patient had normal values in all exploratory analyses done. Specifically: · 3/7  patients  who  achieved  TI  and  had  data  available  had  stable  normal  levels  of  soluble transferrin receptor, 1 patient (Patient 1120) had levels that fluctuated between normal and slightly  above-normal  levels,  and  3/7  patients  had  stable  above-normal  levels  of  soluble transferrin receptor, in the absence of pRBC transfusions.

<!-- image -->

- 5/9 patients who achieved TI at any time during the study had reticulocyte levels within 1% of the upper normal level of 2.36%, and 4 patients had reticulocyte levels ≥ 4%, in the absence of pRBC transfusions.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2.5.2. Main studies

The studies underlying the pooled analysis are presented in Section 2.4.1 and includes Phase 1/2 (HGB-204 and HGB-205) and Phase 3 (HGB-207 and HGB-212) studies, as well as in long-term followup Study LTF-303.

- Study HGB-205, \"A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy  of  the  β -Hemoglobinopathies  (Sickle  Cell  Anemia and  β -Thalassemia  Major)  by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral βA -T87QGlobin Vector (LentiGlobin BB305 Drug Product)\"

Medicinal product no longer authorised · Study HGB-204, a single-arm, multi-site, single dose, \"Phase 1/2, Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Patients with β -Thalassemia Major by Transplantation of  Autologous  CD34+  Stem  Cells  Transduced  Ex  Vivo  with  a  Lentiviral β A-T87Q -Globin  Vector (LentiGlobin BB305 Drug Product)\" · Study HGB-207, \"A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Patients with Transfusion-dependent β -Thalassaemia, who do not have the β 0 / β 0  Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced E x Vivo with a L entiviral β A-T87Q Globin Vector in Patient s ≤50 Years of Age \" Methods Methods for Studies HGB-204 and HGB-205 are described above in Section 2.5.1. Study HGB-207 is a single-arm, multisite, single-dose, Phase 3 study with 2 cohorts of patients with TDT who do not have a β 0  mutation at both alleles of the β -globin (HBB) gene (i.e., nonβ 0 /β 0 ): Cohort 1 includes at least 15 patient s ≥12 and ≤50 years of age Cohort 2 includes at least 8 patients &lt;12 years of age. (Note: as of 22 February 2018, no patients &lt;12 years of age were in the Intent-to-Treat [ITT] population). Study Participants In general, the inclusion and exclusion criteria were comparable among studies HGB-204, HGB-205, HGB-207 and HGB-212. HGB-207 inclusion and exclusion criteria are depicted below, some discrepancies in the inclusion and exclusion criteria between studies are highlighted. Inclusion Criteria Patients must meet all of the following criteria to be considered eligible for enrolment in the study.

1. Patient s ≤50 years of age at the time of consent or ass ent (as applicable), and able to provide written consent (adults, or legal guardians, as applicable) or assent (adolescents or children). Provided that the DMC has approved enrolling patients younger than 5 years of age, patients younger than 5 years of age may be enrolled if they weigh a minimum of 6 kg and are reasonably anticipated to be able to provide at least the minimum number of cells required to initiate the manufacturing process. Study HGB-205 included only patients with age between 5-35 and study HGB-204 included patients 12-35 years of age.

2. Diagnosis of TDT with a history of at least 100 mL/kg/year of pRBCs in the 2 years preceding enrolment (all patients), or be managed under standard thalassaemia guidelines (e.g., (Cappellini et al. 2014)) with ≥8 transfusions of pRBCs per year in the 2 years preceding enrolment ( patient s ≥12 years (Rachmilewitz

<div style=\"page-break-after: always\"></div>

and Giardina 2011)). In study HGB-204, inclusion was for patients with TDT and in study HGB-205 for patients with TDT or severe SCD.

3. Clinically st able, have a Karnofsky performance status of ≥80 for adults (≥16 years of age) or a Lansky performance status of ≥80 for adolescents or children (&lt;16 years of age), and eligible to undergo HSCT. Study HGB-204 included patients with Karnofsky performance st atus ≥ 60, and HGB-205 included patients eligible for allogeneic HSCT.

4. Treated and followed for at least the past 2 years in a specialized centre that maintained detailed medical records on RBC transfusions (including volume and units of RBCs and associated pre-transfusion Hb values, reticulocyte counts and relevant blood bank details as available), in-patient hospitalization, and iron chelation history.

7. Immediate family member (i.e., parent or siblings) with a known Familial Cancer Syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome and familial adenomatous polyposis).

Medicinal product no longer authorised Exclusion Criteria Patients meeting any of the following criteria are being excluded from the study. 1. Presence of a mutation characterized as β 0  on both HBB alleles. For the purpose of this study, the HBB mutation IVS I-110 (G → A) [HGVS nomenclature: HBB :c.93-21G&gt;A] will be considered equivalent to a β 0  mutation 2 2. Positive for presence of human immunodeficiency virus type 1 (HIV-1) or 2 (HIV-2), HBV, or HCV. Syphilis (RPR) testing is also required and a positive test for syphilis is exclusionary where mandated by regional drug product manufacturing practices. Note that patients who have been vaccinated against hepatitis B [hepatitis B surface antibody-positive] who are negative for other markers of prior hepatitis B infection [e.g., negative for hepatitis B core antibody] are eligible. Patients with past exposure to HBV [HBc Ab positive and/or HBe Ab positive] are also eligible for the study provided they are negative by assessment for HBV DNA. Also note that patients who are positive for anti-hepatitis C antibody are eligible as long as they have a negative HCV viral load. Where clinically and/or regionally indicated, other tests may be performed, in which case positive results would exclude the patient from participating: for example,  human  T-lymphotropic  virus-1  (HTLV-1)  or  -2  (HTLV-2),  tuberculosis,  toxoplasmosis, Trypanosoma cruzi, West Nile Virus, or Zika Virus. 3. Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the clinical investigator. 4.  A  white  blood  cell  (WBC)  count  &lt;3×10^9/L,  and/or  platelet  count  &lt;100×10^9/L  not  related  to hypersplenism. 5. Uncorrected bleeding disorder. 6.  Any  prior  or  current  malignancy  (with  the  exception  of  adequately  treated  cone-biopsied  in  situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin) or myeloproliferative or significant immunodeficiency disorder.

8. Prior HSCT.
9. Advanced liver disease, defined as:

2 Similar to β 0  alleles, the IVS-I110 mutation is widely recognized as producing little to no β -globin (Borgna-Pignatti and Galanello, 2009), thus subjects with β 0 /IVS-I-110 or IVS-I-110/IVS-I-110 genotypes were excluded from Study HGB-207 and grouped with the β 0 /β 0  subjects in Study HGB-212.

<div style=\"page-break-after: always\"></div>

a. Persistent aspartate aminotransferase (AST), alanine transaminase (ALT), or direct bilirubin value &gt;3 × the upper limit of normal (ULN), or b. Baseline prothrombin time or partial thromboplastin time &gt;1.5× ULN, suspected of arising from liver disease, or

c. MRI of the liver demonstrating clear evidence of cirrhosis d.  MRI  findings  suggestive  of  active  hepatitis,  significant  fibrosis,  inconclusive  evidence  of cirrhosis, or liver iron concentration ≥15 mg/g require follow -up liver biopsy in patient s ≥18 years of age. In patients &lt;18 years of age, these MRI findings are exclusionary, unless in the opinion of the investigator, a liver biopsy could provide additional data to confirm eligibility and would be safe to perform. If a liver biopsy is performed based on MRI findings, any evidence of cirrhosis, bridging fibrosis, or significant active hepatitis will be exclusionary.

21.  A  known  and  available  HLA-matched  family  donor.  If  required  by  regional  regulatory  authority, patients with a known and available matched unrelated donor will be excluded from the study.

Medicinal product no longer authorised 10. Baseline estimated GFR &lt;70 mL/min/1.73 m 2 , as determined using the CKD-EPI creatinine equation for ≥18 years of age, and Bedside Schwartz equation calculator for &lt;18 years of age. (http://www.kidney.org/professionals/kdoqi/gfr\\_calculator.cfm) 11. Uncontrolled seizure disorder. 12. Diffusion capacity of carbon monoxide (DLco) &lt;50% of predicted (corrected for Hb and/or alveolar volume, as clinically indicated). 13. A cardiac T2* &lt;10 ms by MRI. 14. Any other evidence of severe iron overload that, in the investigator's opinion, warrants exclusion. 15. Participation in another clinical study with an investigational drug within 30 days of Screening. 16. Any other condition that would render the patient ineligible for HSCT, as determined by the attending transplant physician or investigator. 17. Prior receipt of gene therapy. 18. Diagnosis of significant psychiatric disorder of the patient that could seriously impede the ability to participate in the study. 19. Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile patients. Females of childbearing potential and males are required to use two different effective methods of contraception from Screening through at least 6 months after drug product infusion. If patients are truly sexually abstinent (where true sexual abstinence is defined as being in line with the preferred and usual lifestyle of the patient), no second method is required. 20. An assessment by the investigator that the patient would not comply with the study procedures outlined in the protocol.

22. Any contraindications to the use of G-CSF and plerixafor during the mobilization of HSCs and any contraindications  to  the  use  of  busulfan  and  any  other  medicinal  products  required  during  the myeloablative  conditioning,  including  hypersensitivity  to  the  active  substances  or  to  any  of  the excipients.

<div style=\"page-break-after: always\"></div>

## Treatments

In general, study treatments were comparable among studies HGB-204, HGB-205, HGB-207 and HGB212. HGB-207 study treatments are depicted below.

The study has 4 distinct stages, as follows.

Stage 1: Screening to determine eligibility for treatment. The HBB genotype for nonβ 0 /β 0  patients will be confirmed during Screening along with additional parameters of eligibility.

Stage 2: Autologous CD34+ cell collection, drug product manufacture and disposition.

Medicinal product no longer authorised Each patient will undergo HSC mobilization with a granulocyte colony-stimulating factor (G-CSF; e.g., filgrastim, lenograstim) and plerixafor. Peripheral blood mononuclear cells (PBMCs) will be collected by apheresis. Patients with a spleen were recommended to be dosed with G-CSF at 10 μg/kg/day and patients without a spleen dosed at 5 μg/kg/day, and to be dosed with 0.24 mg/kg/day plerixafor, with adjustments permitted based on white blood cell monitoring. A total of 2 mobilization cycles may be performed if needed and each mobilization cycle may include up to 3 apheresis days. However, patients whose drug product fails to meet specifications for any reason may undergo repeat apheresis and manufacture of new drug product. Apheresis products can also be used for rescue cells; alternatively, a bone marrow harvest is also allowed to procure cells for rescue. Stage 3: Myeloablative conditioning (4 days of conditioning followed by at least 48 hours of washout) and infusion of Zynteglo (Day 1) After the transduced cells are dispositioned for clinical use, and the patient's eligibility has been reconfirmed (by clinical laboratory tests, physical examination, performance status, adverse event [AE] review  and  other  tests  based  on  institutional  requirements),  the  patient  will  undergo  myeloablative conditioning with busulfan. Conditioning only begins after the following criteria are met: · All the drug product to be used for a particular patient has been release tested, dispositioned for clinical use, and is stored at the clinical site; · It is recommended that patients maintain a hypertransfusion regimen at least 30 days prior to conditioning to maintain a pretransfusion Hb of ≥11 g/dL. Iron chelation will likely need to be adjusted to compensate for the increased iron load, until required discontinuation per protocol; · The patient has undergone AE and concomitant medications assessments, physical examination, vital signs, and laboratory tests as per the SOE and continues to meet the eligibility criteria based on these results. Busulfan will be administered at a starting dose of 3.2 mg/kg/day for 4 consecutive days via IV infusion on Days -6 through -3. Please refer to the busulfan prescribing information for details on appropriate method for determination of patient weight; e.g., (Busilvex SmPC).

A dose of 3.2 mg/kg daily, or 0.8 mg/kg every 6 hours, for 4 consecutive days, is recommended, with dose adjustment as needed based on pharmacokinetics monitoring to achieve a target daily busulfan of AUC of 4200 (range 3800 to 4500) μM*min. It is recommended that busulfan is administered a t 0.8 mg/kg every 6 hours in children and adolescents with a target busulfan AUC of 1050 (range 950 to 1125)

<div style=\"page-break-after: always\"></div>

μM*min for every 6 hour dosing to avoid higher peak concentrations while still providing equivalent daily exposure.

After completion of the 4-day course of busulfan, there must be a minimum of 48 hours of washout before drug product infusion. On study Day 1, thawed drug product will be administered via intravenous (IV) infusion at a dose of ≥5.0×10 6  CD34+ cells/kg.

Stage 4: Follow-up, through engraftment and up to 24 months after drug product infusion. Patients will be followed daily in the transplant unit for AEs, and laboratory parameters will be followed to monitor bone marrow engraftment. The patient will be discharged from the transplant unit once the patient is considered medically stable.

To avoid potential toxic drug-to-drug interactions, chelation was required to be stopped 7 days prior to initiating conditioning with busulfan. Iron chelation was at the investigator's discretion and in accordance with institutional protocols. Briefly, for patients who continued to require transfusions, chelation was recommended  to  be  restarted  with  deferasirox  or  deferoxamine  at  hospital  discharge.  It  was recommended  that  deferiprone  not  be  started  for  at  least  6  months  due  to  the  potential  risk  of myelosuppression. For patients who no longer required pRBC transfusions within 3 months after Zynteglo infusion,  the  need  for  starting  iron  reduction  methods  at  Day  +90  post-  Zynteglo  infusion  was recommended to be based on LIC and Cardiac T2* measurements (Table 18).

Medicinal product no longer authorised The goal during the followup period is to maintain Hb ≥9 g/dL. Transfusions should be avoided for Hb ≥9 g/dL unless the need is medically justified (e.g., as a pre -requirement for surgery). It is recommended that patients should receive pRBC transfusions for Hb &lt;7 g/dL, and for clinically symptomatic anaemia, irrespective of Hb level. Patients will be followed in this protocol for a period of approximately 24 months after Zynteglo infusion. Thereafter, patients will be asked to enroll in a separate long-term follow-up protocol (LTF-303) that will assess safety and efficacy beyond Month 24 for a total of 15 years after drug product infusion. The end of Study HGB-207 will be defined as the last visit for the last patient. Concomitant Medications and Therapies Permitted concomitant treatments during conditioning at the Investigator's discretion include but are not limited to: · · Hydration beginning 12 hours before initiating conditioning and continuing through 24 hours thereafter · Ondansetron and/or metoclopramide for prevention or treatment of nausea and vomiting. · Anticonvulsants for seizure prophylaxis with the exception of phenytoin. · Ursodeoxycholic  acid  or  defibrotide  for  prevention  of  hepatic  veno-occlusive  disease/hepatic sinusoidal obstruction syndrome · Anti-infectives for infection prophylaxis or treatment of febrile neutropenia per the study site standard of care Iron Chelating Agents

<div style=\"page-break-after: always\"></div>

Table 18: Iron Reduction Guidelines Post-Zynteglo Infusion

<!-- image -->

| Liver LIC (mg/g)   | Cardiac T2* (ms)                                      | Cardiac T2* (ms)       |
|--------------------|-------------------------------------------------------|------------------------|
|                    | >20 ms                                                | 20 to 10ms             |
| 8mgg               | No chelation is required                              | Chelation is indicated |
| 8-15 mg/g          | Considerbased on senum femitin and hepatitis serology | Chelation is indicated |
| >15 mgg            | Chelation isindicated                                 | Chelation is indicated |

iChelation is recommended only if senumfemitinis &gt;2000 ng/ml at Day +90 or hepatitis B/C serology was positivepre-transplant.

-

Medicinal product no longer authorised Objectives The objectives of the pooled analyses are: · To evaluate and summarise the associations between measures of myeloablation and pharmacodynamic (PD) parameters as well as associations between gene expression and key efficacy transfusion requirement parameters, transfusion independence (TI) and transfusion reduction (TR), among patients with TDT. · To conduct a pooled efficacy analysis, evaluating TI and TR among pooled cohorts of patients with TDT. Outcomes/endpoints Primary Efficacy Endpoint: The primary endpoint was similar for the pooled analyses with Studies HGB-204, HGB-205, and HGB207,  and  for  study  HGB-207:  the  proportion  of  patients  who  meet  the  definition  of  transfusion independence (TI). -TI is defined as a weighted average Hb ≥9 g/dL without any pRBC transfusions for a continuous period of ≥12 months at an y time during the study after drug product infusion. Secondary Efficacy Endpoints for Study HGB-207 · Characterisation of patients achieving TI: -Duration of TI -Time from drug product infusion to last pRBC transfusion prior to becoming TI -Time from drug product infusion to TI -Weighted average nadir Hb during TI -Transfusion-free survival

<!-- image -->

Proportion of patients who meet the definition of TI at End-of-Study Visit

- Characterisation of transfusion reduction (TR):
- -Proportion of patients with a reduction in the mL/kg/year pRBCs transfused from 12 months post-drug product infusion through the Month 24 Visit of at least 50%, 60%, 75%, 90% or 100% compared to the average mL/kg/year pRBC transfusion requirement during the 2 years prior to enrolment
- -Number and volume of pRBC transfusions from 12 months post-drug product infusion through the Month 24 Visit compared to the average number and volume of annual

<div style=\"page-break-after: always\"></div>

transfusions during the 2 years prior to enrolment

- Weighted average nadir Hb during the 2 years prior to enrolment compared to weighted average nadir Hb from 12 months post-DP infusion through the Month 24 Visit
- Characterisation of use of iron chelation among all patients:
- -Proportion of patients who have discontinued iron chelation therapy for at least 6 months
- -Change  in  dose  of  iron  chelation  therapy  from  baseline  for  those  patients  not discontinuing chelation for at least 6 months

Medicinal product no longer authorised · Evaluation of the change in iron burden over time, as measured by: -Change in LIC by MRI at baseline to Month 12 and Month 24 -Change in cardiac T2* on MRI at baseline to Month 12 and Month 24 -Change in serum ferritin from baseline through Month 24 Visit Exploratory Efficacy Endpoints for Study HGB-207 · Evaluation of health-related quality of life (HRQoL) over time using the following validated tools: -Paediatrics: Paediatric Quality of Life Inventory (PedsQL; parent general core and general core) -Adolescents:  PedsQL  (parent general  core  and  general  core)  and  EuroQol5D (Youth version) (EQ-5DY) -Adults: EuroQol-5D (EQ-5D), Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and Short Form-36 (SF-36) v2 · Assessment  of  growth  and  puberty  parameters  (age  appropriate),  bone  density,  diabetes, endocrine evaluations, and neurocognitive development (paediatric patients &lt;18 years of age) · Assessment of improvement in ineffective erythropoiesis · Correlations  of  pre-treatment  variables  (e.g.,  drug  product  vector  copy  number  [VCN])  with response · Measures of health resource utilization (including comparing number of transfusions, number of hospitalizations, and iron chelation usage from 12 months post-drug product infusion through Month 24 Visit with the annual average of the corresponding parameters during the 2 years prior to enrolment. Sample size for Study HGB-207 No formal sample size calculations were done.

Approximately 23 patients in total will be treated with drug product , at least 15 of whom must be ≥ 12 and ≤ 50 years of age (Cohort 1; at least 5 patients in Cohort 1 must be ≥ 12 and &lt;18), and at least 8 of whom must be &lt;12 years of age (Cohort 2). Replacement patients may be added if patients are screen failures or withdraw prior to Stage 3 (conditioning).

The sample size in Cohort 1 is based on the premise that excluding a treatment effect of &lt;30% with a high probability is of value (demonstrating with 97.5% confidence that ≥ 30% of patients become TI). Moreover, a point estimate of the proportion of patients who become TI of at least 60% is considered clinically meaningful. This point estimate was selected based on the minimal criterion to be met in the

<div style=\"page-break-after: always\"></div>

trials  and  was  supported  as  the  minimal  target  based  on  discussions  with  key  opinion  leaders  with expertise in the treatment of β -thalassemia. Therefore, among the proposed sample size of 15 treated patients ≥ 12 and ≤ 50 years of age in Cohort 1, a point estimate for success of 60% is proposed (9 out of 15 patients), which would yield a lower 1-sided 97.5% exact confidence bound of 32.3%, exceeding the 30% minimal criterion. Among the proposed sample size of 8 treated patients &lt;12 years of age in Cohort 2, a point estimate for success of 60% (5 out of 8 patients) would yield a lower 1-sided 97.5% exact confidence bound of 24.5%.

The following patient populations are evaluated and used for presentation and analysis of the data:

Medicinal product no longer authorised · Intent-to-Treat (ITT) population: All patients who initiate any study procedures, beginning with mobilization by G-CSF and/or plerixafor. · Transplant Population (TP): All patients who receive Zynteglo finished product treatment. · Successful Engraftment Population (SEP): All patients who  have  successful neutrophil engraftment (NE) after Zynteglo finished product infusion. The ITT population is the primary population for the analysis of safety parameters. The TP is the primary population  for  the  analysis  of  efficacy,  pharmacodynamic  and  transplant  parameter  endpoints  (i.e., success and kinetics of engraftment, and incidence of transplant-related mortality post-drug product infusion).  The  Successful  Engraftment  Population  (SEP)  was  planned  to  provide  supportive  data  for patients  who  engraft;  however,  given  all  patients  with  sufficient  follow-up  data  for  evaluation  had successful engraftment, this population was not analysed. Randomisation Not applicable. Blinding (masking) Not applicable. Statistical methods The studies are primarily descriptive in nature. Data are presented by patient and summarized overall within  each  analysis  population,  and  by  age  and  sex,  as  applicable.  Tabulations  were  produced  for appropriate demographic, baseline, efficacy, pharmacodynamic, and safety parameters. For categorical variables, summary tabulations of the number and percentage of patients within each category of the parameter are presented. For continuous variables, the number of patients, mean, standard deviation (SD), median, minimum, and maximum values are presented. Descriptive summary statistics as well as 1-sided  97.5%  Clopper-Pearson  exact  binomial  confidence  intervals  are  presented  on  selected parameters expressed as proportions.

## Baseline Definitions

Two years of retrospective pre-study enrolment data is collected for each patient in the study, so that each patient may serve as his/her own control for the parameters of pRBC transfusion requirements, weighted average nadir Hb concentrations, in-patient hospitalizations (number and duration), and iron chelation use. For these parameters, baseline is annualized over the 2 years prior to study entry (date of informed consent). For pRBC transfusion requirements, there is 1 baseline parameter, the average per year. For the number of in-patient hospitalization days (defined as hospitalization duration of at least 24 hours), in addition to the total number of hospitalizations in the 2 years prior to study entry, the baseline average per year is calculated. For iron chelation use, the baseline average dose per year is

<div style=\"page-break-after: always\"></div>

calculated.  For  other  efficacy  parameters  as  well  as  for  pharmacodynamics  parameters,  baseline  is defined as the most recent measurement prior to conditioning; the conditioning start date is defined as the  first  date  of  busulfan  administration.  For  safety  parameters,  including  shifts  in  key  laboratory parameters, the most recent value prior to mobilisation is used as the baseline assessment .

Formal multiplicity adjustment will not be performed. It is expected that the majority of the secondary and exploratory endpoints will demonstrate a positive effect of Zynteglo. There are multiple secondary endpoints,  which  will  enable  a  more  complete  understanding  of  the  clinical  impact  of  therapy  with Zynteglo.

Medicinal product no longer authorised Subpopulations Selected analyses are stratified by age at informed consent/assent ( &lt;12, ≥12 to &lt;18, and ≥18 years ), race  and  sex.  Additionally,  some  endpoints  are  presented  for  subpopulations  by  genotype:  nonβ 0 / β 0  patients ( containing the β E mutation, or the β +  mutation), β 0 /β 0  patients. Withdrawals, Dropouts, Loss to Follow -up Patients withdrawn from the study prior to conditioning (myeloablation) will be replaced. Patients who begin conditioning but are subsequently withdrawn will not be replaced. Patients who enrol in the trial but discontinue prior to myeloablation should be followed for at least 1 month after completion of harvesting, or until resolution of any study procedure-related AEs, whichever is later. In the rare case a patient undergoes myeloablation but does not undergo Zynteglo infusion, follow-up should continue on trial for at least 3 months, or until resolution of any study procedure-related AEs, whichever is later. If withdrawal is after drug product infusion, patients will be asked to complete the same assessments as specified in the SOE for Month 24 (Early Termination Visit assessments) and will be asked to enroll in the long-term follow-up Study LTF-303. Results Participant flow HGB-204:  19  eligible  patients  were  enrolled  in  Study  HGB-204,  and  18  patients  were  infused  with Zynteglo,  all  of  whom  successfully  engrafted. One  patient  was  withdrawn  from  the  study  due  to 'inadequate stem cell mobilization' after a single mobilization/apheresis cycle. 18 patients successfully engrafted completed the Study through their Month 24 Visit. HGB-205: 4 patients with TDT underwent screening, and all were found to be eligible for this study. All 4  were  treated  with  Zynteglo,  all  4  successfully  engrafted  and  completed  the  study  through approximately 2 years post-drug product infusion.

HGB-207: As of 22 February 2018, 23 patients underwent screening, and 4 were found to be ineligible for this study. Three patients were excluded due to advanced liver disease and 1 patient was excluded due to a cardiac T2* &lt;10 ms measured by MRI. 14 patients were mobilized, 1 patient underwent 1 cycle of mobilization and apheresis with G-CSF and plerixafor but discontinued before conditioning because of pregnancy.  10 patients were conditioned with busulfan and were administered Zynteglo (TP); and 3 patients have not yet undergone conditioning/Zynteglo infusion. Of the 10 patients who were infused with drug product at the time of data cut for the interim clinical study report (CSR), all 9 patients with at least 43 days of follow-up had achieved neutrophil engraftment, 6 patients had completed at least their Month 6 Visit and 2 patients had completed at least their Month 12 Visit (Table 19).

<div style=\"page-break-after: always\"></div>

Table 19: HGB-207 disposition (ITT)

<!-- image -->

Medicinal product no longer authorised Data as of 22 February 2018 Figure 10 : Consort diagram showing disposition for Study HGB-207 Data as of 22 February 2018 Recruitment for Study HGB-207 4 patients were found ineligible for the study during screening. 3 patients were excluded due to advanced liver disease and 1 patient was excluded due to a cardiac T2* &lt;10ms measured by MRI. Of  the  14  mobilised  patients,  10  patients  were  infused  with  the  drug  product  of  which  9  engrafted successfully and one patient had insufficient follow up time for successful engraftment. As of 22 February 2018,  follow-up  time  is  limited  and  no  patients  had  sufficient  follow-up  time  that  is  needed  for assessment of the primary endpoint.

## Conduct of Study HGB-207

Enrolment in Study HGB-207 began under protocol version 1.3 (27 January 2016). The protocol was amended 3 times (Table 20).

<div style=\"page-break-after: always\"></div>

Table 20: Substantive Changes in Protocol Amendments

<!-- image -->

| Version, Date, Countries Effective   | Key Substantive Changes                                                                                                                                                                                               |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| V1.3, 27JAN2016, Global              | Original to enroll patients                                                                                                                                                                                           |
| V1.4, 06FEB2016, UK                  | Added new exclusion criteria to exclude any subjects with known sensitivities to drugs being used in the trial                                                                                                        |
| V1.5,14NOV2016, Germany              | Added criteria to exclude patients with a known and available HLA-matched umrelated donor Added success criteria defined based on the proportion of subjects achieving transfusion independence drug product infusion |

207

ii. Exploratory endpoints of Quality of life (QoL), assessment of growth and puberty parameters, assessment of improvement in ineffective erythropoiesis, and measures of health resource utilization for the Month 12 through Month 24 pre-specified period

Medicinal product no longer authorised As of 22 February 2018 Changes to the Planned Statistical Methods for Study HGB -The HGB-207 SAP outlines any differences in the planned analytical objectives relative to those planned in the study protocol. Changes to analyses outlined in the current SAP are as follows: 1. Due to limited follow-up at the time of the data-lock for this interim analysis: a.  The  primary  efficacy  endpoint  TI  and  secondary  efficacy  endpoint  characterising  patients with TI were not performed. b. For transfusion reduction and weighted average nadir Hb analyses that pre-specify a Month 12  to  Month  24  analysis  period  for  comparison  with  baseline,  a  modified  analysis  period  of hospital discharge after drug product infusion to the last visit for each patient was utilized to detect any emerging trends in the data. Data from the pre-enrollment period and the posthospital discharge period were annualized for the purposes of comparison. c. Any data for the following endpoints are included only in data listings: i. Secondary efficacy endpoints of chelation therapy discontinuation and change in chelation therapy dose, and change in iron burden over time (LIC, cardiac T2*)

<!-- image -->

2.  The  characterisation  of  patients  with  TI  endpoint,  'Time  from  drug  product  infusion  to  last  pRBC transfusion  prior  to  becoming  TI'  was  evaluated  as  'Time  from  drug  product  infusion  to  last  pRBC transfusion' for all TP patients with available data.
3.  The  characterisation  of  patients  with  TI  endpoint,  'Transfusion-free  survival'  was  evaluated descriptively as 'Time from last pRBC transfusion to last visit' given there were no deaths, and was also analysed for all TP patients with available data.

<!-- image -->

<div style=\"page-break-after: always\"></div>

4. Hb was planned to be included as a parameter for lab shift table safety analysis, however, then was removed since already analysed as part of efficacy analyses.
5.  The  pharmacodynamic  endpoint  for  gene  transfer  efficiency  and  expression  was  quantified  by measuring β A-T87Q -globin expression; however, the protocol and SAP both state this endpoint is assessed by  the  ratio  of β A-T87Q globin  to  α -globin,  which  is  included  in  a  data  listing,  but  this  is  not  how β A-T87Q -globin expression is assessed.
6. The ratio of α -globin chains to all β -globin chains was planned but not analysed given the planned and analys ed ratio of α -globin chains to all β -like  globin chains was the more clinically relevant ratio for pharmacodynamic analysis.

<!-- image -->

Medicinal product no longer authorised 7. The correlation of β A-T87Q -globin expression at early time points post-drug product infusion (e.g., 3 and 6 months) to β A-T87Q -globin expression at later time points, as well as clinical outcomes) was not assessed at this early stage of the trial. 8. Events of interest (EOI) analysis was not performed in the study as the definition of EOI continues to evolve with the development of the product. Treatment procedure for Study HGB-207 Below a short review of the treatment procedure for Study HGB-207 is presented in Table 21 and Table 22. Table 21: Mobilisation/Apheresis Details for Study HGB-207 (ITT Population)

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Parameter                                                      | Statistic (N=5)             | Splenectomized                                 | Not Splenectomized (N=9)                      | Overall (N=14)                                 |
|----------------------------------------------------------------|-----------------------------|------------------------------------------------|-----------------------------------------------|------------------------------------------------|
| Cycle 2                                                        | N Mean (SD) Median Min, Max | 2 23869.0 (4174.76) 23869.0 20917， 26821       | 0                                             | 2 23869.0 (4174.76) 23869.0 20917， 26821       |
| Average Total Blood Volume Processed during Apheresis (mL) [2] | N Mean (SD) Median Min, Max | 5 15761.13 (7316.333) 16362.33 7972.7, 26284.2 | 6 8136.78 3(2220.549) 8769.50 4394.0, 11025.0 | 14 10859.76 (5820.458) 9149.50 4394.0, 26284.2 |
| Number of CD34+ Cells Collected (Cellsx10^6/kg)                | N Mean (SD) Median Min, Max | 5 15.38 (4.061) 16.56 8.9, 18.8                | 9 26.21 (7.602) 23.70 12.3, 35.1              | 14 22.34 (8.344) 21.59 8.9, 35.1               |

| no   |
|------|

<!-- image -->

Medicinal product no longer authorised Data as of 22 February 2018 Table 22: Drug Product Dosing and Infusion Details, by Age Group and Sex (TP) [2]

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

| authorised   |
|--------------|

| Medicinal   | Medicinal   | Medicinal   | Medicinal   | Medicinal   | Medicinal   | Medicinal   | Medicinal   | Medicinal   | Medicinal   | Medicinal   | Medicinal   |
|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|

Medicinal product no longer authorised Data as of 22 February 2018 Baseline data Table 23: Key Demography of Patients with TDT by Parent Study, Genotype, and Overall for Pooled Analyses (TP) [1] [2] [3] []

Sowrce: Table 2.1.2

1 Assent is applicable to subjects ≤18 years old

<div style=\"page-break-after: always\"></div>

## Thalassaemia-Related Medical History

## Table 24: Thalassaemia-Related Medical History by Parent Study, Genotype, and Overall for Pooled Analyses (TP)

Phase 1/2 Studies

HGB-205

All

(N = 18)

Genotypes

8 (44.4)

6 (33.3)

1 (5.6)

Parameter Statistic

HBB genotype

βE/β0

od/o8

n (%)

β%β+

No

|           | no        |           |           |           |           |           |           |           |           |           |
|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| product   | product   | product   | product   | product   | product   | product   | product   | product   | product   | product   |
| Medicinal | Medicinal | Medicinal | Medicinal | Medicinal | Medicinal | Medicinal | Medicinal | Medicinal | Medicinal | Medicinal |

n (%)

n (%)

0d/d-uoN

(N = 10)

0

6 (60.0)

1 (10.0)

HGB-204

β%β0

(N = 8)

8 (100.0)

0

0

Non-β/β0

(N=4)

0

3 (75.0)

0

Pooled

Non-β/β0

Genotypes

(N = 14)

0

9 (64.3)

1 (7.1)

All

(N = 22)

8 (36.4)

9 (40.9)

1 (4.5)

Phase3Studies

HGB-207

HGB-212

0d/od-uoN

(N =10)

0

3 (30.0)

5 (50.0)

0d/o8

(N=1)

1 (100.0)

0

0

All Studies

0d/od-uoN

Genotypes

All

(N = 24)

0

12 (50.0)

6 (25.0)

(N = 33)

9 (27.3)

12 (36.4)

6 (18.2)

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                     |                                     | Phase1/2 Studies                    | Phase1/2 Studies                    | Phase1/2 Studies                    | Phase1/2 Studies                    | Phase1/2 Studies                    | Phase1/2 Studies                    | Phase3Studies                       | Phase3Studies                       | All Studies                         | All Studies                         |
|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                                     |                                     | HGB-204                             | HGB-204                             |                                     | HGB-205 Pooled                      | HGB-205 Pooled                      | HGB-207                             |                                     | HGB-212                             |                                     |                                     |
|                                     | Parameter Statistic                 | Non-β/β0 (N = 10)                   | 0d/od (N =8)                        | AlIl Genotypes (N=18)               | Non-β%β0 (N =4)                     | Non-β/β0 (N =14)                    | All Genotypes (N =22)               | Non-β%β0 (N =10)                    | 08/08 (N = 1)                       | Non-β%/β0 (N = 24)                  | All Genotypes (N=33)                |
| Pre-treatment baseline iron burden? | Pre-treatment baseline iron burden? | Pre-treatment baseline iron burden? | Pre-treatment baseline iron burden? | Pre-treatment baseline iron burden? | Pre-treatment baseline iron burden? | Pre-treatment baseline iron burden? | Pre-treatment baseline iron burden? | Pre-treatment baseline iron burden? | Pre-treatment baseline iron burden? | Pre-treatment baseline iron burden? | Pre-treatment baseline iron burden? |
| Liver iron content (mg/g)           | Liver iron content (mg/g)           | Liver iron content (mg/g)           | Liver iron content (mg/g)           | Liver iron content (mg/g)           | Liver iron content (mg/g)           | Liver iron content (mg/g)           | Liver iron content (mg/g)           | Liver iron content (mg/g)           | Liver iron content (mg/g)           | Liver iron content (mg/g)           | Liver iron content (mg/g)           |
|                                     | N                                   | 10                                  | 8 18                                | 4                                   |                                     | 14                                  | 22                                  | 10                                  |                                     | 24                                  | 32                                  |
|                                     | Min, Max 1.2, 26.4                  |                                     | 0.4, 17.0                           | 0.4, 26.4                           | 3.9, 14.0                           | 1.2, 26.4                           | 0.4, 26.4                           | 1.0, 19.61                          |                                     | 1.0,19.61                           | 0.4, 19.61                          |
| Cardiac T2* measurement (msec)      | Cardiac T2* measurement (msec)      | Cardiac T2* measurement (msec)      | Cardiac T2* measurement (msec)      | Cardiac T2* measurement (msec)      | Cardiac T2* measurement (msec)      | Cardiac T2* measurement (msec)      | Cardiac T2* measurement (msec)      | Cardiac T2* measurement (msec)      | Cardiac T2* measurement (msec)      | Cardiac T2* measurement (msec)      | Cardiac T2* measurement (msec)      |
|                                     | N                                   | 10                                  | 8 18                                | 4                                   |                                     | 14                                  | 22                                  | 10                                  | 04                                  | 24                                  | 32                                  |
|                                     | Min,Max 27, 54                      |                                     | 10, 37                              | 10, 54                              | 29, 46                              | 27, 54                              | 10, 54                              | 35.30, 50.92                        |                                     | 27, 54                              | 10, 54                              |
| Serum ferritin (pmol/L)             | Serum ferritin (pmol/L)             | Serum ferritin (pmol/L)             | Serum ferritin (pmol/L)             | Serum ferritin (pmol/L)             | Serum ferritin (pmol/L)             | Serum ferritin (pmol/L)             | Serum ferritin (pmol/L)             | Serum ferritin (pmol/L)             | Serum ferritin (pmol/L)             | Serum ferritin (pmol/L)             | Serum ferritin (pmol/L)             |
|                                     | N                                   | 10                                  | 7 18                                | 4                                   |                                     | 14                                  | 21                                  | 10                                  | 04                                  | 24                                  | 31                                  |

Across the 4 treatment studies investigating the use of Zynteglo for the treatment of TDT (parent Studies HGB-204,  HGB-205,  HGB-207,  and  HGB-212),  a  total  of  39  patients  with  TDT  have  undergone mobilisation and apheresis for drug product manufacture (i.e., the Intent-to-Treat [ITT] Population) as of the data cuts on 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies. Patient with  TDT  enrolled  in  Phase  1/2  Studies  HGB-204  and  HGB-205  have  completed  these  studies  and continue to be followed in Study LTF-303, whereas patients with TDT are still being followed in ongoing Phase 3 Studies HGB-207 and HGB-212.

Medicinal product no longer authorised Amongst the transplant population (TP), 72.7% of patients (24/33) were of nonβ 0 /β 0  genotype. Out of these 24 nonβ 0 /β 0  patients, 12 patient s (50.0%) had the β E  mutation that occurs with high frequency in many Asian countries, correlating with the predominance of patients of Asian descent in the study populations.  There  were  no  meaningful  differences  in  percent  of  splenectomised  patients  between genotypes or across studies. In  Study  HGB-204,  30.0%  of  nonβ 0 /β 0 patients (3/10) were splenectomis ed versus 37.5% of β 0 /β 0  patient s (3/8). The median ages at which the β 0 /β 0  subgroup in Study HGB-204 was diagnosed, had their first transfusion, began regular transfusions, and began iron chelation, tended to be younger than for the nonβ 0 /β 0  subgroup. All patients were transfusion-dependent in accordance with study entrance criteria for Studies HGB-204, HGB-205, HGB-207, and HGB-212, which included a requirement for patients to have a history of pRBC transfusions  of  at  least  100  mL/kg/year  in  the  2  years  preceding  enrolment,  or  be  managed  under standard  thalassaemia  guidelines with  ≥8  pRBC  transfusions  per  year  in  the  2  years  preceding enrolment. Overall, there were no apparent differences in pre-treatment transfusion requirements or pretreatment weighted nadir Hb between β 0 /β 0  and nonβ 0 /β 0  patients with TDT (either within Study HGB204, or comparing β 0 /β 0  from Study HGB-204 to nonβ 0 /β 0  pooled from Studies HGB-204 and HGB205). Pre-treatment transfusion requirements and weighted nadir Hb also appeared to be similar, with overlapping ranges, across all studies for nonβ 0 /β 0  patients. Pre-treatment baseline value ranges for liver iron burden by liver MRI/SQUID, cardiac iron burden by cardiac T2* measurements, and serum ferritin (defined as the last value prior to conditioning). Overall, there was a wide range in iron burden levels at baseline amongst the patients, spanning across the normal range to iron overload, but ranges overlapped between genotypes and across studies. Numbers analysed

As of the data cuts on 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies:

<div style=\"page-break-after: always\"></div>

- the treated patients from Study HGB-204 (N = 18) have been followed for a median (min, max) of 32.11 (23.1, 41.9) months post-drug product infusion;
- the treated patients with TDT from Study HGB-205 (N = 4) have been followed for a median (min, max) of 38.29 (28.8, 47.7) months post-drug product infusion;
- the treated patients from Study HGB-207 (N = 10) have been followed for a median (min, max) of 5.59 (0.8, 13.2) months post-drug product infusion;
- the single treated patient in Study HGB-212 (who had a β 0 /β 0  genotype) has been followed for a duration of 3.0 months post-drug product infusion.

| longer   | longer   | longer   | longer   | longer   | longer   | longer   | longer   | longer   | longer   | longer   | longer   |
|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| no       | no       | no       | no       | no       | no       | no       | no       | no       | no       | no       | no       |
| product  | product  | product  | product  | product  | product  | product  | product  | product  | product  | product  | product  |

The definition of transfusion independence (TI) requires 12 months without any pRBC transfusions while maintaining a weighted average Hb of ≥9 g/dL after a preceding 60 days without any pRBC transfusion. Therefore, no patients in Study HGB-207 were yet evaluable for TI at the 22 February 2018 data cut due to insufficient follow-up time in the parent study.

Medicinal product no longer authorised There have been 2 discontinuations from these studies; both patients had nonβ 0 /β 0  genotypes, both before the initiation of conditioning. In total as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies, 33 patients were treated with Zynteglo of which 24 had a nonβ 0 /β 0  genotype.  The mean duration of follow up is 21.86 months post drug product infusion for nonβ 0 /β 0  patients, with 14 patients reaching the 14 months of follow up needed for the assessment of the primary endpoint of transfusion independence. Table 25: Disposition for Patients with TDT by Parent Study, Genotype, and Overall (ITT) Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies Outcomes and estimation Transfusion Independence

<div style=\"page-break-after: always\"></div>

Figure 11: Duration of Transfusion Periods for Patients from Parent Studies HGB-204 and HGB-205 Through Last Available Visit in Study LTF-303, by Patient

<!-- image -->

<!-- image -->

<!-- image -->

Medicinal product no longer authorised Data as of 07 March 2018 Table 26: Proportion of Patients Who Achieved Transfusion Independence at Any Time, by Parent Study and Genotype (TP from Studies HGB-204 and HGB-205)

Data as of 07 March 2018.

Sowce: Table 2.2.2.1

Abbrev.:CI,confidence interval:T,tansfusion ndependence:TP,TansplantPopuation

Note: The Clopper-Pearson Exact method is used to caleulate the lower 1-sided 95% CI and the 2-sided 95% CI for the proportion of subjects meeting this criterion.

For patients of nonβ 0 /β 0  genotype treated with Zynteglo in studies HGB-204 and HGB-205, 11 out of 14 patients (78.6%; 95% CI of 49.2% to 95.3%) met the definition of TI at any time, with similar proportion of nonβ 0 /β 0  patients meeting the definition of TI at any time across the 2 studies (8/10, 80%

<div style=\"page-break-after: always\"></div>

for Study HGB-204; 3/4, 75% for Study HGB205). Only 2 out of 8 β 0 /β 0  patients (25.0%; 95% CI of 3.2% to 65.1%) met the definition of TI at any time.

## Characterisation of Transfusion Independence (Secondary Efficacy Endpoints)

Table 27: Time from Drug Product Infusion to Last pRBC Transfusion, and Time to Reach Transfusion Independence (TP; TI Patients Only)

<!-- image -->

<!-- image -->

Medicinal product no longer authorised For nonβ0/β0 patients who achieved TI at any time (N = 11), median (min, max) duration of time from drug product infusion to last pRBC transfusion was relatively short for all patients, at 0.46 (0.2, 5.8) months. Median (min, max) time to reach TI was 15.60 (14.9, 20.9) months. The 3 nonβ0/β0 TI patients from Study HGB-205 were on the lower end of this range for time to reach TI, reporting times of 14.9, 14.9, and 15.6 m onths. For the 2 β0/β0 patients from Study HGB-204 who achieved TI at any time, duration of time from drug product infusion to last pRBC transfusion was more variable at 1.8 and 19.4 months, with time to reach TI of 17.5 and 35.7 months. Duration of Transfusion Independence The duration of TI was analysed using Kaplan-Meier methods, which allows for the censoring of TI at the last Hb assessment if TI is maintained through all Hb assessments, as the true duration of TI cannot be determined when patients continue to maintain their TI status through latest study visit. By assuming TI ended at the last Hb assessment, the observed duration of TI can be calculated.

<div style=\"page-break-after: always\"></div>

Table 28: Duration of Transfusion Independence, by Parent Study and Genotype (TP; TI Patients Only)

<!-- image -->

|                         |                 | HCB-204           | HCB-204    | HCB-204            | HGB-205            | Overall        | Overall              |
|-------------------------|-----------------|-------------------|------------|--------------------|--------------------|----------------|----------------------|
| Parameter               | Statistie       | odlnd-moN (N =10) | β9βo (N=8) | A Cenotypes (N=18) | Al Genotypes (N=4) | Non-β/β (N=14) | AIl Genotypes (N=12) |
| Duuation 11.J0 (months) | #of events      | 0                 | 1          | 1                  | 0                  | 0              | 1                    |
|                         | #of censored    | 8                 | 1          | 9                  |                    | 11             | 12                   |
|                         | 25th percentile |                   | 16.1       |                    |                    |                |                      |

<!-- image -->

Medicinal product no longer authorised All nonβ 0 /β 0  patients who have achieved TI at any time (N = 11) have maintained their TI status through all Hb assessments; thus, the duration of TI was censored at the last Hb assessment and no events for loss of TI have yet been recorded. For these 11 nonβ 0 /β 0  patients who achieved TI at any time, the median duration of TI was not reached and the range for the duration of TI to date was 16.1+ to 45.0+ months. Median observed duration of TI was 32.70 months. The true duration of TI would be longer than these numbers reported. No patient s of β 0 /β 0 genotype were TI at Month 24. One (1) β 0 /β 0  patient had achieved TI during the parent  study  at  17.5  months  post-drug  product  infusion.  However,  they  received  a  single  pRBC transfusion due to an acute event of Cat Scratch Disease prior to their Month 21 Visit and thus lost TI status. At Month 24 they had not yet been followed long enough to regain TI status. Another β 0 /β 0  patient achieved TI at approximately Month 36, which was the last scheduled visit completed for this patient.

## Weighted Average Haemoglobin during Transfusion Independence

For nonβ 0 /β 0  patients who achieved TI at any time (N = 11), median (min, max) weighted average Hb during TI was 10.64 (9.3, 13.1) g/dL. For the 2 β 0 /β 0  patients who achieved TI at any time, their weighted average Hb during TI was 9.8 and 10.1 g/dL. For all patients who achieved TI at any time, during TI their weighted average Hb consists of Hb produced from transgenic and endogenous Hb fractions. This weighted average Hb was generally equal or greater than their baseline pre-treatment weighted average

<!-- image -->

<div style=\"page-break-after: always\"></div>

nadir Hb that was primarily due to chronic pRBC transfusions. These baseline average nadirs ranged from 7.0 to 10.8 g/dL for nonβ 0 /β 0  patients and was 9.6 or 9.3 g /dL for the 2 β 0 /β 0  patients, respectively.

The nonβ 0 /β 0  patients from Studies HGB-204 and HGB-205 who have achieved TI at any time reported median (min, max) total Hb levels of 10.20 (8.6, 13.4) g/dL at Month 6 (N = 11), 10.70 (9.1, 13.7) g/dL at Month 24 (N = 11), and 12.00 (9.4, 13.5) g/dL at Month 36 (N = 7). Four of these 11 TI patients reported total Hb levels within normal range (respective of their gender) at last visit.

## Ancillary analyses

<!-- image -->

| longer   |
|----------|
| no       |

Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies

<!-- image -->

Medicinal product no longer authorised Predicting TI Status in Study HGB-207 From Observed HbA T87Q  at Month 6 and Month 9 in Nonβ 0 /β 0  Patients Maximum likelihood estimators from fitted logistic regression models (shown in PD section)  were applied to predict the probability of achieving TI at any time or Month 24 for patients in Study HGB-207 with observed HbA T87Q  data at Months 6 and/or 9. The model based on month 6 data predicted that 5/6 patients in Study HGB-207 will have approximately 99% probability of achieving TI at any time or Month 24. Results for achieving TI at any time are summarised in Table 29, and observed HbA T87Q  values and predicted probabilities are combined and presented in Figure 12. Table 29: Predicted Probability of Achieving TI of Study HGB-207 Patients Figure 12: HbA T87Q  over Time in Peripheral Blood with Predicted Probability of Achieving TI (TP; HGB-207)

<div style=\"page-break-after: always\"></div>

## Data as of 15 May 2018

Note: Individual patients are indicated by different colors. Patients achieving TI are represented with solid lines, patients not achieving TI are represented with dotted lines, and patients not having sufficient follow-up to be evaluable for TI are presented with dashed lines.

## Transfusion Reduction (Phase 1/2 Studies HGB-204 and HGB-205)

The 3 nonβ 0 /β 0  patients from Studies HGB-204 and HGB-205 who have not achieved TI at any time (2 from Study HGB-204 and 1 from Study HGB-205), their percent change in annualized transfusion volume from the period from 6 months post-drug product infusion through Month 24 as compared to annualized baseline pre-treatment transfusion requirements was  -26.8%, -86.9%, or  -100%, respectively, and they had 3, 11.9, and 13 fewer transfusions per year for the period from 6 months post-drug  product  infusion  through  Month  24  as  compared  to  baseline,  respectively.  All  3  patients maintained similar levels of transfusion reduction from end of the parent study at Month 24 through last study visit.

Medicinal product no longer authorised Transfusion Reduction (Phase 3 Study HGB -207) For the interim analysis, data were not available to analyse the whole time period; therefore, annualized transfusion requirements for the following time periods were compared: 2 years prior to study enrolment versus hospital discharge after drug product infusion through the last visit. Eight patients in the TP had a 'hospitalization for drug product infusion' discharge date, 7 out of 8 patients had 100% reduction in annualized  transfusion  volume  and  frequency  from  hospital  discharge  through  last  study  visit  as compared to pre-enrolment transfusion requiremen ts, with weighted average nadir Hb of ≥11.1 g/dL, which is greater than their pre-enrolment weighted average nadir Hb, indicating that these are likely to be meaningful reductions in transfusion requirements. Total Haemoglobin for Transfusion-free Patients · All transfusion-free nonβ 0 /β 0  patients had their last pRBC transfusion by &lt;178 days post-drug product  infusion  and  remained  transfusion-free  at  last  study  visit.  (A  patient  is  considered transfusionfree if they have a continuous period of ≥12 months without a pRBC transfusion.) · Out  of  the  12  transfusion-free  nonβ 0 /β 0   patients  from  Studies  HGB-204  and  HGB-205,  11 patient s (92%) reported total Hb levels ≥9 g/dL during the major ity of their transfusion-free period, with 4 patients reporting total Hb levels within normal range (respective of their gender) at last visit. · One nonβ 0 /β 0  patient in Study HGB-207 is transfusion-free and this patient reported total Hb levels ranging from 10.6 to 13.3 g/dL post-drug product infusion; their Hb level has been within normal range since Month 6. Change in Iron Burden Iron overload during the study was evaluated by assessing LIC and cardiac T2* by MRI or SQUID, and serum ferritin, serum iron, transferrin, and transferrin saturation in peripheral blood.

In HGB-204: a transient increase in iron burden (as deduced from LIC and serum ferritin levels) was observed  in  several  patients  at  app.  12  months  post  DPI,  presumably  due  to  pre-treatment hypertransfusion and/or delay in restarting chelation regimens after Zynteglo infusion, and to the effect of myeloablation and transplantation.  Cardiac iron content was evaluated by MRI at Baseline (last value prior to conditioning), Month 12 and Month 24. No trend in cardiac iron content is observed. Median % change from Baseline to Month 24 value is -5.26% for patients who achieved TI at any time during the study (N=9) versus 0% change for patients who did not achieve TI.

The  majority  of  patients  who  achieved  TI  and  who  were  evaluable  in  study  HGB-204  showed

<div style=\"page-break-after: always\"></div>

improvements in ferritin (7/8 patients), serum transferrin (7/9 patients), serum iron (7/9 patients), and transferrin saturation (5/7 patients). The decrease in ferritin levels are generally greater for patients who achieved TI status versus patients who did not achieve TI status by Month 24: median change from Baseline at Month 24 was -26.1% for TI patients, versus -5.1% for non-TI patients, although results were variable between patients.

For study HGB-207, iron burden was not analysed in the interim CSR, due to the limited time of follow up. As of the data cut for the interim CSR, 2 out of 10 patients had re-started iron chelation after drug product infusion (follow-up of app. 7 and 12 months after drug product infusion).

Medicinal product no longer authorised Summary of main studies The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections). Table 30: Summary of Efficacy for the pooled efficacy analysis of patients treated in studies HGB-204 and HGB-205: Title: Pooled Efficacy Analysis

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                            | Secondary endpoint                                                         | Secondary endpoint                                                                                                                                                                                                                                                                                        | TR                                                                                                                                                                                                                                                                                                        | defined as the proportion of patients with at least 60% reduction in transfusion requirements compared to that in the 2 years prior to study enrolment                                                                                                                                                    |
|----------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | Secondary endpoint                                                         | Secondary endpoint                                                                                                                                                                                                                                                                                        | Characterization of TI                                                                                                                                                                                                                                                                                    | duration, time to achievement, time from infusion to last pRBC transfusion, weighted Hb during TI, proportion of patients with TI at Months 18 and 24                                                                                                                                                     |
| Database lock              | Data cut date of 7 Mar 2018, only HGB-207 had data cut date of 22 Feb 2018 | Data cut date of 7 Mar 2018, only HGB-207 had data cut date of 22 Feb 2018                                                                                                                                                                                                                                | Data cut date of 7 Mar 2018, only HGB-207 had data cut date of 22 Feb 2018                                                                                                                                                                                                                                | Data cut date of 7 Mar 2018, only HGB-207 had data cut date of 22 Feb 2018                                                                                                                                                                                                                                |
| Results and Analysis       | Results and Analysis                                                       | Results and Analysis                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                      |
| Analysis description       | Analysis description                                                       | Primary Analysis                                                                                                                                                                                                                                                                                          | Primary Analysis                                                                                                                                                                                                                                                                                          | Primary Analysis                                                                                                                                                                                                                                                                                          |
| Analysis population and    | Analysis population and                                                    | Transplant Population (TP): All patients in the ITT population who underwent Zynteglo infusion.                                                                                                                                                                                                           | Transplant Population (TP): All patients in the ITT population who underwent Zynteglo infusion.                                                                                                                                                                                                           | Transplant Population (TP): All patients in the ITT population who underwent Zynteglo infusion.                                                                                                                                                                                                           |
| Descriptive statistics and | Descriptive statistics and                                                 | authorised Treatment group Non- β 0 / β 0                                                                                                                                                                                                                                                                 | authorised Treatment group Non- β 0 / β 0                                                                                                                                                                                                                                                                 | authorised Treatment group Non- β 0 / β 0                                                                                                                                                                                                                                                                 |
|                            |                                                                            | Number of patients 14                                                                                                                                                                                                                                                                                     | Number of patients 14                                                                                                                                                                                                                                                                                     | Number of patients 14                                                                                                                                                                                                                                                                                     |
|                            |                                                                            | longer TI 11 (78.6%)                                                                                                                                                                                                                                                                                      | longer TI 11 (78.6%)                                                                                                                                                                                                                                                                                      | longer TI 11 (78.6%)                                                                                                                                                                                                                                                                                      |
| Medicinal                  | Medicinal                                                                  | product no TR in patients that did not achieve TI at any time (n=3) - %change in annualized transfusion volume from the period from 6 months post-DPI through Month 24 as compared to annualized baseline pre-treatment transfusion requirements: - fewer transfusions per year for -26.8%, -86.9%, -100% | product no TR in patients that did not achieve TI at any time (n=3) - %change in annualized transfusion volume from the period from 6 months post-DPI through Month 24 as compared to annualized baseline pre-treatment transfusion requirements: - fewer transfusions per year for -26.8%, -86.9%, -100% | product no TR in patients that did not achieve TI at any time (n=3) - %change in annualized transfusion volume from the period from 6 months post-DPI through Month 24 as compared to annualized baseline pre-treatment transfusion requirements: - fewer transfusions per year for -26.8%, -86.9%, -100% |
|                            |                                                                            | baseline Observed duration of TI* * median duration of TI not reached Median (min, max): 32.7 (16.1, 45.0)                                                                                                                                                                                                | baseline Observed duration of TI* * median duration of TI not reached Median (min, max): 32.7 (16.1, 45.0)                                                                                                                                                                                                | baseline Observed duration of TI* * median duration of TI not reached Median (min, max): 32.7 (16.1, 45.0)                                                                                                                                                                                                |
|                            |                                                                            | Time to reach TI (months) Median (min, max): 15.6 (14.9, 20.9)                                                                                                                                                                                                                                            | Time to reach TI (months) Median (min, max): 15.6 (14.9, 20.9)                                                                                                                                                                                                                                            | Time to reach TI (months) Median (min, max): 15.6 (14.9, 20.9)                                                                                                                                                                                                                                            |
|                            |                                                                            | weighted average Hb during TI median (min, max) 10.64 (9.3, 13.1) g/dL                                                                                                                                                                                                                                    | weighted average Hb during TI median (min, max) 10.64 (9.3, 13.1) g/dL                                                                                                                                                                                                                                    | weighted average Hb during TI median (min, max) 10.64 (9.3, 13.1) g/dL                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| median Total Hb (g/dl) during TI (min, max)   | Month 6 (n=11): 10.20 (8.6, 13.4) Month 24 (n=11): 10.70 (9.1, 13.7) Month 36 (N = 7): 12.00 (9.4, 13.5)   |
|-----------------------------------------------|------------------------------------------------------------------------------------------------------------|

## Clinical studies in special populations

Study HGB-204 included 3 adolescents (out of 18 patients total), study HGB-205 included 2 adolescents (out of 4 patients total). Study HGB-207 is ongoing, as of the data cut on 22 February 2018, 4 out of 10 included patients were adolescents. It is noted that HGB-207 is designed to include 2 cohorts of patients with TDT of nonβ 0 /β 0  genotype: Cohort 1 should include at least 15 patient s ≥12 and ≤50 years of age, and Cohort 2 should include at least 8 patients &lt;12 years of age.

|                       |   Age 65-74 (Older patients number /total number) |   Age 75-84 (Older patients number /total number) |   Age 85+ (Older patients number /total number) |
|-----------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials     |                                                 0 |                                                 0 |                                               0 |
| Non Controlled Trials |                                                 0 |                                                 0 |                                               0 |

Seventeen patients with TDT treated with Zynteglo (13 from Study HGB-204 and 4 from Study HGB205) consented to enrol in Study LTF-303, and all of these patients continue to participate in Study LTF303 as of the data cut for this interim CSR, with a median (min, max) follow-up time of 29.93 (23.1, 47.3) months post-drug product infusion. Three patients with TDT treated with a related drug product manufactured from the HPV569 LVV encoding β A-T87Q -globin (all from Study LG001) consented to enrol in Study LTF-303. One of these patients subsequently met the VCN discontinuation criterion and was discontinued from the study. The other 2 patients have been followed for approximately 5 or 10 years after drug product infusion.

Medicinal product no longer authorised Moreover, it is noted that the oldest person included in All Studies and all genotypes was 35 years old. The oldest nonβ 0 / β 0  patients was 34 years old (included in HGB-204). Controlled Trials Non Controlled Trials Supportive study Long-term Follow up study LTF-303 This study is a multi-center, long-term safety and efficacy follow-up study. After monitoring of a patient in the parent study was completed (where the parent study includes approximately 2 years of follow-up after drug product infusion), patients were eligible to enrol in Study LTF-303. During Study LTF-303, patients were followed every 6 months from 2 years through 5 years post-drug product infusion and then annually from 5 years through 15 years post-drug production infusion for a total of 13 years of follow-up  in  Study  LTF-303.  The  study  started  on  06  January  2014  (First  patient  signed  informed consent). The interim CSR Data Cut Date: 21 November 2017 (After first patient with TDT treated with Zynteglo in parent study completed the Month 48 Visit). Study LTF-303 continues to be ongoing to date.

Of  the  17  enrolled  Zynteglo-treated  patients  with  TDT,  13  were  female  (76.5%)  and  4  were  male (23.5%). Median (min, max) age at consent or assent in parent study was 20.0 (16, 35) years; 14 patient s were ≥18 years of age (82.4%) and 3 patients were adolescents (17.6%). Twelve patients identified as Asian (70.6%) and 5 patients identified as White (29.4%). Eleven patients were of nonβ 0 /β 0  genotype (64.7%) and 6 patients were of β 0 /β 0  genotype (35.3%). The 2 eligible patients treated

<div style=\"page-break-after: always\"></div>

with the related drug product manufactured from the HPV569 LVV enrolled in Study LTF-303 had the following demographic characteristics were young adults and of β E /β 0  genotype.

## Summary of Efficacy for LTF-303 as of 21 November 2017:

## Transfusion Independence and Transfusion Reduction

- Out of the 17 treated patients with TDT, 10 patients (all with nonβ 0 /β 0  genotype) were TI upon entry into Study LTF-303 at Month 24. For patients who have additional follow-up in Study LTF303 beyond entry at Month 24 (i.e., have completed at least their Month 30 Visit; N = 12 [7 TI and 5 non-TI]), the TI status achieved by the end of the parent study at Month 24 (either TI or non-TI) has been maintained for each patient throughout Study LTF-303.

## Iron Burden

- All  7  TI  patients  who  have  additional  follow-up  in  Study  LTF-303  beyond  entry  at  Month  24 showed lower serum ferritin values at last visit as compared to Month 24. In particular, the TI patient with the longest follow-up showed a reduction in serum ferritin levels from 1393 pmol/L at  Month  24  to  465  pmol/L  a  Month  48,  reaching  well  below  serum  ferritin  levels  typically associated with clinically significant iron overload. For the 5 non-TI patients who have additional follow-up in Study LTF-303 beyond entry at Month 24 (N = 3 with last scheduled visit completed of Month 30 and N = 2 with Month 36), there was no clear trend across these patients for change in serum ferritin levels at last scheduled visit completed as compared to Month 24.
- Medicinal product no longer authorised · For patients who have achieved TI (N = 10), the median (min, max) duration of TI was 30.00 (17.1, 45.0) months as of the data cut, which includes the patient who has been followed for the longest time (with last scheduled visit completed of Month 48). For the 7 TI patients who have completed at least their Month 30 Visit, the weighted average Hb ranged from 9.7 to 13.2 g/dL for the period from 6 months through last visit, as compared their Hb levels during parent study with weighted average Hb ranging from 9.4 to 13.2 g/dL for the period from 6 months through end of parent study at Month 24. · For the 7 patients who have not achieved TI (1 nonβ 0 /β 0 and 6 β 0 /β 0 ), 6 patients have completed at least their Month 30 Visit and their annualized pRBC transfusion requirements (volume or frequency), and weighted average nadir Hb, were relatively stable from end of the parent study at Month 24 through long-term follow-up (up to Month 36). Two of these patients appear to show a  sustained  decrease  in  pRBC  transfusion  requirements  during  Study  LTF-303  compared  to requirements in the parent study but should be followed for a longer period of time to confirm this  trend.  Overall,  for  non-TI  patients  (N  =  7),  reductions  in  annualized  pRBC  transfusion volumes from 6 months through last visit as compared to pre-treatment requirements ranged from 40.1% to 100%, with 1 β 0 /β 0  patient achieving &lt;50% (40.1%), 1 β 0 /β 0  patient achieving ≥50% to &lt;60% (52.8%), 2 β 0 /β 0  patient s achieving ≥60% to &lt;75%, 2 β 0 /β 0  patients achieving ≥75% to &lt;90%, and 1 non -β 0 /β 0  patient achieving 100% reduction. · Only 4 patients had data for LIC beyond Month 24. For the 2 of these patients who had LIC values  &gt;7  mg/g  (the  threshold  at  which  organ  damage  generally  occurs)  at  baseline,  both showed decreases in LIC over time, with the patient with the longest follow-up showing the biggest improvement in LIC. · For the 3 patients with available data for cardiac iron content beyond Month 24, there was not a clear trend across patients for change in cardiac T2* values, with all patients maintaining normal values &gt;20 ms. The patient with the longest follow-up showed improvement in cardiac iron burden.

<div style=\"page-break-after: always\"></div>

## Dyserythro poiesis

- The 7 TI patients, all of whom were of nonβ 0 /β 0   genotype, who have additional follow-up in Study LTF-303 beyond entry at Month 24, maintained the pattern of reticulocyte/erythrocyte % established by the end of the parent study, with 4 patients having normal or near normal %, and 3 having higher than normal %.

For patients treated with the related drug product (N = 2):

- Neither of the 2 patient s were able to achieve a stable total Hb ≥9 g/dL in the absence of pRBC transfusions during long-term follow-up.

| Study   | Total number of patients (young adults/ adolescents)   | Age (years) median (min, max)     | no Pre-enrolment transfusion volumes (mL/kg/year) median (min, max)   | Pre-enrolment transfusion frequency (number/year) median (min, max)   |
|---------|--------------------------------------------------------|-----------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
| HGB-205 | 4 (2)                                                  | product young adults/ adolescents | 181.85 (138.8, 197.3)                                                 | 12.50 (10.5, 13.0)                                                    |
| HGB-204 | 10 (2)                                                 | 19.5 (16, 34)                     | 151.28 (140.0, 234.5)                                                 | 13.75 (10.0, 16.5)                                                    |
| HGB-207 | 15 (6)                                                 | 20.0 (12, 34)                     | 192.92 (152.3, 251.3)                                                 | 17.50 (11.5, 37.0)                                                    |
| HGB-212 | 3 (1)                                                  | young adults/ adolescents         | 175.51 (170.7, 209.6)                                                 | 21.50 (17.5, 39.5)                                                    |

Adolescents were excluded from Phase 3 studies if they had a known and available HLA-matched related HSC donor. The median (min, max) age in the studies was 19.0 (12, 34) years, 56.3% were females, 59.4% were Asian, and 40.6% White/Caucasian. All patients had a Karnofsky performance score ≥80 and the majority had a performance score of 100 at baseline. Cardiac T2* at baseline was &gt;20 msec. The median (min, max) serum ferritin at baseline was 3778.7 (784, 22517) pmol/L and median (min, max) liver  iron  concentration  was  6.75  (1.0,  41.0)  mg/g  (N=10,  HGB-204;  N=4,  HGB-205;  N=15, HGB-207; N=3, HGB-212).

Medicinal product no longer authorised 2.5.3. Updated data on efficacy parameters: 13 December 2018 An additional  data  cut  was  performed  of  the  HGB-207,  HGB-212,  and  LTF-303  clinical  database  on 13 December 2018. A total of 48 patients with TDT have been treated with Zynteglo and followed for up to 60 months (up to 22 months in Phase 3 studies) as of 13 December 2018, including 42 patient s ≥12 years of age with TDT (32 patients with a nonβ 0 /β 0  genotype and 10 patient s with a β 0 /β 0  genotype). Below is a brief overview of the baseline characteristics and efficacy analysis as of 13 December 2018, based on 32 adult and adolescent patients with TDT and a nonβ 0 /β 0  genotype treated with Zynteglo (N=10, HGB-204; N=4, HGB-205; N=15, HGB-207; N=3, HGB-212). Table 31: Baseline characteristics for nonβ 0 /β 0  patients with TDT ≥12 years of age treated with Zynteglo (Studies HGB-204, HGB-205, HGB-207, HGB-212, LTF-303)

## Transfusion Independence:

In  total,  15  out  of  19  nonβ 0 /β 0   patients  have  achieved  TI  (78.9%;  95%  CI  of  54.4% to  93.9%), suggesting that the great majority of patients with a nonβ 0 /β 0   genotype  treated  with  Zynteglo  will

<div style=\"page-break-after: always\"></div>

achieve TI. All nonβ 0 /β 0   patients  who achieved TI have maintained TI. The observed duration of TI ranged from 12.0 to 56.3 months post-drug product infusion.

Most nonβ 0 /β 0  patients treated in Studies HGB-204 and HGB-205 (11/14, 78.6%; 95% CI of 49.2% to 95.3%) have achieved TI (see Table 32 below). Among the 11 nonβ 0 /β 0   patients treated in Studies HGB-204 and HGB-205 who achieved TI, the median (min, max) weighted average Hb during TI was 10.51 (9.3, 13.2) g/dL. These patients have all maintained TI, with a min, max duration of TI of 21.2 to 56.3  months  as  of  13  December  2018  (see  Table  33  below).  Median  (min,  max)  time  to  last  RBC transfusion was 0.46 (0.2, 5.8) months following Zynteglo infusion.

<!-- image -->

| longer   |
|----------|

<!-- image -->

Medicinal product no longer authorised The nonβ 0 /β 0  patients who did not achieve TI in Phase 1/2 studies were either producing relatively low amounts of HbA T87Q  (2 patients with 0.97 and 3.64 g/dL at last study visit, respectively) or low amounts of endogenous HbA (1 patient with 6.72 g/dL of HbA T87Q  at Month 24 but 1.0 g/dL of endogenous HbA at Month 24) compared to the other nonβ 0 /β 0  patients. Table 32: Proportion of patients who achieved transfusion independence at any time, by parent study and genotype (TP from phase ½ studies HGB-204 and HGB-205

<div style=\"page-break-after: always\"></div>

Table 33: Duration of Transfusion Independence, by Parent Study and Genotype (TP; TI Patients Only)

|        | authorised   |
|--------|--------------|
| longer |              |

<!-- image -->

Of the 11 nonβ 0 /β 0  patient s ≥12 years of age who have completed at least their Month 6 Visit in Phase 3 studies, 10 patients (90.9%) have achieved TI (n = 4) or are predicted to achieve TI (n = 6), including 2 patients with the severe nonβ 0  IVS-I-5 mutation (1 patient with IVS-I-5/IVS-I-5 and 1 patient with IVS-I5/β 0 )  who produce approximately 0.3 g/dL or less of endogenous HbA in the absence of pRBC transfusions (1 patient who has achieved TI and the other predicted to achieve TI).

Medicinal product no longer authorised Study HGB-207: A total of 4 out of the 5 TI-evaluable patients achieved TI (80.0%; 95% confidence interval [CI] of 28.4% to 99.5%). Median (min, max) time to reach TI for these 4 patients was 15.15 (15.0, 16.2) months post-drug product infusion with a min, max observed duration of TI to date of 12.0+, 18.2+ months and median (min, max) weighted average Hb during TI of 12.42 (11.5, 12.6) g/dL. Notably all patients who were predicted to achieve TI based on PD modelling that have become evaluable for TI (N = 3) have achieved TI, validating the predictive value of the logistic regression models (see figure below). For the 6 additional nonβ 0 /β 0  patient s ≥12 years of age ( in Study HGB-207) with Month 6 HbA T87Q  data, the updated logistic regression model was applied to predict the probability of achieving TI by Month 24 and at any time. Results predict that they have an approximately 98% or higher probability of achieving TI by end of study.

<div style=\"page-break-after: always\"></div>

Table 34: HbA T87Q  over time in peripheral blood with predicted probability of achieving transfusion independence

<!-- image -->

<!-- image -->

Medicinal product no longer authorised Haemoglobin levels in TI patients Nonβ 0 /β 0   patients  from Studies HGB-204 and HGB-205 who have achieved TI at any time reported median (min, max) total Hb levels in the absence of transfusions of 10.70 (8.6, 13.4) g/dL at Month 6 (N = 9), of 10.70 (9.1, 13.7) g/dL at Month 24 (N = 11), 11.40 (9.1, 13.5) g/dL at Month 36 (N = 10), and 11.10  (10.4, 13.7) g/dL at Month 48 (N = 5). For  the  4  nonβ 0 /β 0   patients  from  Study  HGB-207  who  have  achieved  TI  (which  included  a  patient homozygous  for the  severe  β +   variant  IVS-I-5),  median  (min,  max)  total  Hb  in  the  absence  of transfusions at Month 6 was 12.00 (11.5, 13.3) g/dL. Patients from Study HGB-207 do not yet have Hb data for Month 24 or beyond, but available data at Month 12 for 8 patients from Study HGB-207 (TI and non-TI) reported median (min, max) total Hb values in the absence of transfusions of 12.40 (8.4, 13.1) g/dL. Median total haemoglobin over time for nonβ 0 /β 0  patients who have achieved TI is presented in Figure 13.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 13: Median total haemoglobin over time in nonβ 0 /β 0  patients with TDT treated with Zynteglo who have achieved transfusion independence (Studies HGB-204, HGB-205, HGB-207, LTF-303)

<!-- image -->

<!-- image -->

Medicinal product no longer authorised Bars represent interquartile ranges Data as of 13 December 2018 Transfusion reduction in non-TI patients As of 13 December 2018, 5 out of 8 patients (including 2 out of 3 nonβ 0 /β 0   patients) in Phase 1/2 studies who did not achieve TI attained a &gt;60% reduction in pRBC transfusion volumes. Median (min, max) change in pRBC transfusion volume for the 8 non-TI patient s was -66.55% (-100.0%, -10.3%) from  6  months  post-drug  product  infusion  through  last  follow-up  as  compared  to  their  baseline pretreatment transfusion requirements. In the 3 Phase 1/2 nonβ 0 /β 0  patients who did not achieve TI, reductions of 100%, 86.9% and 26.8% in transfusion volume requirements and of 100%, 85.3% and 20.7% in transfusion frequency were observed between Month 6 through Month 24 visit when compared to their pre-study levels of RBC transfusions. For these patients, the &gt;60% reduction in transfusion requirements were associated with weighted average nadir Hb similar to pre-treatment weighted average nadir  Hb.  Thus,  while  the  transduction  efficiency  in  Phase  1/2  studies  was  not  sufficient  to  provide adequate expression of HbA T87Q  to support TI in these patients, they still received clinical benefit with transfusion reduction. For the 4 patients in Study HGB-207 who have completed at least their Month 12 Visit but have not achieved  TI,  3  patients  demonstrated  100%  reduction  in  annualized  transfusion  volume,  while  the remaining patient had a 75.8% reduction.

Most nonβ 0 /β 0  patients required pRBC transfusions for less than 6 months after drug product infusion in Phase 1/2 studies HGB-204 and HGB-205 and less than 3 months after drug product infusion in Phase 3 study HGB-207. Median (min, max) time from drug product infusion to last pRBC transfusions for nonβ 0 /β 0  patients treated in Studies HGB-204 and HGB-205 was 1.95 (0.2, 31.6) months (N = 14) and for nonβ 0 /β 0  patients in Study HGB-207 was 0.95 (0.5, 19.7) months (N = 15).

<div style=\"page-break-after: always\"></div>

## Use of Iron Removal Therapy

After Zynteglo infusion, patient iron levels were managed at physician discretion.

All patients in HGB-204 restarted iron chelation and continue to use iron chelators. One patient in HGB205 restarted iron chelation and continues to use iron chelators. Three patients in HGB-205 started phlebotomy.

For HGB-207, of the 11 patients followed for at least 6 months after Zynteglo infusion, 6 patients did not restart iron chelation or receive phlebotomy, 3 patients restarted iron chelation, and 2 patients received phlebotomy to reduce iron levels. Of the 9 patients who have not received phlebotomy, 8 of these patients have maintained a weighted average nadir Hb of &gt;11 g/dL from hospital discharge post-drug product infusion through last follow-up, which would be sufficient to stop chelation therapy and support phlebotomy.

Medicinal product no longer authorised Change in Iron Burden The majority of nonβ 0 /β 0   patients  who  have  achieved  TI  in the  Phase  1/2  studies  are  beginning  to demonstrate iron burden levels that are lower than their pre-treatment baseline values at last follow-up. At 48 months after infusion of Zynteglo for patients who achieved TI, the median reduction (min, max) in serum ferritin levels from baseline was 75.02% (39.2, 84.8) (N=3, HGB-204; N=2, HGB-205). The median reduction in LIC from baseline was 67.14%, ranging from an 83.3% reduction to a 269.2% increase (N=3, HGB-204; N=2, HGB-205). Six of the 11 nonβ 0 /β 0  patients from Studies HGB-204 and HGB-205 who have achieved TI (with range of follow-up of 29.3 to 58.6 months post-drug product infusion) had an LIC value at last follow-up that was lower than their pre-treatment baseline value. All 11 nonβ 0 /β 0  patients from Studies HGB-204 and HGB-205 who have achieved TI continue to have normal  cardiac  T2*  values  (i.e.,  &gt;20  ms)  from  Baseline  through  last  follow-up,  with  6  patients demonstrating a cardiac T2* value at last follow-up that was higher than their pre-treatment baseline. Additionally, all 11 nonβ 0 /β 0  patients from Studies HGB-204 and HGB-205 who have achieved TI had a serum ferritin value at last follow-up that was lower than their pre-treatment baseline value (median [min, max] serum ferritin at Baseline was 3885 (1643, 8629) pmol/L. There is not yet sufficient follow-up in Phase 3 studies to make a determination on changes in iron burden. Dyserythropoiesis Exploratory  analyses  were  performed  to  confirm  resolution  of  dyserythropoiesis,  the  fundamental physiologic characteristic of TDT, in the bone marrow. Bone marrow biopsies taken before treatments were consistent  with  a  diagnosis  of  TDT,  including  a  low  myeloid/erythroid  ratio  (N=15,  HGB-207), reflective of erythroid hyperplasia. For 8 patients who had sufficient on-study follow-up to obtain a 12month follow-up bone marrow assessment, myeloid/erythroid ratios for 7 patients increased from a range of 0.1 to 0.5 at baseline to a range of 0.6 to 1.9 approximately 12 months after Zynteglo infusion, suggesting that Zynteglo improves erythropoiesis in patients with TDT.

Additionally, of the 11 nonβ 0 /β 0   patients who have achieved TI in Phase 1/2 studies. 4 patients had normal percent reticulocytes, 4 patients had no nucleated RBCs, and 5 patients had serum transferrin receptor levels within normal range at last follow-up, indicating normalization of dyserythropoiesis for these patients.

In  summary,  key  pharmacodynamic  and  efficacy  outcomes  for  nonβ 0 /β 0   TDT  patients  treated  with Zynteglo in Studies HGB-204, HGB-205, HGB-207, and LTF-303 are included in Table 35.

<div style=\"page-break-after: always\"></div>

Table 35: Efficacy outcomes for nonβ 0 /β 0  TDT patients treated with Zynteglo (Studies HGB-204, HGB-205, HGB-207, LTF-303)

| HbA T87Q (g/dL) at 6 months n median (min, max)   | HbA T87Q (g/dL) at 24 months n median (min, max)   | Hb (g/dL) at 6 months* n median (min, max)   | Hb (g/dL) at 24 months* n median (min, max)   | TI** n/N^ (%) [95% CI]    | WA Hb during TI (g/dL) n median (min, max)   | Duration of TI (months) N median (min, max)   |
|---------------------------------------------------|----------------------------------------------------|----------------------------------------------|-----------------------------------------------|---------------------------|----------------------------------------------|-----------------------------------------------|
| Study HGB-205                                     | Study HGB-205                                      | Study HGB-205                                | Study HGB-205                                 | Study HGB-205             | Study HGB-205                                | Study HGB-205                                 |
| 4 7.543 (4.94, 9.59)                              | 4 8.147 (6.72, 10.13)                              | 4 10.73 (7.6, 13.4)                          | 4 10.91 (8.8, 13.6)                           | 3/4 (75.0%) [19.4, 99.4]  | 3 11.30 (10.5, 13.0)                         | 3 NR (34.9+, 56.3+)                           |
| Study HGB-204                                     | Study HGB-204                                      | Study HGB-204                                | Study HGB-204                                 | Study HGB-204             | Study HGB-204                                | Study HGB-204                                 |
| 10 4.153 (1.03, 8.52)                             | 10 5.418 (1.10, 9.60)                              | 7 9.20 (7.7, 13.3)                           | 8 10.35 (9.1, 13.7)                           | 8/10 (80.0%) [44.4, 97.5] | authorised 8 10.27 (9.3, 13.2)               | 8 NR (21.2+, 45.3+)                           |
| Study HGB-207                                     | Study HGB-207                                      | Study HGB-207                                | Study HGB-207                                 | Study HGB-207             | Study HGB-207                                | Study HGB-207                                 |
| 11 9.494 (3.35, 10.60)                            | NA***                                              | 11 11.90 (8.4, 13.3)                         | NA***                                         | 4/5 (80.0%) [28.4, 99.5]  | 4 12.42 (11.5, 12.6)                         | 4 NR (12.0+, 18.2+)                           |

All three efficacy studies were single arm studies. The natural course of β -thalassaemia is well known with a clinically stable presentation over time, and patients do not spontaneously generate clinically meaningful levels of HbA or become transfusion independent. This notion together with the within-patient comparison where two years of retrospective haematological data was collected from medical records for  each  patient  to  be  enrolled  in  the  study,  and  each  patient  will  serve  as  his/her  own  control  for evaluation of transfusion requirements, reduces the need for a concurrent internal control to isolate the treatment effect. This approach was discussed under the PRIME scheme. Allogeneic HSCT would not be an appropriate control given that there are different conditioning regimens required; therefore allogeneic HSCT is associated with a different benefit/risk as compared to autologous transplantation due to the regimens' different safety profile. The currently applied-for target population for Zynteglo are patients for whom a HLA-matched related donor is not available. Standard supportive care with transfusion and chelation  would  also  not  be  an  appropriate  comparator  for  the  primary  and  key  secondary  study endpoints of transfusion independence and transfusion reduction because patients with TDT receiving supportive care do not spontaneously achieve transfusion independence or have significant reductions

Medicinal product no longer authorised *Patients who have not received transfusions in the prior 60 days. **Transfusion independence (TI): a weighted average Hb ≥9 g/dL without any RBC transfusions for a continuous period of ≥12 months at any time during the study after medicinal product infusion. ***No patients are currently evaluable for these endpoints. ^N represents the total number of patients evaluable for TI, defined as patients who have completed their parent study (i.e., 24 months of follow-up), or achieved TI, or won't achieve TI in their parent study. NR= Not reached. Hb=Total Hb. WA Hb = Weighted average Hb Data as of 13 December 2018 2.5.4. Discussion on clinical efficacy Design and conduct of clinical studies Efficacy results have been presented for HGB-204, 205 and 207 presenting data from 32 patients of the nonβ 0 /β 0 genotype and 9 β 0 /β 0   genotype patients 12 years and older. The pivotal phase 3 study for patients with a nonβ 0 /β 0  genotype is the ongoing study HGB-207 conducted in Europe, US and Thailand. During the clinical studies the process development has been optimised to generate maximum HbA T87Q expression, this resulted in variations in the drug product between the studies.

<div style=\"page-break-after: always\"></div>

in  their  transfusion requirements. Altogether, the single arm study design was agreed in a scientific advice (EMEA/H/SAH/038/1/2015/PA/SME/ADT/II).

This Marketing Authorisation Application (MAA) applies for the treatment of patients with TDT who have a nonβ 0 /β 0  genotype. All patients were transfusion-dependent in accordance with study entrance criteria for Studies HGB-204, HGB-205, HGB-207, and HGB-212, which included a requirement for patients to have a history of pRBC transfusions of at least 100 mL/kg/year in the 2 years preceding enrolment, or to be managed under standard thalassa emia guidelines with ≥8 pRBC transfusio ns per year in the 2 years preceding enrolment.

Medicinal product no longer authorised The primary endpoint, transfusion independence (TI) requires 12 months without any pRBC transfusion while  maintaining  a  weighted  average  Hb  of  ≥9  g/dL  after  a  preceding  60  days  without  any  pRBC transfusion.  The  definition  was  similar  across  all  clinical  studies.  For  comparison,  the  known  rate  of achieving TI in patients with β -thalassaemia who have not received an allogeneic HSCT is zero, as TDT patients do not spontaneously become transfusion independent. Therefore, achieving and maintaining TI  is  attributable  to  the  therapeutic  effect  of  Zynteglo  which  is  considered  clinically  relevant.  The proposed secondary endpoints are considered adequate to provide additional support. To reduce bias in the open-label design the post-treatment transfusion guidelines were pre-specified in the protocol. As patient serves as its own control and for reliability of clinical endpoints, it was of utmost importance to have a well-documented (and standardised) information on pre-baseline transfusion requirements. Thus, centres were carefully selected in clinical trials. Only patients treated and followed for at least the past 2 years in a specialized centre that maintained detailed medical records on RBC transfusions, in-patient hospitalisation and iron chelation history could be included in clinical studies. Treatment was first offered to adults, then expanded to adolescents, and then children, in a staggered fashion, depending upon safety results in each age group. Age limits varied per study, e.g. study HGB205 included only patients with age between 16-19 years and study HGB-204 included patients 12-35 years of age. Patients homozygous or heterozygous for th e β +  allele IVS I-110 (HGVS nomenclature: HBB :c.93-21G&gt;A) were excluded from study HGB-207. Similar to β 0  alleles, the IVS-I-110 mutation is widely recognized as producing little to no β -globin   (Borgna-Pignatti and Galanello, 2009), thus patients with β 0 /IVS-I-110 or IVS-I-110/IVS-I110 genotypes were grouped with the β 0 /β 0  patients in Study HGB212. Efficacy analysis is based on 32 adult and adolescent patients with TDT and a nonβ 0 /β 0  genotype treated with Zynteglo (N=10, HGB-204; N=4, HGB-205; N=15, HGB-207; N=3, HGB-212). The studied patient number is relatively small given the substantial geographic, ethnic and genetic variation encompassed by  β -thalassaemia  globally.  It  is  noted  that  the  patients  in  the  study  were  of  multiple  races  and nationalities,  and  had  multiple  different  genotypes  with  varying  levels  of  endogenous  β -globin production, and that the included patients do seem to reflect global diversity of TDT. Further, while it is not possible to include all hundreds of mutations at the HBB locus which have been associated with the phenotype of β -thalassaemia in a clinical trial, it is noted that patients with wide range of endogenous β -globin production (from 0.4 to 5.1 g/dL; still meeting criteria for transfusion dependence) were treated.

<div style=\"page-break-after: always\"></div>

These endogenous β -globin production levels could be seen as representative for the range expected in real world TDT patients.

Current treatment experience is limited to patients aged 35 years or younger. The comparison of the &lt;18 years vs ≥18 years of age subpopulations do not suggest a change in efficacy or safety by age (see also discussion on clinical safety).

## Efficacy data and additional analyses

Medicinal product no longer authorised The majority of patients with TDT who have a nonβ 0 /β 0  genotype treated with Zynteglo in study HGB204 and HGB-205 have achieved TI (11 out of 14; 78.6%). The achievement of TI is clinically meaningful eliminating the need for regular blood transfusions and associated comorbidities due to iron overload. Out of the 3 nonβ 0 /β 0  patients from Studies HGB-204 and HGB-205 who had not achieved TI, transfusion requirements  were  reduced  by  more  than  60%  in  annualised  transfusion  volume  and  annualised transfusion frequency in 2 patients. The percent change in annualized transfusion volume from the period from 6 months post-drug product infusion through Month 24 as compared to annualised baseline pretreatment transfusion volume was 26.8%, 86.9%, or 100%. These patients reported similar reductions in annualized transfusion frequency for the period from 6 months post-drug product infusion through Month 24 as compared to baseline, with 3, 11.9, and 13 fewer transfusions per year (i.e., reductions of 20.7%, 85.3%, and 100.0%). Support of efficacy of Zynteglo is derived from t he β 0 /β 0  patient s. Even though only a minority of β 0 /β 0 patient s achieved TI, the 6 β 0 /β 0  patients in Study HGB-204 who have not achieved TI did demonstrate a median transfusion volume reduction of -63.30% (-76.3%, -8.3%). The primary endpoint of the phase 3 study HGB-207 has not been reached due to limited follow-up for patients in this ongoing study. From all included patients (N=15), TI was evaluable for 5 patients of whom 4 (80%) achieved TI. For the 6 nonβ 0 /β 0  patient s ≥12 years of age (in Study HGB-207) with Month 6 HbA T87Q  data, the logistic regression model was applied to predict the probability of achieving TI  by  Month  24  and  at  any  time.  Results  predict  that  they  have  an  approximately  98%  or  higher probability of achieving TI, including 1 patient with an IVS-I-5/IVS-I-5 genotype and 1 patient with an IVS-I5/β 0  genotype who produce approximately 0.3 g/dL or less of endogenous HbA in the absence of pRBC transfusions (1 patient who has achieved TI and the other predicted to achieve TI). Therefore, the results appear to be in line with those of studies HGB-204 and HGB-205. Even so, it is important to keep in mind that the prediction is derived from a limited number of patients and hence accompanied with uncertainty. For the 4 patients in Study HGB-207 who have completed at least their Month 12 Visit but have not achieved  TI,  3  patients  demonstrated  100%  reduction  in  annualized  transfusion  volume,  while  the remaining patient had a 71.4% reduction.

Due to the limited follow-up time, the majority of secondary endpoints could not be analysed in HGB207 as these compared data from the 2 years prior to enrolment with data from 12 months after drug product infusion to Month 24. Moreover, it is expected that secondary endpoint analyses will be further substantiated through the long-term follow-up study LTF-303 (specific obligation) and registry (Annex II condition). Data with respect to a decrease in iron overload is of interest. It is acknowledged that reduction of the iron burden is a continuing process which takes time and thus requires long-term follow up. Further, data from patients treated in Study HGB-204 showed that LIC transiently increases after transplantation, with elevated levels observed at Month 12 before declining towards baseline at Month 24. Updated data indicate lower LIC and higher cardiac T2* values when compared to baseline levels in 6 of 11 patients treated in Studies HGB-204 and HGB-205 who have achieved TI, and lower serum ferritin

<div style=\"page-break-after: always\"></div>

levels in all 11 of these patients at last follow-up. These data suggest a trend towards decreasing iron levels.

Of note, patients with severe iron overload for whom iron accumulation is hard to reverse were excluded from the studies, e.g. patients with a cardiac T2* &lt;10 ms by MRI (severe cardiac iron storage) because of safety considerations.

One patient in study HGB 207, showed a 90%-lower PB VCN than DP VCN. Findings from additional analyses  were  consistent  with  the  hypothesis  that  there  may  be  an  uneven  distribution  of  LVV transduction between short-lived and long-lived CD34+ cells during manufacturing of the drug product. Even though this effect seems to be an outlier, the negative clinical implication of this sharp decrease is worth keeping PB VCN under close scrutiny in the ongoing clinical trials.

Medicinal product no longer authorised Efficacy results across studies have been durable within the duration of follow-up. Once TI is achieved, TI status was durable for nonβ 0 /β 0  patients with a range for the duration of TI to date (up to 60 months follow up). No nonβ 0 / β 0  patient across all studies who achieved TI has since required a transfusion, so TI status was maintained. Nonβ 0 /β 0  patients who have completed at least their Month 30 Visit (N = 7) all had their last pRBC transfusion in the parent study and remained transfusion-free throughout Study LTF-303. The fact that stem cells are transduced and the consideration that immunisation against the transgene is unlikely, provide some level of confidence in the sustainability of the correction of the β thalassaemia. This is further reinforced by the 10 years followup of a patient with β -thalassaemia being treated with a similar approach (LG001 HPV569, Cavazzana-Calvo 2010) and preliminary evidence of long-term haemoglobin stability over time in two patients from study HGB-205 with approximately 45 years of follow up. Overall, the follow-up time for a substantial number of patients is limited. During  the  clinical  studies,  the  drug  product  manufacturing  process  was  optimised  for  transgene expression. This change in manufacturing process in studies HGB-205, HGB-204, and HGB-207 had an influence  in  several  PD  parameters.  In  line  with  the  PD  section  of  this  report,  the  manufacturing processes used to make DP impacted the DP VCN, PB VCN and HbA T87Q  expression and will impact efficacy parameters to improve efficacy outcomes. Only limited data for the commercial manufacturing process are available. Additional data obtained with the commercial manufacturing process will be provided and is a specific obligation of the marketing authorisation. In addition, in order to further confirm the appropriateness of the acceptance criteria, the Marketing Authorisation Holder (MAH) should re-evaluate the acceptance criteria for attributes related to potency tests using batch release data and clinical results after 6 months follow-up of 20 patients treated with commercial batches. Assessment of paediatric data on clinical efficacy This application is for patients 12 years and older and in total 11 adolescents have been treated as of December  2018.  Overall,  the  population  consisted  of  young  patients  with  age  range  12-35  years. Currently, there is no reason to assume differences in efficacy of Zynteglo based on age.

## Additional efficacy data needed in the context of a conditional MA

Comprehensive data will be provided by proposing the following specific obligations: the HGB-207 study with two-year follow-up on adults and adolescents (N=15) enrolled in the study, the HGB-212 with additional data in patients with the nonβ 0 /β 0  genotype and the LTF-303 interim study report that will include data on patients treated with Zynteglo with at least 5 years of follow-up.

<div style=\"page-break-after: always\"></div>

## 2.5.5. Conclusions on the clinical efficacy

The number of patients is low with limited follow-up time for patients in Phase 3 studies, but the overall presented data show clinically relevant and meaningful results by achieving TI in 11 out of 14 patients in studies HGB-204 and HGB-205 and 4 of 5 evaluable patients in study HGB-207. The preliminary data from study HGB-207 are consistent with early results and demonstrate improvement in total Hb levels to be achieved.

The CAT considers the following measures necessary to address the missing efficacy data in the context of a conditional MA:

Medicinal product no longer authorised · In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with TDT who do not have a β 0 /β 0  genotype, the MAH should submit interim and final data on Study HGB-207. · In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with TDT who do not have a β 0 /β 0  genotype, the MAH should submit interim and final data from patients with a severe nonβ 0 /β 0  genotype such as IVS-I-110/IVS-I-110 and IVS-I110/β 0  from Study HGB-212. · In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with TDT who do not have a β 0 /β 0  genotype, the MAH should submit interim data and the 5 years followup results of study LTF-303. The CAT considers the following measures necessary to address issues related to efficacy: · Non-interventional post-authorisation safety and efficacy study: In order to further characterise and contextualise the long-term safety and efficacy of Zynteglo in patients 12 years and older with TDT who do not have a β 0 /β 0  genotype, the MAH should conduct and submit the results of a study based on data from a product registry (REG-501) and use data on patients treated with transfusions and/or HLA-matched allogenic HSCT treated patients from an established European registry as a comparator group. The CHMP endorse the CAT conclusion on clinical efficacy as described above. 2.6. Clinical safety The information presented in Section 2.6 includes safety data from multiple data cuts as noted throughout. Safety analyses focused on patients with TDT (across all genotypes) and included patients with SCD treated with LentiGlobin for SCD (drug product manufactured with the same BB305 LVV as Zynteglo) in the assessment of gene therapy-related risks. Treatment paradigm

Treatment with Zynteglo is preceded by procedural and medical interventions, namely haematopoietic stem cell collection (mobilisation with G-CSF and plerixafor followed by apheresis), and myeloablative conditioning using busulfan, that carry their own risks. Thus, describing the overall extent of the safety profile of Zynteglo in patients with TDT also includes exposure to mobilisation and conditioning agents.

## Patient exposure

The primary safety analysis population is based on one completed Phase 1/2 clinical study (HGB-204) in adult and adolescent patient s (≥12 years of age) with TDT and five ongoing studies: HGB -205, HGB207, HGB-212, HGB-206, and the long-term follow up study LTF-303 (see Table 36). LTF-303 captures

<div style=\"page-break-after: always\"></div>

data for all Zynteglo-treated patients from the Month 24 visit in the parent study through 15 years post drug product infusion.

Data  in  patients  with  sickle  cell  disease  (SCD)  treated  with  LentiGlobin  for  SCD  were  submitted  as supportive data.

Table 36: Overall Extent of Exposure to Zynteglo or LentiGlobin for SCD

<!-- image -->

| Study Identifier (Status)   | Study Design                             | Study Population                                                                                    | Primary Objective(s)                                              | Number of Patients 1                                                                                            | Data Cut Dates                                                                                                                                    | Test Product(s); Dosage Regimen; Manufacturing Process for Zynteglo                                                            |
|-----------------------------|------------------------------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| HGB-204 (completed)         | Open-label, uncontrolled                 | Patients with TDT                                                                                   | safety and efficacy                                               | 18 TDT treated (all ≥12 years of age)                                                                           | authorised CSR Data Lock: 07 Mar 2018 Module 2.7.4 Data Cut: 07 Mar 2018 Additional Data Cut: 13 Dec 2018                                         | Zynteglo; ≥3.0×10 6 CD34+ cells/kg (apheresis); Base manufacturing process                                                     |
| HGB-205 (ongoing)           | Open-label, uncontrolled                 | Patients with SCD or TDT                                                                            | safety, tolerability, and success of engraftment                  | longer 4 TDT and 3 SCD treated (all ≥12 years of age)                                                           | Interim CSR Data Cut: 11 Oct 2017 Module 2.7.4 Data Cut: 07 Mar 2018 Additional Data Cut: 13 Dec 2018                                             | Zynteglo; ≥3.0×10 6 CD34+ cells/kg (apheresis; TDT) ≥2.0×10 6 CD34+ cells/kg (BM harvest; SCD); Original manufacturing process |
| HGB-207 (ongoing)           | Open-label, uncontrolled                 | product Patients with TDT with non- β 0 /β 0 genotypes                                              | no efficacy and safety                                            | 20 TDT treated (15 ≥12 years of age and 5 <12 years of age)                                                     | Interim CSR Data Cut: 22 Feb 2018 Module 2.7.4 Data Cut: 22 Feb 2018 Module 2.7.4 Late-Breaking Data Cut: 15 May 2018 Additional Data Cut: 13 Dec | Zynteglo; ≥5.0×10 6 CD34+ cells/kg (apheresis); Refined or commercial manufacturing process                                    |
| HGB-212 (ongoing)           | Medicinal Open-label, uncontrolled       | Patients with TDT with β 0 /β 0 , IVS-I-110/ β 0 , and IVS-I-110/IVS-I- 110 genotypes               | efficacy and safety                                               | 6 TDT treated (2 β 0 /β 0 ≥12 years of age; 3 non- β 0 /β 0 ≥12 years of age; 1 non- β 0 /β 0 <12 years of age) | 2018 CSR Data Cut: Not applicable Module 2.7.4 Data Cut: 07 Mar 2018 Additional Data Cut: 13 Dec 2018                                             | Zynteglo; ≥5.0×10 6 CD34+ cells/kg (apheresis); Refined or commercial manufacturing process                                    |
| LTF-303 (ongoing)           | Long-term follow-up; safety and efficacy | Patients with haemoglobinopathies who have been treated with the drug product in the parent studies | monitor for the long-term safety and efficacy of the drug product | 22 TDT and 8 SCD enrolled                                                                                       | Interim CSR Data Cut: 21 Nov 2017 Module 2.7.4 Data Cut: 07 Mar 2018 Additional Data Cut: 13 Dec                                                  | Not applicable                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Study Identifier (Status)   | Study Design             | Study Population        | Primary Objective(s)   | Number of Patients 1   | Data Cut Dates                                                                                   | Test Product(s); Dosage Regimen; Manufacturing Process for Zynteglo                                             |
|-----------------------------|--------------------------|-------------------------|------------------------|------------------------|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| HGB-206 (ongoing)           | Open-label, uncontrolled | Adult patients with SCD | safety                 | 19 SCD treated         | CSR Data Cut: Not applicable Module 2.7.4 Data Cut: 07 Mar 2018 Additional Data Cut: 13 Dec 2018 | LentiGlobin for SCD; ≥2.0×10 6 CD34+ cells/kg (BM harvest) ≥3.0×10 6 CD34+ cells/kg (apheresis); Not applicable |

| product   |
|-----------|
| Medicinal |

Medicinal product no longer authorised 1  Number of patients treated as of 13 December 2018 Subgroups for safety analyses included the NB0 pool (all patients with TDT with a nonβ 0 /β 0  genotype) and the TDT pool (all patients with TDT). As of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies, the main safety analysis of the ITT population consists of 39 patients with TDT who initiated mobilisation, 33 (85%) of whom had received Zynteglo (i.e., transplant population, TP). Of the 6 patients in the TDT pool who were not treated with drug product, 2 patients discontinued after 1 cycle of mobilization and apheresis (due to  inadequate  stem  cell  mobilisation  and  pregnancy)  and  4  were  pending  treatment.  Several  other subgroups were defined in order to evaluate variations in safety and tolerability in major categories of genotype and drug manufacturing processing. Patients were followed for a median (min, max) of 24.15 (0.8, 47.7) months after drug product infusion in the TDT pool, and 23.7 (0.8, 47.7) months after drug product infusion in the NB0 pool (see Table 37). Table 37: Length of Follow-Up Post-Drug Product Infusion (TP) Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies

Patient demographics were reflective of that for patients with TDT in Europe and globally. Certain patients were excluded from clinical studies for safety reasons, i.e. patients with hypersensitivity to the active substance or excipients, current or previous history of leukaemia or lymphoma, positive test for human immunodeficiency virus (HIV)-1, HIV-2, HTLV-I, and HTLV-2, pregnancy or breastfeeding, or unable to undergo HSCT safely, as determined by a healthcare professional.

<div style=\"page-break-after: always\"></div>

## Adverse events

For all studies, AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) (Version 19.0) and collected according to each protocol. For data analysis of AEs, the studies have been divided into periods corresponding to study milestones and by duration of time post-Zynteglo infusion.

The following study periods have been defined:

- ICF to &lt;MB: Date of informed consent until either date of initiation of mobilization (TDT patients  or  some  SCD  patients,  as  applicable)  or  bone  marrow  harvest  (some  SCD patients, as applicable)*

| Medicinal   |
|-------------|

Medicinal product no longer authorised · MB to &lt;C: date of initiation of mobilization/bone marrow harvest until date of initiation of conditioning · C to &lt;NE: Date of initiation of conditioning until the date of neutrophil engraftment (NE) · NE to &lt;M24: Date of NE through Month 24 · Day 1 (date of drug product infusion) through Month 24; annual periods thereafter · D1 to last visit: Day 1 through Last Visit+ · Total: Date of informed consent through Last Visit*+ * Excluded from laboratory summaries. + Last visit defined to include all safety data, even if it is after a scheduled visit; could occur either in the parent study or in the LTF-303 study. AEs are summarised by category for the TDT pool and the NB0 pool (see Table 38). TEAE was defined as those events that occur during or after the drug product infusion, i.e. Day 1. This is at least 7 days after start of conditioning with busulfan (4-5 days conditioning, at least 72 hours washout). All but 1 patient in the TDT pool had experienced at least 1 AE, with 12.8% experiencing at least 1 AE related to drug product; all of these latter events were Grade 1. Nineteen patients (48.7%) experienced at least 1 SAE; no drug product-related SAEs were reported. No deaths were reported and no patients discontinued from their respective studies due to an AE. Table 38: Overall Summary of Adverse Events, NB0 and TDT Pools (ITT)

TE, treatment-emergent. Study Pools: NB0 = nonβ 0 /β 0  genotype; TDT = All TDT. Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies

<div style=\"page-break-after: always\"></div>

<!-- image -->

Table 39: Incidence of All AEs Occurring in ≥3 Patients: TDT Pool (ITT) by system organ class and preferred term

|           |         | longer   |
|-----------|---------|----------|
|           | no      |          |
|           | product |          |
| Medicinal |         |          |

Data as of 22 February 2018 for Study HGB -207 and 07 March 2018 for all other studies

<div style=\"page-break-after: always\"></div>

A bbrev: C, Initiation of conditioning; ICF, informed consent form (date of signature); MB, initiation of mobilization; NE, neutrophil engraftment; TDT, transfusion -dependent thalassaemi a.

Study Pool: TDT = All TDT.

Note: Study periods are mutually exclusive, with the exception of Day 1 to Last Visit and ICF to Last Visit study periods. La st visit defined to include all relevant safety data, even if it is after a scheduled visit; could occur either in the parent study or in the LTF -303 study;

Note: Hematologic abnormalities reported as AEs that were coded to PTs in the Investigations SOC (e.g., Platelet count decreased) have been pooled with appropriate terms in the Blood and Lymphatic System SOC (e.g., Thrombocytopenia) for tabulation;

Note: If event started in the reporting period and continues into the next reporting period, it will be counted only in the first period. If event starts and stops in the reporting period and then recurs in the next reporting period, it will be counted in both periods;

Note: Number of patient

s at risk for each period includes

Note: C to &lt;NE includes AEs occurring during D1 to &lt;NE.

No adverse events have been reported during the &gt;M24 to M36 (N=17) and &gt;M36 to M48 (N = 7) or &gt;M48 to M60 (N = 0) periods so these columns are not displayed in the table.

Medicinal product no longer authorised From ICF to M24, the highest percentage of patients with AEs was during the C to &lt;NE period, and the lowest during the ICF to &lt;MB period. No events were reported between M24 and M60. For the ICF to Last Visit study period, most patients experienced events of thrombocytopenia (84.6%), anaemia  (76.9%),  stomatitis  (66.7%),  alopecia  (64.1%),  nausea  (61.5%),  vomiting  (59.0%),  and neutropenia  (56.4%).  The  events  of  thrombocytopenia,  anaemia,  stomatitis,  and  neutropenia  were primarily reported at a severity grade of ≥Grade 3, whereas the events of alopecia, nausea, and vomiting were primarily reported at a maximum of Grade 1 or Grade 2. All patient s (33/33, 100%) in the TDT pool had an AE ≥Grade 3 in severity in the 'Blood and lymphatic system disorders' SOC during the C to &lt;NE study periods. AEs reported as ≥Grade 3 that occurred in at least 20 patients (50%) were thrombocytopenia, anaemia, neutropenia, and stomatitis. Infections: Eleven (28.2%) patient s in the TDT pool reported a total of 19 ≥Grade 3 and/or serious infections, of which  7  were  non-serious  and  12  were  serious.  Three  serious  infections  occurred  prior  to  Zynteglo finished product infusion. Of the remaining 9 serious infections, 1 occurred prior to NE (Appendicitis) and 8  occurred  after  NE  (Cat  scratch  disease,  Gastroenteritis,  Diarrhoea  infectious,  Asymptomatic  HIV infection, Salmonella sepsis, Cellulitis, Tooth infection, and Pneumonia). Nonserious ≥Grade 3 infections included cystitis, herpes simplex, influenza, lung infection, oral herpes, pseudomonal bacteraemia, and Staphylococcal infection. All but the events of asymptomatic HIV infection (wildtype etiology confirmed by western blot) and Salmonella sepsis (both in the same patient) resolved as of 07 March 2018. Bleeding-related events: All patients in the TDT pool experienced significant thrombocytopenia and 22 (56.4%) patients in the ITT population experienced a bleeding event, with most events occurring following busulfan treatment. Almost  all  bleeding  events  were  non-serious  and  did  not  require  blood  transfusion.  One  SAE  of Hypotension (secondary to recurrent epistaxis) occurred 11 days after drug product infusion in a patient whose platelet level was &lt;30,000. This patient required multiple blood and platelet transfusions and local intranasal therapy.

The non-serious bleeding events occurring after infusion of Zynteglo finished product included: Epistaxis (14 patients), Vaginal haemorrhage (6 patients), Gingival bleeding (3 patients), Haematuria (2 patients), and 1 patient each with Conjunctival haemorrhage, Rectal haemorrhage, Metrorrhagia, Anal haemorrhage,  and  Menorrhagia.  These  events  occurred  within  60  days  of  treatment  with  Zynteglo, except for the event of Rectal haemorrhage which occurred on Day 718.

All events resolved with either standard treatment or were self-limited.

## Thrombotic events:

Five thrombotic events were experienced by 3 patients, all occurring after treatment with Zynteglo. Two events  were  serious  and  3  were  non-serious  and  included:  Intracardiac  thrombus  (splenectomised;

patient s who enter the period;

<div style=\"page-break-after: always\"></div>

Grade  3  SAE  on  Day  357);  2  events  of  Vena  cava  thrombosis  related  to  central  venous  catheter placement (Grade 2 AE on Day 51 which became an SAE on Day 58 in the same patient) and 2 events of Deep vein thrombosis in the same patient (both related to oral contraceptive use, splenectomised; Grade 2 AEs on Days 91 and 661).

## Hepatic events

In the TDT pool, 9 patients (23.1%) reported 15 hepatic events. There were no cases reported as Druginduced liver injury or cases that met Hy's Law criteria. Four (4) patients (10.3%) experienced a serious hepatic event (veno-occlusive disease; VOD).

Medicinal product no longer authorised Reproductive and fertility events A review of the 'Reproductive system and breast disorders' SOC in the TDT pool resulted in 3 reproductive and fertility events in the ITT population: 1 case of Premature menopause and 2 cases of Ovarian failure. All 3 were non-serious, attributed to busulfan by the Investigator, and were ongoing as of 07 March 2018. Drug product-related adverse events Five patients in the TDT pool reported 8 events (all nonserious and Grade 1) assessed by the Investigator as related or possibly related to Zynteglo (3 events of Abdominal pain, 2 events of Hot flush, and 1 event each of Dyspnoea, Non-cardiac chest pain, and Dysplasia).  All events, except for dysplasia, occurred on Day 1 in 4 patients and resolved on the same day without treatment. The event of dysplasia was reported at the Month 24 Visit (Day 723) and remained ongoing as of 07 March 2018. The Month 24 bone marrow biopsy revealed mild dysplastic changes in the erythroid series which were more prominent than in the previous bone marrow aspirate at Month 12. The pathology report stated that no significant neoplastic blast population was identified; normal cytology was observed for lymphocytes, monocytes, and neutrophils; WBC and platelet counts were normal. Integration Site Analysis (ISA) from peripheral blood did not indicate emergence of a dominant clone derived from LVVtransduced cells. Procedure-related adverse events The  treatment  with  Zynteglo  is  accompanied  by  procedures  involved  in  preparation  for  Zynteglo administration,  such  as  mobilisation  with  G-CSF  and/or  plerixafor,  apheresis  and  conditioning  with busulfan.  The  Investigators  had  the  option  of  attributing  an  AE  to  a  study  procedure,  specifically 'Mobilisation/Apheresis', or to the drugs used for mobilisation or conditioning. Events attributed by the Investigator to mobilisation and apheresis were mostly non-serious and typical of  the  intervention  and  treatment.  Specifically,  very  common  adverse  reactions  attributed  to mobilisation/apheresis included thrombocytopenia, peripheral sensory neuropathy, headache, nausea, and hypocalcaemia. Two  SAEs  were  attributed to mobilisation/apheresis: one event each of Thrombocytopenia and Hypokalaemia, which occurred in the same patient. All AEs occurred in the period between mobilization and conditioning and resolved prior to conditioning.

The majority of events attributed by the Investigator to conditioning with busulfan were non-serious. Specifically, very common adverse reactions attributed to busulfan included thrombocytopenia, anaemia, neutropenia,  febrile  neutropenia,  leukopenia,  decreased  appetite,  headache,  insomnia,  epistaxis, pharyngeal inflammation, stomatitis, nausea, vomiting, diarrhoea, abdominal pain, constipation, anal inflammation, dyspepsia, veno-occlusive liver disease (VOD), alopecia, pruritus, skin hyperpigmentation, petechiae, vaginal haemorrhage, pyrexia, ALT increased, AST increased, blood bilirubin increased, and gamma-glutamyltransferase (GGT) increased. Six events in 5 patients were reported as SAEs: 4 events

<div style=\"page-break-after: always\"></div>

of veno-occlusive liver disease, 1 event of hypotension (secondary to epistaxis), and 1 event of hypoxia. All events resolved.

## Adverse Events of Special Interest

The EOI pre-specified in the safety SAP were:

- Neutrophil engraftment failure
- HIV  infection  (defined  using  a  custom  MedDRA  query:  HLT='Acquired  immunodeficiency syndromes' or 'Retroviral infections')

Nineteen (48.7%) of TDT patients (ITT) reported a total of 31 SAEs, none of which were assessed as drug-product related. Of the 31 SAEs, 10 events occurred in 8 patients prior to drug product infusion and were attributed to study procedures, mobilization, apheresis, or other unknown reasons.

Medicinal product no longer authorised · Autoimmune disorders (defined using a custom MedDRA query: HLGT='Autoimmune disorders' or HLT= 'Autoimmunity analyses) · Lack of efficacy (defined using the Lack of efficacy/effect SMQ) · Malignancies  (defined  using  the  following  SMQs:  Malignant  tumors,  Malignant  lymphomas, Myelodysplastic syndromes [MDS], and Blood premalignant disorders) No cases of neutrophil engraftment failure, autoimmune disorders, or lack of efficacy were noted in the TP population (n=33).  No events or laboratory values indicative of graft-vs-host disease (GVHD) or other autoimmune diseases were noted. Platelet Engraftment (PE): As of 07 March 2018, the 33 patients who achieved PE had a median (min, max) Day of PE of 41.0 (19, 191). This time to platelet engraftment is longer than previously reported for  TDT in the allogenic transplant setting where a median time to PE was reported from published literature to be within 30 days of transplant. Delayed time to PE did not appear to be associated with an increased risk of bleeding. HIV infection: One patient (3%) in Study HGB-204 was found to have asymptomatic HIV infection at the Month 24 study visit. The Investigator assessed that the asymptomatic HIV infection was not related to drug product or procedures and was attributed to conventional routes of transmission. The event was ongoing at the time of the report. The patient remained in the study. Malignancy: No malignancies were noted in the TP population (n=33). One patient treated with drug product manufactured with the same BB305 LVV as Zynteglo experienced an SAE of myelodysplasia. A male patient with SCD participating in Study LTF-303 presented with cytopenia and peripheral blast cells approximately 3 years after busulfan conditioning. A bone marrow aspirate suggested MDS. The patient's cytogenetic analysis revealed a chromosomal abnormality which has been associated with secondary leukaemia. An assessment of a tumour cell-enriched cell population for LVV insertion was negative. Serious adverse event/deaths/other significant events No deaths have been reported in the Zynteglo program to date, with 100% overall survival and no transplant related mortality including in 23 TDT patients with at least 365 days of follow-up.

The incidence of all SAEs in patients in the TDT pool is presented in Table 40 by study period, with SOCs listed alphabetically and PTs within each SOC listed in descending order of occurrence in the Total (ICF to Last Visit) column.

<div style=\"page-break-after: always\"></div>

Table 40: Incidence of All Serious Adverse Events: TDT Pool (ITT)

Medicinal product no longer authorised

|           |         |    | longer   |
|-----------|---------|----|----------|
|           |         | no |          |
|           | product |    |          |
| Medicinal |         |    |          |

Data as of 22 February 2018 for Study HGB -207 and 07 March 2018 for all other studies

Abbrev.: C; Initiation of conditioning; ICF, informed consent form (date of signature); MB, initiation of mobilization or bone marrow harvest; NE, date of neutrophil engraftment; TDT, transfusion -dependent thalassaemi a.

Study Pool: TDT = All TDT.

Note: Study periods are mutually exclusive, with the exception of Day 1 to Last Visit and ICF to Last Visit study periods. La st visit defined to include all relevant safety data, even if it is after a scheduled visit; could occur either in the parent study or in the LTF -303 study.

Note: Hematologic abnormalities reported as AEs that were coded to PTs in the Investigations SOC (e.g., platelet count decreased) have been pooled with appropriate terms in the Blood and Lymphatic System SOC (e.g., thrombocytopenia) for tabulation.

Note: If event started in the reporting period and continues into the next reporting period, it will be counted only in the first period. If event starts and stops in the reporting period and then recurs in the next reporting period, it will be counted in both periods.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Note: Number of patient s at risk for each period includes patient s who enter the period.

Note: C to &lt;NE includes AEs occurring during D1 to &lt;NE.

No adverse events have been reported during the &gt;M24 to M36 (N=17) and &gt;M36 to M48 (N = 7) or &gt;M48 to M60 (N = 0) periods so these columns are not displayed in the table.

Of the 31 SAEs, the following 21 SAEs were treatment-emergent and occurred in 13 patients:

Infections (9): Of the 9 treatment-emergent serious infections, 1 occurred prior to NE (Appendicitis) and 8  occurred  after  NE  (cat  scratch  disease,  gastroenteritis,  diarrhoea  infectious,  asymptomatic  HIV infection, salmonella sepsis, cellulitis, tooth infection, and pneumonia). All but the events of HIV infection and salmonella sepsis (both in the same patient) were resolved as of 07 March 2018.

Medicinal product no longer authorised Bleeding Events (1): One event of hypotension (secondary to epistaxis) occurred 11 days after drug product infusion in a patient whose platelet level was &lt;30,000. This patient required multiple blood and platelet transfusions and local intranasal therapy. The event of epistaxis was attributed to conditioning and resolved. Thrombotic Events (2): One event each of intracardiac thrombus and Vena cava thrombosis, both of which resolved. In addition to the risk factor of having TDT, these patients had risk factors of asplenia and an in-dwelling catheter, respectively. Hepatic Events (4): All were veno-occlusive liver disease (VOD) and assessed by the Investigator as related to busulfan conditioning; all resolved after treatment with defibrotide. VOD is a reported, severe AE associated with the use of busulfan. Lab Findings (1): One event of Hyperglycaemia which resolved. Other (4): One event each of Transfusion reaction (platelets), Anaemia, Major depression, and Hypoxia, all of which resolved. Laboratory findings Haematology parameters Potentially clinically significant (PCS) haematology values are summarized by parameter for the TDT pool in Table 41. All patients had low PCS values for leukocytes (&lt;3 × 10 9 /L), erythrocytes (≤3.5 × 10 12 /L), and platelets (≤75 × 10 9 /L)  in  the  C  to  NE  period.  This  significant  pancytopenia  occurred  following busulfan conditioning and improved with subsequent bone marrow reconstitution and engraftment. Following NE and subsequent PE, most PCS abnormalities were in the erythrocyte line. Following PE, all patients maintained platelet levels of &gt;20 × 10 9 /L in the absence of platelet transfusions.

<div style=\"page-break-after: always\"></div>

Table 41: Summary of Potentially Clinically Significant Haematology Laboratory Abnormalities: TDT Patients (ITT)

<!-- image -->

|                       |                          |                 | Time Period   | Time Period   | Time Period   | Time Period          | Time Period   | Time Period      | Time Period        | Time Period        | Time Period        |
|-----------------------|--------------------------|-----------------|---------------|---------------|---------------|----------------------|---------------|------------------|--------------------|--------------------|--------------------|
| Laboratory test       | PCS Threshold            | Statistic       | MB to <C      | MB to <C      | Cto<NE        | Cto<NE               | NE to M24     | NE to M24        | Day1 to Last Visit | Day1 to Last Visit | Day1 to Last Visit |
| Leukocytes            | <3.0x10~9/L >=16x10~9/L  | n/N (%) n/N(%)  | 0/39 39/39    | (100.0)       | 5/33          | 33/33 (100.0) (15.2) | 3/32          | 30/32(93.8) 9.4) | EE/EE              | (100.0)            |                    |
| Lymphocytes           | <0.8x10~9/L >12x10~9/L   | n/N (%) n/N(%)  | 17/39 6/39    | (15.4) (43.6) | 26/33 0/33    | (78.8)               | 21/32 0/32    | (65.6)           | EE/OE 5/33         | (90.9) 15.2)       |                    |
| Neutrophils           | >13.5x10~9/L <1.5x10~9/L | n/N n/N (%) （）  | 38/39 2/39    | 97.4) 5.1)    | 33/33 4/33    | (100.0) 12.1)        | 32/32 2/32    | (100.0) 6.3)     | EE/EE 0/33 4/33    | (100.0) （12.1]     |                    |
| Monocytes Eosinophils | >2.5x10~9/L >1.6x10~9/L  | n/N (%) n/N (%) | 19/39 33/39   | 84.6) 48.7)   | 2/33 0/33     | 6.1)                 | 4/32 4/32     | (12.5) (12.5)    | 4/33               | （12.1}             |                    |
| Basophils             | >1.6 x10~9/L             | n/N(%)          | 4/39          | 10.3)         | 0/33          |                      | 0/32          |                  | 0/33 EE/           | (12.1)             |                    |

<!-- image -->

<!-- image -->

| product   |
|-----------|
| Medicinal |

Medicinal product no longer authorised Data as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies PCS = Potentially Clinically Significant Note: n/N is the number of patients with a potentially clinically significant laboratory abnormality divided by the number of patients that enter the period with at least one post-baseline value in the period. Note: The laboratory value has to represent a worsening from baseline in order to qualify as potentially clinically significant in this analysis. Baseline is defined as value closest but prior to date of mobilization. Clinical chemistry Clinical chemistry values are summarized by parameter for the TDT pool in Table 42. Changes to clinical chemistry values were observed frequently during the NE to M24 period, including elevated phosphate (17/32, 53.1%) and elevated glucose (6/32, 18.8%) levels. Transient elevations of ALT (13/32, 40.6%) and bilirubin (10/32, 31.3%) were also observed, often attributed by the Investigator to concurrent treatment with busulfan, azole antifungals, and sulfa antibiotics. Table 42: Summary of Potentially Clinically Significant Chemistry Values: TDT Pool (ITT)

<div style=\"page-break-after: always\"></div>

Data as of 22 February 2018 for Study HGB -207 and 07 March 2018 for all other studies Abbrev.: ULN, upper limit of normal.

Study Pool: TDT = All TDT.

Note: n/N is the number of patient s with a potentially clinically significant laboratory abnormality divided by the number of patients that enter the period with at least one post -baseline value in the period.

Note: The laboratory value has to represent a worsening from baseline in order to qualify as potentially clinically significant in this analysis. Baseline is defined as value closest but prior to date of mobilization.

## Replication Competent Lentivirus

Two methods were used for screening blood samples from patients receiving Zynteglo for the detection of replication-competent Lentivirus (RCL). Initially an enzyme-linked immunosorbent assay (ELISA) for HIV-1 p24 capsid protein was used. However, as there were some caveats with the ELISA assay, a qPCR for detection of VSV-G DNA was adopted as an alternative method for detection of RCL.

The Applicant has analysed the potential impact of age (adult, n=23 vs adolescent, n=9; ≥18 years  vs ≥12 and &lt; 18 years of age), race (white, n=23 vs Asian, n=10), gender and genotype (non -β 0 /β 0 , n=21 vs β 0 /β 0 , n=9) on the safety profile (neutrophil and platelet engraftment, AEs, and SAEs) of Zynteglo.

Medicinal product no longer authorised Blood was tested for LVV-derived RCL at protocol-defined visits up to month 24. No LVV-derived RCL was detected in any patient treated with Zynteglo (RCL testing results available for 46 patients). Integration Site Analysis Integration site analysis (ISA) was based on published methods (Schmidt et al. 2007), performed as a qualified  method  at  Genewerk  (Heidelberg,  Germany)  according  to  Testing  Facility  SOPs.  ISA  was performed using replicate linear amplification-mediated polymerase chain reaction (LAM-PCR) and the non-restrictive (nr) LAM-PCR variant, followed by subsequent deep sequencing. The method was not validated nor GLP compliant, however, according to the Applicant the methods were 'fit-for-purpose' and conducted with a focus on high quality and reliability. BB305 LVV integration site (IS) monitoring was performed in 40 patients (TDT and SCD) who were enrolled in the open-label Phase 1/2 clinical Studies HGB-204 (n=18), HGB-205 (n=7), and HGB-206 (n=9), and in Phase 3 Study HGB-207 (n=6), from 3 to 6 months after drug product infusion up to the most recent time point (with 2 patients in Study HGB-205 being followed for approximately 48 months after drug product infusion as of 07 March 2018). Highly polyclonal repopulation was observed in all patients assayed for ISA as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies (N=37), detected as the presence of multiple unique integration sites in genomic DNA isolated from peripheral blood cells (minimum and maximum of 207 and 21,149 unique sites). In total, &gt;550,000 unique IS were identified. Results showed that all patients were repopulated with a highly polyclonal population of HSCs. None of these IS showed an individual contribution of &gt;30% of all integration sites at any specific time point. Clonal selection or outgrowth was not observed. Safety in special populations Intrinsic and extrinsic factors There is no experience in patients older than 35 years of age.

Platelet engraftment (PE) differed between genotypes (median day of PE on Day 44.0 (19, 191; N=21) vs Day 36.0 (28, 55; N=9) for nonβ 0 /β 0  patients and β 0 /β 0  patients respectively), age (Day 37.0 (19, 191, N=23) versus 53.0 (20, 65, N=9) for adults vs adolescents and race (Day 41.0 [20,191, n=23] versus Day 36.0 [19,51, n=10] for Asian and White patients).

Further, 3 of the 4 cases of VOD occurred in patients &lt; 18 years of age.

The Applicant also analysed the potential impact of the manufacture process (extrinsic factor) on the

<div style=\"page-break-after: always\"></div>

safety profile (neutrophil engraftment (NE) and platelet engraftment (PE), AEs, and SAEs) of Zynteglo.

The day of NE was fastest (median [min, max; N]) with the original manufacturing process (Day 16.5 [14, 29; N=4]), followed by the base manufacturing process (Day 18.5 [14, 30; N=18]) and the refined or commercial manufacturing processes (Day 21.5 [14, 28;N=11]). The day of PE occurred earliest with the original manufacturing process (Day 23.0 [20,26]) followed by the base manufacturing process (Day 39.5 [19,191]) and the refined or commercial manufacturing processes (Day 44.0 [28,51]).

No notable differences in the incidence or severity of AEs were observed between groups that differed by the manufacturing drug process used. However, there were differences in numbers of patients and varying lengths of follow-up by group (up to 4 years for patients with the original manufacturing process, 2 years for patients with the base manufacturing process, and 12 months for patients with the refined manufacturing process as of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies).

Medicinal product no longer authorised Immunological events The formation of antibodies against transgenic β A-T87Q -globin have not been studied in Studies HGB-204, HGB-205, HGB-207, HGB-212 and LTF-303. No immunogenicity-related events (e.g., accelerated clearance or destruction of erythrocytes containing β A-T87Q -globin  that  would  result  in  decreases  in β A-T87Q -globin  concentrations  over  time,  and/or hypersensitivity reactions) were noted in any of the clinical trials conducted with Zynteglo. Safety related to drug-drug interactions and other interactions No  formal  drug-drug  interaction  studies  were  submitted.  There  were  no  AEs  observed  in  patients suggestive of any potential drug-drug interaction with Zynteglo. Discontinuation due to adverse events There were no AEs leading to discontinuation or withdrawal from study. Post marketing experience Zynteglo  is  not  approved  for  any  indication  in  any  region.  Therefore,  no  post-marketing  data  are available. Supportive safety data from patients with sickle cell disease (SCD) As of 07 March 2018, 24 patients with SCD underwent mobilization or bone marrow harvest; 2 patients discontinued prior to drug product infusion (reasons: withdrawal by patient and physician decision); 6 patients had not yet received the drug product infusion; 16 patients were infused with drug product manufactured with the same BB305 LVV as Zynteglo (TP), 7 patients completed their parent study and have enrolled in long-term follow-up Study LTF-303.

All patients in the TP of the SCD pool (16/16, 100%) achieved NE on median (min, max) Day 22.5 (17, 38).  Fourteen  of  16  treated  patients  (87.5%)  had  platelet  engraftment  (defined  as  an  unsupported platelet count of ≥50 × 10 9 /L in SCD) on median (min, max) Day 46.5 (12, 92). The 2 patients who had not had PE had been followed for 28 and 92 days as of07 March 2018.

Of the 16 SCD patients infused with drug product manufactured with the same BB305 LVV as Zynteglo, 1  (6.3%)  patient  experienced  an  AE  related  to  drug  product  (hot  flush),  and  14  (87.5%)  patients experienced an SAE, 11 (68.8%) patients experienced TESAEs.

<div style=\"page-break-after: always\"></div>

The majority of TESAEs (n=7) in SCD patients were pain crises which led to hospitalization, an event specific to the SCD population. Excluding TESAEs considered by the Investigator to be related to sickle cell disease, 9/16 (56.3%) patients experienced 20 TESAEs. Pyrexia, Bacteraemia, and Hepatic enzyme increased were the only PTs unrelated to SCD reported as TESAEs by more than 1 patient. No drug product-related  SAEs  were  reported  in  SCD  patients.  All  SAEs  resolved  (one  with  sequalae:  a  pretreatment event of Device related thrombosis), except for an event of Patellofemoral pain syndrome and of Device related infection, which were not resolved as of 07 March 2018.

An SAE of myelodysplasia was reported. A patient with SCD participating in Study LTF-303 presented with  cytopenia  and  peripheral  blast  cells  approximately  3  years  after  busulfan  conditioning.  A  bone marrow aspirate suggested MDS. The patient's cytogenetic analysis reveals a chromosomal abnormality which  has  been  associated  with  secondary  leukaemia.  An  assessment  of  tumour  cell-enriched  cell populations for LVV  insertion was  negative, providing convincing evidence against insertional oncogenesis. The event is attributed by the Investigator and the Sponsor to busulfan conditioning.

- One serious event of Thrombocytopenia assessed as possibly related to Zynteglo was reported in a patient in Study HGB-207. The patient achieved PE on Day 53, but platelets remained persistently below 35,000/μL and an SAE of Thrombocytopenia was reported on Day 114.  The event was considered medically significant but was not life-threatening and did not require hospitalization. The Investigator considered the SAE of Thrombocytopenia resolved when the patient's platelet count was &gt;50,000/uL on Day 162.- One additional patient in the TDT pool reported an event of Grade 2 Abdominal pain on Day 1 assessed by the Investigator as related or possibly related to drug product. The event resolved without treatment.

Medicinal product no longer authorised 2.6.1. Updated data on safety: 13 December 2018 (Studies HGB-205, HGB206, HGB-207, HGB-212, and LTF-303) As of 13 December 2018, the Intent-to-Treat (ITT) population included 57 patients in the TDT pool who initiated  mobilisation.  All  57  ITT  patients  in  the  TDT  pool  underwent  mobilization  with  G-CSF  and plerixafor. Forty-eight of these patients (84.2%) underwent myeloablative conditioning with busulfan as a single agent and received Zynteglo. Patients were followed for a median (min, max) of 18.71 (0.5, 58.6) months after drug product infusion in the TDT pool, and 15.16 (0.5, 58.6) months after drug product infusion in the NB0 pool. All patients who were followed to at least Day 43 post drug product infusion had neutrophil engraftment (NE). For patients 12 years and older (N=42), neutrophil engraftment occurred on median (min, max) Day 19.5 (13, 38) after medicinal product infusion. Platelet engraftment was recorded for 42/48 (87.5%) patients in the TDT pool. Patients with TDT 12 years and older treated with Zynteglo who achieved platelet engraftment had a median (min, max) platelet engraftment on Day 41.0 (19, 191) (N=39). The AEs and clinical laboratory findings remain consistent with the known effects of mobilization/apheresis, conditioning, and HSCT. All patients remain alive at last follow-up, with a median (min, max) follow-up duration of 18.71 (0.5, 58.6) months for patients with TDT treated with Zynteglo. The safety profile was in line with what was reported at the initial submission. The following additional product-related AEs were reported:

- One patient experienced an event of Grade 1 Pain in extremity on Day 14, a case of leg pain  assessed  by  the  Investigator  as  related  to  neutrophil  engraftment;  the  event resolved on Day 39 without treatment.

The following additional SAEs were reported:

<div style=\"page-break-after: always\"></div>

- One new event each of Bacillus bacteraemia, Neutropenic sepsis, Sepsis, and Lower respiratory tract infection. These events resolved.
- One new event of VOD which resolved after treatment with defibrotide.
- New events of Pyrexia (3), Neutropenia (2), Thrombocytopenia (2) one of which one was assessed as possibly related to drug product, as discussed above, and 1 event each of Febrile neutropenia, Major depression, and Stomatitis. All of these events have resolved except for 1 event each of Thrombocytopenia, Neutropenia, and Pyrexia, which were all reported in the same patient and attributed to the conditioning agent.

Medicinal product no longer authorised All patients remain alive at last follow-up, with a median (min, max) follow-up duration of 18.71 (0.5, 58.6) months as of 13 December 2018 (N = 48). There were no cases of graft-versus-host disease (GVHD). There were no cases of transplant-related mortality including in 29 patients with at least 1 year of follow-up. No  cases  of  insertional  mutagenesis  leading  to  clonal  dominance,  leukaemia  or  lymphoma,  or LVV-derived RCL have been reported (including approximately 20 patients with at least 2 years of followup). 2.6.2. Discussion on clinical safety Safety database The analysis of the safety profile of Zynteglo as of 13 December 2018 is limited to 48/57 TDT patients that have been treated. Support is provided by the experience gained in 16 patients with SCD treated with LentiGlobin for SCD manufactured with the same BB305 LVV as Zynteglo. Treatment with Zynteglo is preceded by haematopoietic stem cell collection (mobilisation with G-CSF and plerixafor followed by apheresis), and myeloablative conditioning using busulfan. Due to the limited sample size, the single-arm design of the studies and concomitant treatment, it is difficult to establish whether exposure to Zynteglo may have contributed to the occurrence of AEs and thus to the overall safety profile of the whole treatment procedure. Notably, as Zynteglo treatment is inherently linked to a HSCT procedure also the well-known risks associated with this procedure should be taken into account when  determining  the  benefit-risk  of  Zynteglo  treatment.  Adverse  reactions  have  been  described specifically for the mobilisation/apheresis, myeloablative conditioning and product related in the SmPC. As patient numbers are limited, safety data are pooled across all studies, TDT genotypes, cell doses and drug  product  manufacturing  processes.  The  refinements  made  to  the  drug  product  manufacturing process aimed to increase transgene expression. No substantial difference in drug product composition is noted between the overall TDT population and the nonβ 0 /β 0  population patients when treated with batches made from several improved manufacturing processes.

Patients were followed for a median (min, max) of 18.71 (0.5, 58.6) months after drug product infusion in the TDT pool, and 15.16 (0.5, 58.6) months after drug product infusion in the NB0 pool. The duration of follow-up for patients treated with the refined or commericial manufacturing process is more limited than the follow-up for patients treated with the original or base manufacturing processes.

## Safety profile

As of 13 December 2018, all but 1 patient in the TDT pool had experienced at least 1 AE, with 14.6% experiencing at least 1 AE related to drug product.  Twenty-nine patients with TDT in the ITT population (50.9%) reported a total of 51 SAEs, one of which was assessed as possibly related to drug product. Of

<div style=\"page-break-after: always\"></div>

the 51 SAEs, 15 events occurred in 13 patients prior to drug product infusion and were attributed to study procedures, mobilisation, apheresis, or other unknown reasons. No deaths were reported and no patients discontinued from their respective studies due to an AE. The only case of drug product-related SAE concerned one event of thrombocytopenia. The event was considered medically significant but was not life-threatening and did not require hospitalisation.

As of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies, most patients experienced  events  of  thrombocytopenia  (84.6%),  anaemia  (76.9%),  stomatitis  (66.7%),  alopecia (64.1%), nausea (61.5%), vomiting (59.0%), and neutropenia (56.4%, with 33% febrile neutropenia). The events of thrombocytopenia, anaemia, stomatitis, and neutropenia were primarily reported at a severity  grade  of  ≥Grade  3,  whereas  the  events  of  alopecia,  nausea,  and  vomiting  were  primarily reported at a maximum of Grade 1 or Grade 2.

Medicinal product no longer authorised As of 22 February 2018 for Study HGB-207 and 07 March 2018 for all other studies, 30 patients in the TDT pool experienced at least one event in the SOC infection or infestation, of which 11 (28.2%) patients reported a total of 19 ≥Grade 3 and/or serious infections, with 7 non -serious and 12 serious infections. Of the 9 serious infections occurring after Zynteglo treatment, 1 occurred prior to neutrophil engraftment (NE) (appendicitis) and 8 occurred after NE (cat scratch disease, gastroenteritis, diarrhoea infectious, asymptomatic HIV infection, salmonella sepsis, cellulitis, tooth infection, and pneumonia). All but the event of asymptomatic HIV infection (wildtype aetiology confirmed by western blot) and salmonella sepsis (both in the same patient) resolved as of 07 March 2018. As of 22 nd  February 2018 for Study HGB-207 and 07 March 2018 for all other studies, thrombocytopenia was accompanied by a bleeding event in 22 (56.4%) patients in the ITT population. Most events occurred following busulfan treatment, were considered non-serious and did not require blood transfusion. As of 22 nd  February 2018 for Study HGB-207 and 07 March 2018 for all other studies, five thrombotic events  were  experienced  by  3  patients;  2  events  were  serious  (Intracardiac  thrombus,  Vena  cava thrombosis).  In  the  TDT  pool  9  patients  (23.1%)  reported  15  hepatic  events,  4  patients  (10.3%) experienced  a  serious  hepatic  event  (VOD).  It  is  noted  that  3/4  serious  VOD  observed  occurred  in paediatric population (3 adolescents with VOD in 9 adolescents treated), all related to busulfan that is known to induce such events. As of 22 nd  February 2018 for Study HGB-207 and 07 March 2018 for all other studies, most of the AEs were attributed to the HSCT procedure and not the Zynteglo product. Only 8 events in 5 patients in the TDT pool were assessed by the Investigator as related or possibly related to Zynteglo. Of these, 7 events occurred on Day 1 in 4 patients (3 events of abdominal pain, 2 events of hot flush, and 1 event each of dyspnoea and non-cardiac chest pain). These events were Grade 1 and all resolved on the same day without treatment and were attributed by the Applicant to the presence of the dimethyl sulfoxide (DMSO) cryoprotectant. This is agreed, such infusion-related reactions have often been attributed to DMSO. One case of dysplasia was also attributed to Zynteglo treatment by the Investigator. This patient had an AE of Grade 1 dysplasia at the Month 24 Visit.  This event was more likely a consequence of longstanding dyserythropoiesis considering that no dysplasia was noted at Month 30.

Many of the AEs were attributed to the HSCT procedure and confirm the toxicity profile associated with HSCT.

As of 13 December 2018, the median time (min, max) to neutrophil engraftment (NE) of Day 20.5 (13, 38)(N=46) is in line with what is usually seen in TDT patients receiving allogeneic HSCT, but the time to platelet engraftment (PE) seems substantially prolonged in the studied population with a median (min, max) of Day 41.5 (19, 191), while usually PE is recorded within 20-30 days in TDT patients receiving allogeneic HSCT, per published literature. The cause of this apparent delayed engraftment could not be identified. As prolonged time to PE carries the risk for bleeding, it is reassuring that no excess of bleeding

<div style=\"page-break-after: always\"></div>

events has occurred in the patients with prolonged PE time. Delayed platelet engraftment is listed as identified risk in the Risk Management Plan (RMP) and neutrophil engraftment failure as a potential risk.

Substantial changes in the haematology and clinical chemistry parameters were frequently observed, but these can be expected in patients undergoing HSCT. No unexpected effects were noted.

No cases of malignancies were noted in the TDT population, however one case of myelodysplasia was reported in a patient with SCD participating in Study LTF-303. As no LVV insertion was found in tumour cell-enriched cell population and the cytogenetic analysis revealed a chromosomal abnormality which has  been  associated  with  secondary  leukaemia,  it  is  considered  likely  that  this  event  is  caused  by exposure to busulfan.

At the time of MAA review, the safety and efficacy of plerixafor in children less than 18 years was not yet established according to the SmPC of Mozobil. Based on the review of publicly available data and preliminary data in the &lt; 18 years of age patients mobilised with plerixafor submitted by the applicant, plerixafor appears to add minimal safety risks in children beyond the risks associated with the use of single agent G-CSF and does seem to decrease the rate of failed mobilisations. One exception may be a concern regarding the spleen as splenomegaly is a common feature in TDT patients and mobilisation with plerixafor has been implicated in splenic rupture. It is reassuring that apart from a Grade 1 nonSAE of splenomegaly no AEs related to the spleen have been observed, yet it is noted patient numbers are limited to 34 non-splenectomised patients (as of 13 December 2018). Therefore, the proposal to monitor for AEs of splenic rupture is endorsed. Splenic rupture has been added as potential risk in the safety specifications of the RMP.

Medicinal product no longer authorised The potential for generation of replication competent virus and insertional mutagenesis are concerns associated with retroviral gene therapies (i.e. therapies using an integrating LVV), and thus also with Zynteglo. It is noted that these risks have already been mitigated by the choice for and design of the LVV (i.e.  replication-defective,  SIN,  lentiviral  vector  lacking  enhancer/promoter  long  terminal  repeat sequences),  the  manufacture  process  (screening  each  LVV  batch  for  potential  RCL,  extensive  posttransduction washing), and patient selection (exclusion of patients with pre-treatment evidence of HIV1  or  HIV-2  infection).  No  RCL  was  detected  in  blood  samples  up  to  24  months  after  Zynteglo administration.  As  the  risk  for  the  occurrence  of  recombination  in  patients  infected  with  HIV  is hypothetical no contraindication for HIV and HTLV were considered necessary. Still seropositive patients will currently not be treated as seropositive samples are not accepted for manufacturing. The integration site  analyses  did  not  reveal  any  data  suggesting  that  oncogenesis  occurred  due  to  integration  site mutagenesis. Section 4.4 of the SmPC provides recommendations to monitor annually for leukaemia or lymphoma (including with a complete blood count) for 15 years post treatment with Zynteglo and that patients who have received Zynteglo should not be screened for HIV infection using a polymerase chain reaction (PCR)-based assay. The Applicant performed an analysis of the impact of some intrinsic (age, race, gender, genotype) and extrinsic factor (manufacturing process) on the safety profile. However, population size is too small and there are too many variables to allow any meaningful comparisons. The most remarkable difference might be the fact that most cases of VOD occurred in the adolescent population. However, considering the adult population is still rather young (no patients &gt;35 years were enrolled and median age of overall TDT population is 20 years), it may be questioned whether age is such a discriminating factor and this could just as well be a chance finding.

Further with regards to age, it is noted that current treatment experience is limited to patients aged 35 years or younger. The observed benefit-risk in the studied population can be extrapolated to the older population (i.e. &gt;35) as long as transplant eligibility criteria for patients with TDT are met. It is agreed that the decision to start treatment should be based on specific co-morbid factors known to impact the safety  of  treatment  including  myeloablative  conditioning,  rather  than  a  strict  upper  age  limit  in  the

<div style=\"page-break-after: always\"></div>

indication. Therefore, section 4.4 of the SmPC includes specific criteria to help health care providers identify patients with TDT for whom HSC transplantation is appropriate. Moreover, patients older than 35 has been included as 'missing information' in the safety specifications of the RMP.

The following restrictions on concomitant medications are recommended in the SmPC:

- Iron chelation should be stopped at least 7 days prior to myeloablative conditioning. Prophylaxis for  hepatic  veno-occlusive  disease  (VOD)  is  recommended.  Depending  on  the  myeloablative conditioning agent administered, prophylaxis for seizures should be considered.
- Patients should not take anti-retroviral medications or hydroxyurea from at least one month prior to mobilisation until at least 7 days after Zynteglo infusion.

Additional data will be obtained with the commercial drug product manufacturing process in study HGB207 and additional safety data will also be made available with studies HGB-212 and LTF-303 which are specific obligations of the marketing authorisation.

Medicinal product no longer authorised As of 07 March 2018, a separate high-level analysis of the safety profile in patients with SCD treated with drug product manufactured with the same BB305 LVV as Zynteglo (n=16) was provided. Apart from the events of hospitalisation due to pain crises (attributable to the underlying disease) only numerical differences in AE frequencies were noted. However, no conclusions can be drawn on the differences considered the small populations. Overall the available safety data in the SCD population are generally supportive of that seen in the TDT population. No studies aiming to investigate the immunogenicity of Zynteglo have been performed that is justified as risk assessment indicated a lack of immunogenic potential of the gene product. This claim is supported by the fact that no immunogenicity-related events were noted in the studies. The lack of immunogenic potential can be explained by the fact that β A-T87Q -globin is highly similar to naturally occurring proteins: the modification of the single amino acid (T87Q) was chosen because of its presence of the Q in the γ -and δ -globin chains. Pregnancy and breast-feeding as well as previous treatment with HSC gene therapy have been added as a contraindication (please see section 4.3 of the SmPC. In addition, contraindications to the mobilisation agents and the myeloablative conditioning agents must be considered (see section 4.3 of the SmPC). From the safety database all the adverse reactions reported in clinical trials have been included in the SmPC. Additional safety data needed in the context of a conditional MA There are still some uncertainties on the safety profile of Zynteglo due to the limited data on long-term safety of Zynteglo, the limited data in patients treated with the drug product manufactured with the commercial  manufacturing  process,  and  the  limitations  of  single-arm  trial  design,  in  particular considering that treatment is irreversible and with an intended life-long effect. The current analyses provide an idea of the safety profile associated with Zynteglo, in part due to the already well-known safety profile of the mobilisation/apheresis regimen and of the conditioning regimen with busulfan.

## 2.6.3. Conclusions on the clinical safety

Overall, due to the limitations in the safety database it is not possible to fully discriminate between effects  caused  by  Zynteglo  and  those  by  the  concomitant  treatment/HSCT  procedure.  Nevertheless, adverse  reactions  have  been  described  specifically  for  the  mobilisation/apheresis,  myeloablative conditioning and product related in the SmPC. Common AEs that may be caused by Zynteglo may also

<div style=\"page-break-after: always\"></div>

be missed due to the limited number of patients included in the safety database. Furthermore, the safety data were pooled across studies, TDT genotypes, cell doses and manufacturing processes. No apparent differences in the safety profile have been observed based on these factors, although patient numbers are low. Similarly, a conclusion on the effect of intrinsic factors (age, race, gender, genotype) on the safety profile of Zynteglo is complicated by low patient numbers.

Overall, the safety profile seems to be in line with that what is known for HSCT. As treatment with Zynteglo encompasses an HSCT procedure, the risks associated with mobilisation and conditioning are also part of the benefit:risk of Zynteglo. This includes the risk for secondary malignancies, as is illustrated by the event of myelodysplasia in an SCD patient, VOD (5 serious events) and impairment of fertility.

- Medicinal product no longer authorised The CAT considers the following measures necessary to address the missing safety data in the context of a conditional MA: · In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with TDT who do not have a β 0 /β 0  genotype, the MAH should submit interim and final data on Study HGB-207. · In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with TDT who do not have a β 0 /β 0  genotype, the MAH should submit interim and final data from patients with a severe nonβ 0 /β 0  genotype such as IVS-I-110/IVS-I-110 and IVS-I110/β 0  from Study HGB-212. · In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with TDT who do not have a β 0 /β 0  genotype, the MAH should submit interim data and the 5-year followup results of study LTF-303. The CAT considers the following measures necessary to address issues related to safety: · In addition, as a condition to the MA, a non-interventional post-authorisation safety and efficacy study should be conducted in order to further characterise and contextualise the longterm safety and efficacy of Zynteglo in patients 12 years and older with transfusion-dependent β thalassaemia (TDT) who do not have a β 0 /β 0  genotype.  The MAH should conduct and submit the results of a study based on data from a product registry (REG-501) and use data on patients treated with transfusions and/or HLA-matched allogenic HSCT treated patients from an established European registry as a comparator group. The registry will specifically address the risk of delayed platelet engraftment, insertional oncogenesis, loss of response to gene therapy and neutrophil engraftment failure. Interim data on the registry should also be submitted at each annual renewal of the conditional marketing authorisation. The CHMP endorse the CAT conclusion on clinical safety as described above.

<div style=\"page-break-after: always\"></div>

## 2.7. Risk Management Plan

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                              |
|------------------------------|---------------------------------------------------------------------------------------------------------|
| Important identified risks   | Delayed platelet engraftment                                                                            |
| Important potential risks    | Insertional oncogenesis Loss of response to gene therapy Neutrophil engraftment failure Splenic rupture |
| Missing information          | Long-term safety and efficacy Use in patients over 35 years of age                                      |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study / Status                                                                                                                                                                                                                       | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                | Safety concerns addressed                                                                                                                                                                                                            | Milestones                                                                                                                                                                                                                           | Due dates                                                                                                                                                                                                                            |                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                           | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                                                                                                                                                                                           | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                           | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                           | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                           | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                           |
| Long-term observational registry study (including product registry REG- 501) Planned                                                                                                                                                 | To evaluate long-term safety and effectiveness of treatment with Zynteglo finished product in patients 12 years and older with transfusion- dependent β thalassaemia (TDT) who do not have a β 0 /β 0 genotype.                                                                                                                                                                                      | Delayed platelet engraftment Insertional oncogenesis Loss of response to gene therapy Neutrophil engraftment failure Splenic rupture Long-term safety and efficacy                                                                   | authorised Protocol submission Interim data analysis Final study                                                                                                                                                                     | February 2020 At each annual renewal - December 2024 - December 2034 4Q 2039                                                                                                                                                         |                                                                                                                                                                                                                                      |
| no longer Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | no longer Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                                                                                                                                                 | no longer Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | no longer Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | no longer Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | no longer Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| Study HGB- 207 Ongoing                                                                                                                                                                                                               | Medicinal product To evaluate the efficacy of treatment with Zynteglo finished product in patient s ≥50 years of age with transfusion- dependent β thalassaemia (TDT) who do not have a β 0 /β 0 genotype at the β globin ( HBB ) gene To evaluate the safety of treatment with Zynteglo finished product in patient s ≤50 years of age with TDT who do not have a β 0 /β 0 genotype at the HBB gene | Delayed platelet engraftment Insertional oncogenesis Loss of response to gene therapy Neutrophil engraftment failure Splenic rupture Long-term safety and efficacy                                                                   | Interim results Interim study report when all included adolescents and adults have completed the study                                                                                                                               | At each annual renewal of the conditional marketing authorisation December 2021                                                                                                                                                      |                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study / Status         | Summary of objectives                                                                                                                                                                                                                                                                                                                                    | Safety concerns addressed                                                                                                                                                 | Milestones                                                                                                                                                                     | Due dates                                                                       |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Study HGB- 212 Ongoing | To evaluate the efficacy of treatment with Zynteglo finished product in patient s ≤50 years of age with transfusion-dependent β -thalassaemia (TDT) who have a β 0 /β 0 genotype at the HBB gene To evaluate the safety of treatment with Zynteglo finished product in patient s ≤50 years of age with TDT who have a β 0 / β 0 genotype at the HBB gene | longer Delayed platelet engraftment Insertional oncogenesis Loss of response to gene therapy Neutrophil engraftment failure Splenic rupture Long-term safety and efficacy | authorised Annual data update Interim study report when all included adolescents and adults with an IVS- I-110/IVS-I- 110 or IVS-I- 110/ β 0 genotype have completed the study | At each annual renewal of the conditional marketing authorisation December 2021 |
| Study LTF- 303 Ongoing | Medicinal product Monitor for long-term safety of the gene therapy drug product (i.e., the 'drug product') used in bluebird bio-sponsored clinical studies (i.e., the 'parent studies') in treated patients with haemoglobinopathies. Monitor for long-term efficacy of the drug product                                                                 | no Insertional oncogenesis Loss of response to gene therapy Long-term safety and efficacy                                                                                 | Annual data update Interim Study Report                                                                                                                                        | At each annual renewal of the conditional marketing authorisation December 2024 |

Risk minimisation measures

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Safety concern               | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                            | Pharmacovigilance activities                                                                                                                                                                                                       |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Delayed platelet engraftment | Routine risk minimisation measures - SmPC sections 4.4, and 4.8 - PL section 2 Sign and symptoms of bleeding and recommendations if present included in PL section 2. Restricted prescription medicine Additional risk minimisation measures - Educational materials for healthcare professionals - Educational materials for patients - Patient alert card                                                                                                           | authorised Routine pharmacovigilance beyond adverse reactions reporting and signal detection: - Quarterly review of aggregate safety data Additional pharmacovigilance - Study REG-501 - Study HGB-207 - Study HGB-212             |
| Insertional oncogenesis      | Medicinal product no Routine risk minimisation measures - SmPC sections 4.3, 4.4, and 5.3 - PL section 2 Recommendations for annual monitoring for leukaemia/lymphoma given in SmPC section 4.4 Collection of blood samples for testing if leukaemia/lymphoma is diagnosed given in SmPC section 4.4 Restricted prescription medicine Additional risk minimisation measures - Educational materials for healthcare professionals - Educational materials for patients | longer Routine pharmacovigilance beyond adverse reactions reporting and signal detection: - Quarterly review of aggregate safety data Additional pharmacovigilance - Study REG-501 - Study HGB-207 - Study HGB-212 - Study LTF-303 |

<div style=\"page-break-after: always\"></div>

| Safety concern                   | Risk minimisation measures                                                                                                                                                                                                                   | Pharmacovigilance activities                                                                                                                                                                                       |
|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Loss of response to gene therapy | Routine risk minimisation measures - SmPC section 4.4 Restricted prescription medicine Additional risk minimisation measures - Educational materials for healthcare professionals - Educational materials for patients - Patient alert cards | authorised Routine pharmacovigilance beyond adverse reactions reporting and signal detection: - none Additional pharmacovigilance - Study REG-501 - Study HGB-207 - Study-HGB-212 - Study LTF-303                  |
| Neutrophil engraftment failure   | no Routine risk minimisation measures - SmPC section 4.4 - PL sections 2 and 3 Restricted prescription medicine Additional risk minimisation measures - Educational materials for healthcare professionals                                   | longer Routine pharmacovigilance beyond adverse reactions reporting and signal detection: - Quarterly review of aggregate safety data Additional pharmacovigilance - Study REG-501 - Study HGB-207 - Study HGB-212 |
| Splenic rupture                  | Medicinal product Routine risk minimisation measures: - SmPC section 4.4 Restricted prescription medicine Additional risk minimisation measures - Educational materials for healthcare professionals                                         | Routine pharmacovigilance beyond adverse reactions reporting and signal detection: - Quarterly review of aggregate safety data Additional pharmacovigilance - Study REG-501 - Study HGB-207 - Study HGB-212        |

<div style=\"page-break-after: always\"></div>

| Safety concern                       | Risk minimisation measures                                                                                                                                                    | Pharmacovigilance activities                                                                                                                                                                                                           |
|--------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Long-term safety and efficacy        | Routine risk minimisation measures - SmPC section 4.4 Restricted prescription medicine Additional risk minimisation measures - Patients alert cards - Controlled distribution | authorised Routine pharmacovigilance beyond adverse reactions reporting and signal detection: - Quarterly review of aggregate safety data Additional pharmacovigilance - Study REG-501 - Study HGB-207 - Study HGB-212 - Study LTF-303 |
| Use in patients over 35 years of age | no Routine risk minimisation measures - SmPC section 5.1 Restricted prescription medicine Additional risk minimisation measures - none                                        | longer Routine pharmacovigilance beyond adverse reactions reporting and signal detection: - Subpopulation analysis of safety in patients over the age of 35 years will be included with each PSUR. Additional pharmacovigilance - none |

## 2.9. New Active Substance

Medicinal product no longer authorised The CHMP, CAT and PRAC considered that the risk management plan version 1.0 is acceptable. 2.8. Pharmacovigilance Pharmacovigilance system The CHMP and CAT considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC. Periodic Safety Update Reports submission requirements The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The new EURD list entry will therefore use the EBD to determine the forthcoming Data Lock Points.

Autologous CD34+ cell-enriched population that contains hematopoietic stem cells transduced with lentiviral vector encoding the β A-T87Q -globin gene has not been previously authorised in a medicinal product in the European Union (EU).

<div style=\"page-break-after: always\"></div>

## 2.10. Product information

## 2.10.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.10.2. Labelling exemptions

Medicinal product no longer authorised A request to omit certain particulars from the labelling as per Art.63.3 of Directive 2001/83/EC has been submitted by the applicant and has been found acceptable by the QRD Group for the following reasons: The QRD agreed to use the particulars for small immediate packaging units for the infusion bags. Whilst this labelling text is only intended for small containers of 10 mL or less and the Zynteglo infusion bag has a volume of 20 mL, a large amount of information needs to be included on the primary packaging label for this autologous ATMP. The limitations of the available space for the label of the infusion bag only allow for the inclusion of the labelling text for small immediate containers. The QRD agreed that a Lot Information Sheet containing the strength (cell concentration) of each lot, the dose, the number of lots,  the  total  number  of  infusion  bags  for  the  individual  patient,  would  supplement  the  minimum particulars to appear on the infusion bag label. 2.10.3. Additional monitoring Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Zynteglo (autologous CD34+ cell-enriched population  that  contains  hematopoietic  stem  cells  (HSCs)  transduced  with  lentiviral  vector  (LVV) encoding the β A-T87Q -globin gene) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU and it is approved under a conditional marketing authorisation. Therefore, the SmPC and the package leaflet includes a statement that this medicinal product is subject to  additional  monitoring  and  that  this  will  allow  quick  identification  of  new  safety  information.  The statement is preceded by an inverted equilateral black triangle. 3. Benefit-Risk Balance 3.1. Therapeutic Context 3.1.1. Disease or condition

The claimed indication is the treatment of patients 12 years and older with transfusiondependent β -thalassaemia  (TDT)  who  do  not  have  a β 0 /β 0   genotype,  for  whom  haematopoietic  stem  cell  (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.

## 3.1.2. Available therapies and unmet medical need

TDT is most frequently managed with supportive care that includes lifelong regular RBC transfusions, given every 2 to 5 weeks, aimed at maintain ing Hb levels ≥ 9 g/dL (Cappellini et al. 2014) to mitigate symptoms of anaemia and suppress ineffective erythropoiesis. Due to excess iron introduced through chronic transfusions, patients with TDT also require an intensive regimen of iron chelation using oral and/or injectable chelating agents to minimize iron overload in organs, particularly in the liver, heart,

<div style=\"page-break-after: always\"></div>

and endocrine system.

No medicinal product has been approved to date to address the underlying cause of TDT. At the time of MAA review, allogeneic HSCT was the only potential cure for TDT where cure is defined as a treatment that  may  achieve  near  normal  or  normal  levels  of  total  haemoglobin  and  eliminate  the  need  for transfusions.  Allogeneic  HSCT  addresses  the  underlying  genetic  cause  of  TDT  and  can  restore production of functional  RBCs.  If  allogeneic  HSCT  is  performed  early  enough,  it  is  also  possible  to prevent iron overload and its associated complications. Allogeneic HSCT is associated with risks for serious complications, such as graft-rejection, graft-versus-host disease (GVHD), and infection. Due to well-documented safety concerns, allogeneic HSCT is offered primarily to the minority of children and adolescents who have an available human leukocyte antigen (HLA)-matched sibling donor [&lt;25% of cases (Angelucci et al. 2014)]. However, in practice, a far smaller proportion of eligible patients actually undergo allogeneic HSCT due in part to persistent concerns over procedure-related toxicity.

All nonβ 0 /β 0  patients who received Zynteglo produced Hb containing β A-T87Q -globin (HbA T87Q ). Median HbA T87Q  levels increase from month 1 through approximately month 6 to month 9 post-HSCT, after which stabilisation is observed. For patients with the nonβ 0 /β 0  genotype, HbA T87Q  expression level at any time point was variable between patients, but kinetics were similar between patients.

Medicinal product no longer authorised 3.1.3. Main clinical studies The clinical development program of Zynteglo for the treatment of patients with TDT includes 5 single arm clinical studies: 2 Phase 1/2 studies (Studies HGB-205 and HGB-204), 2 Phase 3 studies (Studies HGB-207 and HGB-212), and 1 long-term follow-up study (Study LTF-303). The manufacturing process was refined to ultimately achieve higher levels of HbA T87Q  values in patients following the clinical finding from study HGB 204 that the base manufacturing process would not be sufficient  in  patients  with  no  endogenous  HbA,  i.e.  patients  with  β 0 /β 0   genotype.  The  refined  and commercial manufacturing process have only been used in the pivotal studies HGB-207 and HGB-212 in patients with TDT. As  of  13  December  2018,  a  total  of  32  nonβ 0 /β 0   patients  have  been  treated,  of  which  11  were adolescents and 21 were adults. The age range was 12 to 35 years, the youngest patient (age 12 years) was enrolled in study HGB-207. The  ongoing  long-term  follow-up  Study  LTF-303  includes  patients  treated  with  Zynteglo  who  have completed any of the above parent studies for an additional 13 years of follow-up, for a total of 15 years of follow-up post-drug product infusion. As of 13 December 2018, the follow-up time has been up to approximately 60 months post-drug product infusion. 3.2. Favourable effects The natural history of β -thalassaemia is well known and patients do not spontaneously produce higher levels of HbA or become transfusion independent. The mechanism of action of Zynteglo addresses the underlying genetic cause of the disease by the administration of HSCs containing functional copies of the β A-T87Q -globin gene through an autologous HSCT procedure.

A correlation between PB VCN and transgene expression (HbA T87Q ) and efficacy outcomes (total Hb, transfusion independence and reduction) has been shown. Although limited clinical data are available for study HGB-207 performed with drug product produced from the refined and commercial manufacturing processes, the preliminary results showed an improved efficacy with a similar safety.

The majority of patients with TDT who do not have a β 0 /β 0  genotype treated with Zynteglo in study HGB204 and HGB-205 have achieved TI (11 out of 14; 78.6%). For study HGB-207, 4 out of 5 TI-evaluable

<div style=\"page-break-after: always\"></div>

patients  achieved  TI  (data  cut:  13  December  2018),  and  based  on  a  developed  prediction  model (generated from Studies HGB-204, HGB-205 and the 5 TI-evaluable patients in Study HGB-207), an additional 6 patients from Study HGB-207 produced close to 8 g/dL or more HbA T87Q  at Month 6 and are predicted to achieve TI with ≥98% probability. Therefore the results appear to be in line with the results of studies HGB-204 and HGB-205. Achievement of TI is clinically meaningful, eliminating the need for regular blood transfusions and associated comorbidities due to iron overload.

In patients with TDT who do not have a β 0 /β 0  genotype who have not achieved TI (n=4), reductions in transfusion volume requirements and/or transfusion frequency were observed, ranging from 26.8% to 100% reduction in transfusion volume (compared to baseline pre-treatment requirements). While the transduction efficiency was not sufficient to provide adequate expression of HbA T87Q  to support TI in these patients, they still received clinical benefit by meaningful reduction in transfusions.

Medicinal product no longer authorised Support of efficacy of Zynteglo is partially derived from the β 0 /β 0  patients. Although only a minority of β 0 /β 0  patients achieved TI, the 6 out of 8 β 0 /β 0  patients in Study HGB-204 who have not achieved TI achieved a median transfusion volume reduction of -63.3% (-76.3%, -8.3%). Clinical responses across studies have been durable. Once TI was achieved, TI status was durable for nonβ 0 /β 0   patients  with  the  minimum  duration  of  TI  to  date  ranging  from  12.0+  to  56.3+  months (depending  on  the  time  of  follow-up).  No  nonβ 0 /β 0   patient  who  achieved  TI  has  since  required  a transfusion and TI status was maintained. Nonβ 0 /β 0  patients who achieved TI and who have completed at least their Month 30 Visit (N = 7) all had their last pRBC transfusion in the parent study and remained transfusion-free  throughout  the  follow-up  Study  LTF-303,  demonstrating  stable  integration  of  LVV provirus into long-term progenitor HSCs and stable expression of the transgene in erythroid cells. PD  parameters  and  efficacy  results  showed  consistency  across  studies  (HGB-204  and  HGB-205) irrespective of the drug process change. HGB-207 is performed with the refined and commercial drug manufacturing processes, which are expected to increase achievement of TI in even a larger portion of treated patients, due to increased DP VCNs. For a number of patients, a higher expression of HbA T87Q was observed in study HGB-207. As of December 2018, all patients who were predicted to achieve TI based on pharmacodynamic modelling and who have become evaluable for TI have achieved TI. Across all clinical studies to date, no significant or clinically relevant differences in effect of treatment were observed across gender, age, or race, although the sample size is small. A main long-term benefit of TI and the normalisation of Hb levels is expected to be a limitation or reduction  in  organ  damage  from  iron  overload.  The  follow-up  is  too  short  to  accurately  determine whether a decrease in iron burden in the liver and heart are obtained in all patients who achieved TI status but the preliminary data do seem to indicate a reduction in serum iron burden-related parameters, as  indicated  by  improvements in  ferritin  (7/8 patients  with  Baseline  values),  serum  transferrin  (7/9 patients), serum iron (7/9 patients), and transferrin saturation (5/7 patients with Baseline and M24 values). 3.3. Uncertainties and limitations about favourable effects

Endogenous Hb fractions contribute to total Hb in patients with TDT with nonβ 0 /β 0  genotype and may complement HbA T87Q  production and thus help to achieve TI. Two non -β 0 /β 0  patients in Study HGB-207 with the severe nonβ 0  mutation IVS-I-5 (1 patient with IVS-I-5/IVS-I-5 and 1 patient with IVS-I-5 /β 0 ) have &lt;1 g/dL of endogenous HbA. At the opposite end of the spectrum, a patient with a HBB :c.92+1G&gt;T β 0   mutation  compound heterozygous with an unknown second HBB mutation is an outlier with high endogenous β -globin production of 5.1 g/dL of endogenous HbA. In spite of these substantial differences

<div style=\"page-break-after: always\"></div>

in endogenous β -globin production, these 3 patients met the criteria for TI, thus the level of endogenous Hb influences only to a small extent the total Hb level post-HSCT with Zynteglo transduced cells.

Products manufactured using the base manufacturing process cannot be considered fully comparable with  those  manufactured  with  the  refined  or  commercial  manufacturing  processes,  and  thus  data obtained with material from the original or base manufacturing processes can only be considered as supportive for a full MAA. Ongoing Phase 3 Studies (HGB-207 and HGB-212), which used the refined and commercial manufacturing processes, have treated 3 patient s of the β 0 /β 0  genotype (in Study HGB-212). To guarantee that no patient is treated with a sub-optimal batch, tight control of the drug product potency attributes was implemented to ensure that the benefit of treatment with the commercial process is clinically in line with that of Phase 3 studies, which is of particular importance for patients with very low endogenous Hb production. Furthermore, it is proposed to re-evaluate the acceptance criteria for attributes related to drug product potency tests using batch release data and clinical results after 6 months follow-up of 20 patients treated with commercial batches.

When compared to allogeneic HSCT a delay in platelet engraftment was noted. This has been reflected in section 4.4 of the SmPC.

Medicinal product no longer authorised Overall, the number of patients is limited and patients were selected using an extensive list of inclusion and exclusion criteria. Even so, the efficacy is consistent over the clinical studies and has shown to be durable, the follow-up time for a substantial number of patients in Phase 3 studies is limited. As this application concerns a conditional approval, specific obligations have been proposed in order to obtain more efficacy and safety results from studies HGB-207, HGB-212 and LTF-303. 3.4. Unfavourable effects 48 patients with TDT have received Zynteglo. The overall safety profile seems to be in line with HSCT procedures.  The  most  common  AEs  were  thrombocytopenia  (84.6%),  anaemia  (76.9%),  stomatitis (66.7%), alopecia (64.1%), nausea (61.5%), vomiting (59.0%), and neutropenia (56.4%). The AEs related  to  Zynteglo  are  thrombocytopenia,  abdominal  pain,  non-cardiac  chest  pain,  pain  in  the extremities, dyspnoea and hot flush. SAEs  included  infections,  bleeding  events,  thrombotic  events,  hepatic  events  (including  VOD), hyperglycaemia  and  others  (transfusion  reaction,  anaemia,  depression  and  hypoxia).  One  SAE (thrombocytopenia) was considered due to drug product (Zynteglo) infusion. The safety profile of Zynteglo also takes into consideration the AEs of the mobilisation/apheresis and especially conditioning regimen, carrying a particular risk of veno-occlusive disease and infertility. It is noted that pyrexia was only reported in patients &lt;18 years (n=3, 16%) and that VOD occurred relatively more frequent in &lt; 18 years old patients (16% vs 7%). Please refer to section 4.8 of the SmPC for the list of AEs related to the mobilisation, apheresis and myeloablative conditioning. Contraindications to the mobilisation agents and the myeloablative conditioning agent must be considered. Zynteglo  is  contraindicated  in  pregnant  and  breast-feeding  women  (see  section  4.3  and  4.6  of  the SmPC). In addition, Zynteglo is contraindicated in previous treatment with HSC gene therapy.

The parameters indicative of iron load in patients in the study are rather variable. The values are within the range reported in literature. No analyses on potential relationship between the other parameters for iron overload (T2* and ferritin) was provided. The risk of iron load has been adequately described section 4.4 in the SmPC and there is currently no indication for a relation between baseline iron load and clinical outcome.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

Due to the limitations in the safety database (such as the limited number of patients, single arm trial design) it is difficult to fully discriminate between adverse effects caused by Zynteglo and those by the concomitant treatment/HSCT procedure, or determine whether Zynteglo exposure may have contributed to  the  occurrence  of  AEs.  Nevertheless,  adverse  reactions  have  been  described  specifically  for  the mobilisation/apheresis, myeloablative conditioning and product in the SmPC. Also common AEs that may be caused by Zynteglo treatment may be missed. As patient numbers are limited, safety data were pooled across studies, TDT genotypes, cell doses and manufacturing processes. No apparent differences in the safety profile have been observed based on these factors, although patient numbers are low. Similarly, a conclusion on the effect of intrinsic factors (age, race, gender, genotype) on the safety profile of  Zynteglo  is  complicated  by  low  patient  numbers.  Long-term  follow  up  is  limited,  in  particular considering the expected life-long activity of the product. This is especially the case for patients treated with the commercial manufacturing process. Study HGB-207 was performed with product made using the refined or commercial manufacturing processes; the preliminary results show an improved efficacy with a similar safety. Additional safety data are expected with studies HGB-207, HGB-212 and LTF-303 as well as with the registry (REG-501).

Zynteglo is a gene therapy product using an LVV to genetically modify HSCs. Theoretical safety concerns mainly  consist  of  insertional  oncogenesis  and  replication  competent  retrovirus,  these  have  been minimised by the design of the lentiviral construct and through the manufacturing process. Integration site analyses (ISA) have been performed through the non-clinical investigations and repeatedly analysed using linear amplification mediated PCR (LAM-PCR) in patients included in clinical studies. Of the patients with available ISA data (N=59), no evidence of clonal dominance has been reported. Potential effects due to transgene overexpression, loss of efficacy and the possibility for the formation of replication competent lentiviral cannot be fully excluded. No clinical symptoms of myeloproliferation have been seen in patients treated with Zynteglo. The SmPC recommends that patients should be monitored annually for leukaemia or lymphoma (including with a complete blood count) for 15 years post treatment with Zynteglo. If leukaemia or lymphoma is detected in any patient who received Zynteglo, blood samples should be collected for ISA. Additional long-term safety data will be provided by a 15-year long-term follow-up observational registry for patients treated with Zynteglo which will monitor the identified and potential risks in an increased number of patients and according to the safety specifications of the RMP.

Medicinal product no longer authorised With  respect  to  the  treatment  protocol,  the  mobilisation  was  conducted  with  plerixafor  and  G-CSF. Plerixafor was not authorised in the EU for use in paediatric patients at the time of MAA review and did not have an indication for use in non-malignant diseases (Mozobil SmPC). The applicant has committed to continue to monitor the safety of using G-CSF and plerixafor for mobilisation, through the Registry REG-501 to collect all serious adverse reactions related to mobilisation agents, including plerixafor. A later platelet engraftment in the younger age group (median day of engraftment 51 days in younger vs 36 days in adult patients) has been shown, as well as neutrophil engraftment which seems to be somewhat later in the younger age group (median 26 d vs 19 d &lt;18y vs ≥18y). As there are confounding factors and population is limited, it cannot be established whether indeed age was a contributing factor for this apparent delayed engraftment. The SmPC provides recommendations to monitor patients for thrombocytopenia and bleeding according to standard guidelines. Blood cell count determination and other  appropriate  testing  should  be  promptly  considered  whenever  clinical  symptoms  suggestive  of bleeding arise. Section 4.4 of the SmPC recommends that patients should receive rescue treatment with the back-up cell collection when experiencing neutrophil engraftment failure (see also section 4.2 of the SmPC). In clinical trials, no patients failed to engraft bone marrow, as measured by neutrophil engraftment (N=42).

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 43: Effects Table for Zynteglo for Patients with TDT (data as of 13 December 2018)

| Effect                                                                                         | Short Description                                                                                                                                                                                  | Unit                 | Treatment                                                     | Control              | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                                                       | References                                  |
|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|---------------------------------------------------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Favourable Effects                                                                             | Favourable Effects                                                                                                                                                                                 | Favourable Effects   | Favourable Effects                                            | Favourable Effects   | Favourable Effects                                                                                                                                                                                                                                                                                                                                        | Favourable Effects                          |
| Transfusion Independence (TI) for evaluable non- β 0 /β 0 patients                             | Proportion of patients with a weighted average haemoglobin (Hb) ≥ 9 g/dL without any pRBC transfusions for a continuous period of ≥ 12 months at any time during the study after Zynteglo infusion | n/N (%)              | 15/19 (79%; 95% CI: 54% to 94%)                               | NA                   | longer authorised The single patient in Study HGB-207 who has not achieved TI exhibited a substantial decline from DP VCN to PB VCN, resulting in low HbA T87Q production Study HGB-205 was performed with the base manufacturing process, HGB-204 with the original manufacturing process, HGB-207 with the refined or commercial manufacturing process. | Studies HGB-204, HGB-205, HGB-207, LTF-303. |
| Observed duration of TI for non- β 0 /β 0 patients                                             |                                                                                                                                                                                                    | min, max             | no 12.0+ to 56.3+ months. * median duration of TI not reached |                      | All non- β 0 /β 0 patients who have achieved TI at any time have maintained their TI status through all Hb assessments. True duration of TI is unknown as follow up time is limited.                                                                                                                                                                      | Studies HGB-204, HGB-205, HGB-207, LTF-303. |
| Transfusion Reduction (TR) in non- β 0 /β 0 patients that did not achieve TI at any time (n=4) | Medicinal % change in annualized transfusion volume from the period from 6 months post- DPI through Month 24 as compared to annualized baseline pretreatment transfusion requirements              | %                    | product -26.8%, -71.4% -86.9%, -100%                          | NA                   | Small number of patients                                                                                                                                                                                                                                                                                                                                  | Studies HGB-204, HGB-205, HGB-207.          |
| Unfavourable Effects                                                                           | Unfavourable Effects                                                                                                                                                                               | Unfavourable Effects | Unfavourable Effects                                          | Unfavourable Effects | Unfavourable Effects                                                                                                                                                                                                                                                                                                                                      | Unfavourable Effects                        |
| AE for all patients with TDT (ITT)                                                             | Patients with at Least 1 AE                                                                                                                                                                        | % (n)                | 98.2% (n=56)                                                  | NA                   | Limited safety database, contribution of Zynteglo to the overall safety profile cannot be distinguished from that of concomitant treatment/HSCT procedure                                                                                                                                                                                                 |                                             |

<div style=\"page-break-after: always\"></div>

| Effect                                                 | Short Description                                           | Unit         | Treatment                                                                                                               | Control   | Uncertainties/ Strength of evidence                                                                                                                                                  | References   |
|--------------------------------------------------------|-------------------------------------------------------------|--------------|-------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| SAE for all patients with TDT (ITT)                    | Patients with at Least 1 SAE                                | % (n)        | 50.9% (n=29)                                                                                                            | NA        | Limited safety database, one AE was assessed as possibly related                                                                                                                     |              |
| Common AE for all patients with TDT (ITT)              | AEs occurring in at least 50% of patients                   | %            | Thrombocytopenia (82.5%), Anaemia (71.9%), Stomatitis (64.9%), Vomiting (50.9.%), Neutropenia (57.9%), Alopecia (52.6%) | NA        | authorised to drug product Limited safety database, contribution of Zynteglo to the overall safety profile cannot be distinguished from that of concomitant treatment/HSCT procedure |              |
| Delayed platelet engraftment for all patients with TDT | Time to platelet values ≥ 20 ×10 9 /L on 3 consecutive days | Median, days | 41.5 (min 19, max 191).                                                                                                 | < 30 days | contribution of Zynteglo to the delayed platelet engraftment remains unexplained                                                                                                     |              |

While the benefit of treatment in the studied population is evident, uncertainties regarding this benefit remain. The safety profile also includes the AEs related to mobilisation, apheresis and myeloablative conditioning. There is a theoretical risk associated with genetically modified cells involving an integrative LVV (and notably the risk of insertional oncogenesis). The limited patient numbers and long-term safety data complicate the evaluation of the contribution of Zynteglo to the safety profile of HSCT.

Medicinal product no longer authorised Delayed platelet engraftment for all patients with TDT Abbreviations: DPI = drug product infusion, ITT = Intent-to-Treat, TI= transfusion independence 3.7. Benefit-risk assessment and discussion 3.7.1. Importance of favourable and unfavourable effects TDT is a severe condition in which patients require regular pRBC transfusions for survival, resulting in unavoidable iron overload which in turn, in the absence of appropriate and maintained iron chelation, can cause serious cardiac, liver, and endocrine comorbidities, and shortened lifespan compared to the general  population.  At  the  time  of  MAA  review,  the  only  potential  curative  treatment  option  was allogeneic HSCT. Despite the fact that allogeneic HSCT is associated with significant risks, this has been the  preferred treatment  option  for  TDT  patients  who  have  an  HLA-matched sibling  stem  cell  donor, indicating  the  benefit  obtained  by  the  transplantation  process,  i.e.  becoming  transfusion  free  and avoiding the risk of iron overload and the need for iron chelation therapy. 15/19 (79%) patients with TDT, who do not have a β 0 /β 0  genotype and who were eligible for HSCT but had no matched sibling donor, were treated with Zynteglo in study HGB-204, HGB-205, and HGB-207, and achieved TI. This can be considered as a major clinical benefit of Zynteglo treatment. This clinically relevant effect is supported by pharmacodynamic parameters.

Additional efficacy and safety data will be further substantiated by the ongoing clinical development (study HGB-207 and study HGB-212) and the long-term follow-up monitoring of patients (LTF-303 and registry  REG-501).  Finally,  further  support  for  the  assumption  that  the  commercial  manufacturing process is clinically in line with the refined manufacturing process batches is expected to be obtained by

<div style=\"page-break-after: always\"></div>

a re-evaluation of the acceptance criteria for attributes related to potency tests using batch release data and clinical results after 6 months follow-up of patients treated with commercial batches.

## 3.7.2. Balance of benefits and risks

The benefit-risk balance of Zynteglo for the indication: ' Zynteglo is indicated for the treatment of patients 12 years and older with transfusion -dependent β -thalassaemia (TDT) who do not have a β 0 /β 0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA) -matched related HSC donor is not available' is positive.

<!-- image -->

- Medicinal product no longer authorised 3.7.3. Additional considerations on the benefit-risk balance Conditional marketing authorisation The product falls within the scope of Regulation (EC) No 507/2006 concerning conditional marketing authorisations, as it aims at the treatment of a seriously debilitating disease and is duly recognised by the EU as an orphan medicinal product. Zynteglo has been accepted as PRIME, acknowledging that it addresses an unmet medical need and that its early availability would be considered beneficial. The development has been the patient of several protocol assistance advices to determine the most appropriate time and endpoint for the submission of the marketing authorisation and to support the design of the post-authorisation studies. These included two parallel advices with Health Technology assessment bodies. The product falls within the scope of Article 14-a of Regulation (EC) No 726/2004 concerning conditional marketing authorisations, as it aims at the treatment of a seriously debilitating disease. Furthermore, the CAT/CHMP considers that the product fulfils the requirements for a conditional marketing authorisation: · The benefit-risk balance is positive. · It is likely that the applicant will be able to provide comprehensive data. The applicant is likely to be able to provide comprehensive data relevant to the initial indication including long-term safety and efficacy data for adult and adolescent patients with TDT who have a nonβ 0 /β 0  genotype, post initial approval from the following sources: Phase 3 Study HGB-207, Phase 3 study HGB-212 and Long-term follow-up Study LTF-303. · The unmet medical need has been addressed. The therapeutic armamentarium for the treatment of TDT can be considered insufficient. The symptomatic approach of transfusions combined with iron chelation therapy may result in a certain improvement of life expectancy. The challenges with regard to side effects, insufficiency of a non-curative approach as well as non-adherence as a result of the burden of treatment remain. The only curative treatment option on the other hand, allogeneic HSCT,  is  associated  with  severe  side-effects  and  reactions.  The  treatment  of  TDT,  therefore, represents an unmet medical need.
- The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. The majority of patients with TDT who have a nonβ 0 /β 0 genotype treated with Zynteglo in study HGB-204 and HGB-205 have achieved TI (11 out of 14; 78.6%). For study HGB-207, 4 out of 5 TI-evaluable patients achieved TI (data cut: 13 December 2018), and based on a developed prediction model (generated from Studies HGB-204, HGB-205 and the 5 TI-evaluable patients in Study HGB-207), an additional 6 patients from Study HGB-207 produced close to 8 g/dL or more HbA T87Q at Month 6 and are predicted to achieve TI with ≥98% probability.  Achievement  of  TI  is  clinically  meaningful,  eliminating  the  need  for  regular  blood

<div style=\"page-break-after: always\"></div>

transfusions and associated comorbidities due to iron overload. These effects are expected to be life-long, following successful engraftment in the patient.

As comprehensive data on the product are not available, a conditional marketing authorisation was requested by the applicant in the initial submission and is agreed by the CAT and CHMP.

Because of the limited number of patients in the clinical studies; comprehensive data is required to be provided by the applicant as laid down in the following specific obligations:

- In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with TDT who do not have a β 0 /β 0  genotype, the MAH should submit interim and final data on Study HGB207.

Medicinal product no longer authorised · In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with TDT who do not have a β 0 /β 0  genotype, the MAH should submit interim and final data from patients with a severe non β 0 /β 0   genotype such as IVS I-110/IVS-I-110 and IVS I110/β 0   from Study HGB-212. · In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with TDT who do not have a β 0 /β 0  genotype, the MAH should submit interim data and the 5 years followup results of study LTF-303. In addition, the following two Annex II conditions are requested: · In order to further confirm the appropriateness of the acceptance criteria, the MAH should reevaluate the acceptance criteria for attributes related to potency tests using batch release data and clinical results after 6 months follow-up of 20 patients treated with commercial batches. · Non interventional post-authorisation safety and efficacy study: In order to further characterise and contextualise the long-term safety and efficacy of Zynteglo in patients 12 years and older with TDT who do not have a β 0 /β 0  genotype, the MAH should conduct and submit the results of a study based on data from a product registry (REG-501) and use data on patients treated with transfusions and/or HLA-matched allogenic HSCT treated patients from an established European registry as a comparator group. Accelerated assessment This application has been assessed on an accelerated timetable. 3.8. Conclusions The overall benefit-risk profile of Zynteglo is positive. The CHMP endorse the CAT conclusion on benefit-risk balance as described above. 4. Recommendations

## Outcome

Based on the CAT review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Zynteglo is favourable in the following indication:

'Zynteglo is indicated for the treatment of patients 12 years and older with transfusiondependent β -thalassaemia  (TDT)  who  do  not  have  a β 0 /β 0   genotype,  for  whom  haematopoietic  stem  cell  (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.'

<div style=\"page-break-after: always\"></div>

The CHMP therefore recommends the granting of the conditional marketing authorisation patient to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal  product  patient  to  restricted  medical  prescription  (see  Annex  I:  Summary  of  Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

The educational and controlled distribution programme is aimed at providing information on the safe use of Zynteglo.

Medicinal product no longer authorised Periodic Safety Update Reports The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation. Conditions or restrictions with regard to the safe and effective use of the medicinal product Risk Management Plan (RMP) The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. An updated RMP should be submitted: · At the request of the European Medicines Agency (EMA); · Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. Additional risk minimisation measures Prior to launch of Zynteglo in each Member State the Marketing Authorisation Holder (MAH) must agree about  the  content  and  format  of  the  educational  and  controlled  distribution  programme,  including communication  media,  distribution  modalities,  and  any  other  aspects  of  the  programme,  with  the National Competent Authority.

The MAH shall ensure that in each Member State where Zynteglo is marketed, all healthcare professionals and patients/carers who are expected to prescribe, dispense and/or use Zynteglo have access to/are provided with the following educational package to be disseminated through professional bodies:

- Physician educational material
- Patient information pack

<div style=\"page-break-after: always\"></div>

## The physician educational material should contain:

- o The Summary of Product Characteristics
- o Guide for healthcare professionals
- o Guide for handling and method of administration

## The Guide for healthcare professionals shall contain the following key elements:

- o Warnings and precautions of the mobilisation agents and the myeloablative conditioning agent must be considered.

-

Medicinal product no longer authorised o Treatment with Zynteglo in the clinical trials was associated with delayed platelet engraftment. No correlation was observed between incidence of bleeding AE and time to platelet engraftment. Precautions regarding bleeding consequences of thrombocytopenia need to be taken. Patients should be made aware of the risk of bleeding events that are not easily identifiable, such as internal bleeding. o Treatment with Zynteglo is in theory associated with the risk of insertional mutagenesis, potentially leading to development of malignancy. All patients must be advised on signs of leukaemia and to seek immediate medical attention if these signs are present. o A negative serology test for HIV is necessary to ensure acceptance of apheresis material for Zynteglo manufacturing. o The potential risk of loss of response to gene therapy may lead to loss of transfusion independence or increase transfusion needs for patients who did not reach transfusionindependence. o All patients should receive annual monitoring of complete blood counts and total haemoglobin levels to monitor for leukaemia/lymphoma and maintenance of efficacy, respectively. o The short-term potential risk of treatment with Zynteglo represents failure of engraftment, which shall be managed by administration of rescue cells. o The need to explain and to ensure that patients understand: -potential risks of treatment with Zynteglo -signs of leukaemia/lymphoma and what action to take -content of patient's guide the need to carry the patient alert card and show it to every healthcare professional -enrolment in the drug product Registry

- o Scope of the Registry and how to enrol patients

## The Guide to handling and method of administration for healthcare professionals shall contain the following key elements:

- o Instructions on receiving and storing of Zynteglo and how to check Zynteglo prior to administration
- o Instructions about the thawing of Zynteglo
- o Instructions on protective equipment and treatment of spills.

<div style=\"page-break-after: always\"></div>

## The patient information pack should contain:

- o Package leaflet
- o A patient/carer guide
- o A patient alert card

## The patient/carer guide shall contain the following key messages:

- o Treatment with Zynteglo is in theory associated with the risk of development of malignancy. Signs of leukaemia and the need to obtain urgent medical care if these signs are present.

o

The MAH shall ensure that in each Member State where Zynteglo is marketed, a system aimed to control distribution to Zynteglo beyond the level of control is ensured by routine risk minimisation measures. The following requirements need to be fulfilled before the product is prescribed, manufactured, dispensed and used:

Medicinal product no longer authorised o Patient alert card and the need to carry it on their person and tell any treating healthcare professional that they were treated with Zynteglo. o The potential risk of loss of response to gene therapy may lead to loss of transfusion independence or increase transfusion needs for patients who did not reach transfusionindependence. o The importance of annual check-ups. o Treatment with Zynteglo is associated with the risk of delayed platelet engraftment that could lead to an increased tendency for bleeding. o Signs and symptoms of bleeding and the need to contact the physician if any signs of unusual or prolonged bleeding or any other relevant signs are present. o Enrolment in the drug product Registry. The patient alert card shall contain the following key messages: o Information of risk of delayed platelet engraftment, potentially leading to bleeds, and theoretical risks. o Statement that the patient was treated with gene therapy and should not donate blood, organs, tissues, or cells. o Statement that the patient was treated with Zynteglo, including LOT number and treatment date(s). o Details on reporting of adverse effects. o Information on the possibility of false positivity of certain commercial HIV tests because of Zynteglo. Contact details where a health care professional can receive further information.

- Zynteglo will only be available through bluebird bio qualified treatment centres to ensure traceability of the patient's cells and manufactured drug product between the treating hospital and manufacturing site. The selection of the treatment centres will be conducted in collaboration with national health authorities as appropriate.

<div style=\"page-break-after: always\"></div>

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

<!-- image -->

| Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Due date                                                                                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| In order to further confirm the appropriateness of the acceptance criteria, the MAH should re-evaluate the acceptance criteria for attributes related to potency tests using batch release data and clinical results after 6 months follow-up of 20 patients treated with commercial batches.                                                                                                                                                                                                                                                                                   | authorised Interim report: at each annual renewal When 20 patients have been treated with 6 months follow-up                |
| no longer Non interventional post-authorisation safety and efficacy study: In order to further characterise and contextualise the long-term safety and efficacy of Zynteglo in patients 12 years and older with transfusion- dependent β - thalassaemia (TDT) who do not have a β 0 /β 0 genotype, the MAH should conduct and submit the results of a study based on data from a product registry (REG- 501) and use data on patients treated with transfusions and/or HLA-matched allogenic HSCT treated patients from an established European registry as a comparator group. | Protocol submission: February 2020 Interim results: - at each annual renewal - Dec. 2024 - Dec. 2034 Final results: Q4 2039 |

<!-- image -->

| Description                                                                                                                                                                                                                                  | Due date                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with transfusion- dependent β -thalassaemia (TDT) who do not have a β 0 /β 0 genotype, the MAH should submit interim and final data on Study HGB- 207 | Interim results: at each annual renewal Final results: December 2021 |
| In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with transfusion- dependent β -thalassaemia (TDT) who do not have a                                                                                   | Interim results: at each annual                                      |

Medicinal product no longer authorised Specific Obligation to complete post-authorisation measures for the conditional marketing authorisation This being a conditional marketing authorisation and pursuant to Article 14-a of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures:

<div style=\"page-break-after: always\"></div>

| Description                                                                                                                                                                                                                                                          | Due date                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| β 0 /β 0 genotype, the MAH should submit interim and final data from patients with a severe non- β 0 /β 0 genotype such as IVS-I-110/IVS-I-110 and IVS-I- 110/β 0 from Study HGB-212.                                                                                | renewal Final results: December 2021                                 |
| In order to confirm the efficacy and safety of Zynteglo in patients 12 years and older with transfusion- dependent β -thalassaemia (TDT) who do not have a β 0 /β 0 genotype, the MAH should submit interim data and the 5 years follow-up results of Study LTF-303. | Interim results: at each annual renewal Final results: December 2024 |

<!-- image -->

Medicinal product no longer authorised Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States Not applicable. New Active Substance Status Based on the CHMP review of the available data, the CHMP considers that autologous CD34+ cellenriched population that contains hematopoietic stem cells transduced with lentiviral vector encoding the β A-T87Q -globin gene is a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union. Paediatric Data Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0257/2015 and the results of these studies are reflected in the SmPC and, as appropriate, the Package Leaflet.